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The insulin/IGF1 signalling pathway is one of the best-characterized pathways affecting 
longevity. Indeed, a partial reduction of the pathway has been shown to extend healthy lifespan, 
protect against cancer, improve insulin sensitivity and promote longevity in a great variety of 
organisms including worms, flies and mice. Similarly, dietary restriction is also considered a 
robust and conserved intervention to slow ageing and expand lifespan. In this thesis, we have 
focussed on two different aspects of the pathway: in the first place, we have analysed the in vivo 
effects of the pharmacological inhibition of PI3K, a key mediator of the pathway; and secondly, 
we have investigated the role of tumour suppressor genes in the response to fasting, the most 
extreme form of dietary restriction. 
 Genetic inhibition of PI3K signalling has been shown to increase energy expenditure, 
protect from obesity and the metabolic syndrome, and extend lifespan. Here, we wanted to 
explore whether the in vivo pharmacological inhibition of PI3K led to comparable effects. 
Interestingly, treatment with two PI3K inhibitors, CNIO-PI3Ki and GDC-0941, both 
preferentially selective for the ! and " isoforms, reduces adiposity of obese mice, exclusively, 
without affecting lean mass content. Furthermore, in the context of continuous nutritional 
excess, long-term treatment of obese mice with CNIO-PI3Ki reduces body weight, until 
reaching a new balance that is stable for months and as long as the treatment is administered, by 
inducing energy expenditure. CNIO-PI3Ki treatment, additionally, reverts liver steatosis, 
improves glycemia and reduces inflammation, thereby improving some signs of the metabolic 
syndrome. Finally, we have extended the use of the CNIO-PI3Ki treatment to rhesus monkeys, 
showing that a daily oral dose decreases adiposity and lowers glycemia of obese monkeys 
treated for 3 months, in the absence of detectable toxicities. Thus, pharmacological inhibition of 
PI3K is an effective and safe anti-obesity intervention in obese mice and monkeys that could 
conceivably reduce adiposity and reverse some of the symptoms of the metabolic syndrome in 
humans. 
 Fasting is a physiological stress that elicits well-known metabolic and molecular 
adaptations. However, little is known about the role of stress-responsive tumour suppressor 
genes in the fasting response. Therefore, we examined the expression of several tumour 
suppressors in mice upon fasting, finding that the expression of p21 is uniquely induced in a 
great variety of tissues, particularly in the liver (>10 fold), in a process that is independent of 
p53. Remarkably, p21-deficient mice cannot efficiently adapt to long-term fasting (48 hours), 
becoming severely morbid and prematurely energy exhausted. Analysis of the liver 
transcriptome and cell-based assays revealed that the absence of p21 impairs the activity of 
PPAR!, which is known to be critical for the adaptation to fasting by inducing fatty acid #-
oxidation and ketogenesis. Therefore, we conclude that p21 is a fasting-induced factor that 
positively regulates PPAR! and plays a relevant role in the adaptation to fasting. 
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La ruta de señalización de la insulina/IGF1 es una de las principales vías implicadas en el 
envejecimiento. De hecho, su inhibición parcial protege frente al cáncer, mejora la sensibilidad 
a insulina y aumenta la longevidad en una gran variedad de organismos, incluyendo nematodos, 
moscas y ratones. De igual modo, se ha demostrado que la restricción calórica es una 
intervención robusta y conservada capaz de frenar el envejecimiento y alargar la longevidad. En 
esta tesis nos hemos centrado en dos aspectos de la ruta: por un lado, hemos analizado los 
efectos in vivo de la inhibición farmacológica de PI3K, un mediador clave de la vía; y en 
segundo lugar, hemos investigado el papel de los genes supresores de tumores en la respuesta al 
ayuno, considerado la forma más agresiva de restricción calórica.   
 La inhibición genética de la señalización de PI3K incrementa el gasto energético, 
protege frente a la obesidad y el síndrome metabólico, y aumenta la longevidad. En este trabajo 
hemos querido verificar si la inhibición farmacológica de PI3K in vivo tenía como resultado 
efectos similares. En concreto, observamos que el tratamiento con dos inhibidores de PI3K, 
CNIO-PI3K y GDC-0941, ambos inhibidores preferentes de las isoformas ! y ", reduce la 
adiposidad de ratones obesos. Además, en un contexto de exceso nutricional, el tratamiento 
prolongado con CNIO-PI3Ki, al inducir el gasto energético, reduce el peso corporal de los 
ratones hasta alcanzar un equilibrio que se mantiene estable mientras se administra el 
tratamiento. Dicho tratamiento revierte la esteatosis hepática, reduce los niveles de glucosa y la 
inflamación. Finalmente, hemos extendido el uso del CNIO-PI3Ki a macacos rhesus, 
demostrando que una dosis oral diaria durante 3 meses disminuye la adiposidad y la glucemia 
en monos obesos en ausencia de toxicidad. Por ello consideramos que la inhibición 
farmacológica de PI3K es una intervención anti-obesidad efectiva y segura en ratones y monos 
obesos, que podría llegar a reducir la adiposidad y revertir algunos síntomas del síndrome 
metabólico en humanos.  
 El ayuno es un estrés fisiológico que promueve múltiples adaptaciones metabólicas y 
moleculares. Sin embargo, teniendo en cuenta que los genes supresores de tumores se activan en 
respuesta a diferentes estímulos, se desconoce el papel que éstos juegan durante el ayuno. Por 
esta razón, analizamos la expresión de varios supresores de tumores en ratones en ayuno, 
descubriendo que únicamente la expresión de p21 se induce en una gran variedad de tejidos, 
especialmente en el hígado (>10 veces), y de manera independiente de p53. Asimismo 
comprobamos que los ratones deficientes en p21 no son capaces de adaptarse eficientemente a 
periodos largos de ayuno (48 horas), ya que presentan síntomas graves de debilidad y una 
pérdida acelerada de energía. Esto es debido a que la ausencia de p21 impide la correcta 
actividad de PPAR!, un factor crítico en la adaptación al ayuno. Por tanto, concluimos que p21 
es un factor inducido en respuesta a ayuno, que regula positivamente la actividad de PPAR! y 
que juega un papel clave en la adaptación al ayuno. 
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1. The insulin/IGF1 signalling pathway  
The insulin/IGF1 signalling (IIS) pathway is one of the most important and highly conserved 
nutrient-sensing pathways. In mammals, the pathway is activated when different growth factors 
such as insulin or IGF1, whose production is stimulated by growth hormone (GH), bind to their 
correspondent receptors and activate PI3K either through a direct binding or through the IRS1 
scaffold protein. Activation of PI3K is followed by phosphorylation of AKT, which, in turn, 
triggers a complex cascade of events that include the activation of mTORC1 and the 
inactivation of FOXO. 
 Importantly, the IIS pathway is the best characterized pathway affecting longevity, as a 
partial reduction of the pathway has been shown to improve healthy lifespan, protect against 
cancer, improve insulin sensitivity and expand lifespan in a great variety of organisms including 
worms, flies and mice (Houtkooper et al., 2010; Kenyon, 2010). In addition, external 
interventions that downregulate insulin/IGF1 signalling such as dietary restriction or rapamycin 
treatment have been shown to be robust anti-aging methods as well (Fontana et al., 2010). 
 
1.1  The insulin/IGF1 axis in longevity 
Ageing is a complex process that results from the accumulation of molecular, cellular and organ 
damage that ultimately leads to a progressive decline in physiological function. Despite this 
complexity, many studies suggest that most of the mutations and interventions that extend 
lifespan in a great variety of organisms are directly related to a downregulation of nutrient-
sensing pathways, such as the insulin/IGF1 and TOR pathways (Houtkooper et al., 2010; 
Kenyon, 2010) (Figure 1).  
 Yeast and invertebrate models have played an important role in establishing the main 
genes, pathways and mechanisms involved in lifespan extension. In S. cerevisiae, deletion or 
inhibition of SCH9 (the S6K homolog) (Fabrizio et al., 2001) and TOR1 (Kaeberlein et al., 
2005; Powers et al., 2006) increases lifespan by more than a 2 fold by providing increased 
resistance against oxidants, genotoxins and heat. Similarly, reduction of the IIS pathway in C. 
elegans by either daf-2 (insulin/IGF1 receptor homolog) (Kenyon et al., 1993), age-1 (PI3K 
homolog) mutation (Friedman and Johnson, 1988) or reduction of TOR (Jia et al., 2004), leads 
to an extension in the lifespan of about 65-100%. This lifespan expansion depends on the 
enhanced activity of the forkhead FOXO transcription factor daf-16 (Libina et al., 2003), which 
regulates the expression of genes like superoxide dismutase (MnSOD) and heat shock proteins 
(HSPs) involved in oxidative and stress resistance respectively. In D. melanogaster, genetic 
deletion of insulin-like peptides (dilps) (Gronke et al., 2010) or insulin receptor substrate Chico 
(Clancy et al., 2001), as well as the downregulation of the TOR pathway activity either 
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genetically (Kapahi et al., 2004) or by rapamycin (Bjedov et al., 2010), also increases longevity. 
This has been associated with an increase in stress resistance and autophagy together with a 
reduction in protein turnover.  
 As in yeast, worms and flies, reduced activity of the nutrient-sensing IIS pathway can 
increase lifespan in mouse in about a 20-70% depending on gender, mouse background and diet 
(Bartke, 2005). Mutations in genes that impair the biosynthesis, binding or activity of GH and 
IGF1 (Junnila et al., 2013) as well as alterations in various downstream members of the 
pathway such as PTEN upregulation (Ortega-Molina et al., 2012) or deletion of PI3K! (Foukas 
et al., 2013) lead to lifespan extension in mouse. In addition, inhibition of the mTOR pathway 
either with rapamycin treatment (Harrison et al., 2009) or deletion of S6K1 (Selman et al., 2009) 
has been demonstrated to promote lifespan too. Some of the mechanisms thought to be involved 
in this lifespan extension include reduced inflammation, proliferation, oxidative damage and ER 
stress, accompanied by increased autophagy, regenerative capacity, and mitochondrial function.  
 Lastly, studies of human populations have led to the identification of a number naturally 
occurring deficiencies in the GH/IGF1 axis associated with reduced cancer incidence, insulin 
sensitivity and, possibly, increased longevity. This is the case of subjects with GH-receptor, 
IGF1 and IGF1-receptor deficiencies (Guevara-Aguirre et al., 2011; Laron, 2008). 
 
1.2  Dietary restriction 
To date, dietary restriction is the most robust and best-characterized intervention to extend 
lifespan. Numerous studies demonstrate that dietary restriction (DR), avoiding malnutrition, 
expands lifespan in a great variety of organisms including yeast, flies, worms, fish and rodents, 
and increases healthy lifespan in primates (Fontana and Partridge, 2015; Fontana et al., 2010) 
(Figure 1).  
 In the case of mouse, a reduction in food intake of about 25-55% results in a 30-50% 
lifespan extension (Weindruch et al., 1986). Of note, DR inhibits spontaneous, chemically-
induced and radiation-induced tumours in several mouse models (Albanes, 1987; Thompson et 
al., 2003). In monkeys DR greatly delays the onset of age-associated pathologies such as 
sarcopenia, presbycusis and brain atrophy as well as reduces the incidence of type II diabetes, 
cancer and cardiovascular disease (Colman et al., 2014; Mattison et al., 2012). Importantly, in 
humans DR promotes healthy lifespan by reducing the incidence of type II diabetes, insulin 
resistance, inflammation, cancer and cardiovascular disease (Cava and Fontana, 2013; Fontana 
et al., 2010).  
INTRODUCTION 
 
25 
apoptosis, DNA repair, stress resistance, autophagy, stem 
cell function, mitochondrial function, tissue repair, 
immunosurveillance, regenaration 
healthspan & longevity!
TOR 
SCH9 
RIM15 
yeast!
glucose 
amino acids DR!
AGE-1 
TOR AKT 
RSK-1 DAF-16 
    HIF-1 
worms!
ins/IGF1-like 
DAF-2 
DR!
PI3K 
TOR AKT 
S6K FOXO 
    ? 
flies!
ins/IGF1-like 
INR 
CHICO 
4E-BP 
DR!
RAPA!
GH 
PI3K 
TOR AKT 
S6K 
GHR 
FOXO 
    ? 
mammals!
IGF1 
IGF1R 
DR!
RAPA!
 Although the mechanisms and key players responsible for the beneficial health effects 
observed under DR are still poorly understood, it is well accepted that, at least in part, some of 
them are mediated by the reduction of IGF1 levels and consequent inhibition of the PI3K/AKT 
pathway and enhanced FOXO activity. FOXO not only reduces proliferation but also stimulates 
apoptosis, DNA repair, stress resistance and autophagy (Webb and Brunet, 2014). Another key 
player accounting for the positive effects of DR is mTOR (Johnson et al., 2013), whose 
reduction improves proteostasis and increases autophagy (Rubinsztein et al., 2011). The 
activation of SIRT1 (Guarente, 2013) and AMPK (Burkewitz et al., 2014) are also considered 
key mechanisms that promote longevity under DR by enhancing genome stability together with 
reduced NF-$B signalling and antioxidant defences, respectively. As a consequence of all these 
adaptations, organisms show increased genome stability, stem cell and mitochondrial function, 
autophagy, stress resistance and tissue repair accompanied by a reduced inflammatory response 
that may eventually contribute to the observed and health- and liespan expansion (Fontana and 
Partridge, 2015).  
 Importantly, further reports have demonstrated that it is the restriction of proteins, 
particularly of methionine, rather than the total calorie intake restriction the leading cause that 
promotes lifespan extension in model organisms. This is thought to me mediated via the 
suppression of mTOR activity (Solon-Biet et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Conserved role of the insulin/IGF1 signalling (IIS) pathway in ageing. 
The IIS pathway is conserved across various species including yeast, worms, flies and mammals. The pathway is 
activated upon binding of insulin/IGF1 to their receptor, which, in turn, activates PI3K and AKT. Following 
activation, AKT induces the activity of FOXO and TOR/S6K, two of the principal mediators of healthspan and 
longevity extension that stimulate apoptosis, DNA repair, stress resistance, autophagy, stem cell function, 
mitochondrial function, tissue repair, immunosurveillance and regeneration. External interventions such as dietary 
restriction (which reduces nutrients and IGF1 levels) as well as rapamycin treatment (which inhibits TOR) reduce the 
activity of the pathway and delay ageing and age-associated diseases.  
DR: dietary restriction. Homologous pathways and proteins are indicated with the same colour code. Figure adapted 
from (Fontana et al., 2010). 
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2. The phosphatidylinositol 3 kinase PI3K 
Phosphatidylinositol-3-kinases (PI3Ks) are a family of proteins involved in multiple cellular 
functions such as cell growth, proliferation, metabolism, glucose homeostasis, differentiation 
and survival (Engelman et al., 2006). They are divided into three different members according 
to their structural characteristics and substrate specificity (Table 1): class I, class II and class III 
(Vanhaesebroeck et al., 2010). 
 Class I PI3Ks, which are further divided into class IA and IB, are a group of PI3Ks 
located right in the centre of the insulin/IGF1 pathway that are able to phosphorylate the inositol 
ring of the membrane phospholipid phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to 
generate phosphatidylinositol-3,4,5-trisphosphate (PIP3) upon activation. Class IA PI3Ks are 
composed of heterodimers consisting of a p110 catalytic subunit (p110!, p110# or p110") that 
interacts with a p85 regulatory subunit (p85!, p85#, p55!, p50! or p55%). While p110! and 
p110# are ubiquitously expressed, p110" is principally present in hematopoietic cells and, to a 
lesser extent, in the nervous system (Eickholt et al., 2007). Although class IA PI3K are 
predominantly activated by receptor tyrosine kinases (RTKs), recent data demonstrate that they 
can also respond to G protein-coupled receptors (GPCRs). Class IB PI3Ks consist of a single 
type of catalytic subunit (p110%), which is activated by directly interacting with the G#% subunit 
of GPCRs, and a regulatory subunit (p87 or p101). In contrast to class IA PI3Ks, class IB is 
primarily expressed in leukocytes but can also be found in the liver, skeletal muscle, heart and 
pancreas. Of note, the signal transmitting small GTPase Ras plays a primordial role in the 
activation of both class I PI3Ks by RTKs (Katso et al., 2001; Vanhaesebroeck et al., 2010). 
 Class II PI3Ks consist of a single catalytic isoform (C2!, C2# or C2%), as they do not 
require a regulatory subunit to function. These PI3Ks utilize phosphatidylinositol (PI) or 
phosphatidylinositol-4-phosphate (PI-4-P) to produce phosphatidylinositol-3-phosphate (PI-3-P) 
and phosphatidylinositol-3,4-bisphosphate (PI-3,4-P2) respectively. Following activation by 
RTKs or GPCRs, class II PI3Ks can stimulate cell migration, glucose metabolism, exocytosis 
and apoptosis, through a mechanism that is still unclear (Falasca and Maffucci, 2012).  
 Class III PI3Ks, which consist of the catalytic subunit VPS34 associated to the 
regulatory subunit VPS15, promote the phosphorylation of PI to form PI-3-P. VPS34 is located 
at autophagosomal or endosomal structures and is involved in vesicle trafficking. Even though it 
is not clear whether class III PI3K are regulated by extracellular stimuli, there is evidence that 
VPS34 activity can be regulated by GPCRs, glucose and amino acids, thereby mediating 
signalling through mTOR (Backer, 2008; Nobukuni et al., 2005; Schu et al., 1993).  
 As class I PI3K is the most studied member of the family and study-objective of this 
thesis, we will continue focussing on this class, referring to it as PI3K. 
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Table 1. The three PI3K classes. 
The phosphatidylinositol-3-kinases (PI3Ks) are divided into three different classes characterized by specific catalytic 
and regulatory subunits, distribution, substrate specificity and activity, PI3K activator and function.  
 
2.1 The canonical PI3K/AKT pathway  
The PI3K/AKT pathway can be activated in response to nutrient and growth factor stimulation 
including insulin, IGF1, cytokines or chemokines, thereby regulating cellular growth, 
metabolism and survival (Manning and Cantley, 2007) (Figure 2). Upon binding of these 
factors to their correspondent RTKs and consequent activation, PI3K is recruited to the 
membrane by a direct interaction of the p85 subunit with the tyrosine phosphate motifs on 
receptors, by binding of p85 to the scaffold protein IRS1, or through the interaction with RAS. 
As previously mentioned, PI3K can also be activated by GPCRs through the binding to the #% 
subunit (Carracedo and Pandolfi, 2008). Once active, PI3K phosphorylates the membrane 
phospholipid PI-4,5-P2 to generate PIP3 at the cytoplasmic face of the plasma membrane. PIP3 
acts then as a second messenger by transmitting the signal to a subset of pleckstrin homology 
(PH) and PH-like domain containing proteins (Engelman et al., 2006) such as AKT (Franke et 
al., 1997) , PDK1 (Currie et al., 1999) and mTORC2 (Liu et al., 2015), this last one consisting 
of the mTOR, Rictor, MSin1 (PH-containing subunit) and mLST8 proteins. After PIP3 
stimulation, AKT anchors to the plasma membrane together with PDK1 and mTORC2, which 
fully activate AKT by phosphorylating AKT in Thr308 (Alessi et al., 1997; Stephens et al., 
1998) and Ser473 residue (Dos et al., 2004; Sarbassov et al., 2005) respectively. Once activated, 
AKT is able to phosphorylate up to 100 different substrates and is thereby responsible of 
modulating a great variety of cellular functions including most of the well-described PI3K 
responses.  
 AKT activity negatively regulates FOXO phosphorylating FOXO1 at Thr24, Ser256 
and Ser319 (Rena et al., 1999) as well as FOXO3 (Brunet et al., 1999) and FOXO4 (Kops et al., 
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1999) at equivalent sites. This phosphorylation leads to FOXO retention in the cytoplasm and 
inhibition of FOXO activity (Biggs et al., 1999; Tang et al., 1999). Thus, AKT is able to block 
the FOXO-dependent transcriptional programme of genes involved in gluconeogenesis (PEPCK 
and G6Pc) (Hall et al., 2000; Schmoll et al., 2000), oxidative stress resistance (SOD and 
MnSOD) (Kops et al., 2002), apoptosis (PUMA and BIM) (Sunters et al., 2003; You et al., 2006) 
and cell proliferation (p21Cip1 and p27Kip1) (Dijkers et al., 2000; Seoane et al., 2004). Moreover, 
AKT phosphorylates and inhibits PGC1!, which is a transcriptional coactivator that, together 
with FOXO1, promotes the transcription of genes related to fatty acid #-oxidation and 
gluconeogenesis (Puigserver et al., 2003). AKT plays also an important role in promoting 
glucose transport in response to insulin stimulation. By phosphorylating AS160, AKT is able to 
inhibit its GAP activity and stimulate the vesicle translocation of GLUT4 to the plasma 
membrane, thereby allowing the influx of glucose to the cytoplasm (Sano et al., 2003). 
Furthermore, AKT phosphorylates and inhibits GSK3# (Cross et al., 1995), thus promoting 
glycogen synthesis (through the activation of glycogen synthase) as well as lipid synthesis 
(through the stabilization of SREBP1). Besides, AKT also exerts an important antiapoptotic 
effect through the phosphorylation and inhibition of BAD (del Peso et al., 1997), MDM2 (Mayo 
and Donner, 2001) and members of the FOXO family (Biggs et al., 1999; Tang et al., 1999). In 
particular, AKT promotes the translocation of MDM2 to the nucleus by phosphorylating the 
Ser166 and Ser186 residues of MDM2, which finally negatively regulates p53 (Mayo and 
Donner, 2001; Zhou et al., 2001). 
 Additionally, AKT is one of the main regulators of mTORC1, a protein complex 
involved in autophagy, energy metabolism, protein translation and ribosome biogenesis, that is 
composed of the catalytic subunit mTOR, the regulatory subunit Raptor, the protein mLST8 and 
two endogenous inhibitors of the complex called PRAS40 (proline-rich AKT substrate of 40 
kDa) and Deptor (DEP domain-containing mTOR-interacting protein) (Laplante and Sabatini, 
2013). Active AKT regulates this complex in two different ways. On the one hand, AKT 
phosphorylates and inactivates the GTPase-activating protein (GAP) called TSC2 (Potter et al., 
2002), which, in turn, forms a complex with TSC1 to inhibit the small GTPase Rheb (Ras-
homolog enriched in brain) (Inoki et al., 2003a). Rheb is then responsible of activating 
mTORC1 through the inhibition of FKBP38, which is a negative regulator of mTORC1 (Bai et 
al., 2007). On the other hand, AKT regulates mTORC1 activity by phosphorylating and 
inhibiting PRAS40, which is a negative regulator of mTORC1 through the competition of 
GTPase Rheb (Sancak et al., 2007; Wang et al., 2007). Once active, mTORC1 phosphorylates 
and activates S6K1 and S6K2 (Brown et al., 1995) thereby triggering the phosphorylation of 
different substrates including the ribosomal protein S6 (Chung et al., 1992), PDCD4 (Dorrello 
et al., 2006), eEF2 kinase (Wang et al., 2001) and eIF4B (Raught et al., 2004) to promote 
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protein synthesis and ribosome biogenesis. Additionally, mTORC1 also phosphorylates and 
inactivates 4E-binding protein 1 (4EBP1), thereby releasing the inhibition of the eukaryotic 
initiation factor 4E (eIF4E) and promoting protein translation (Brown et al., 1995).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The PI3K/AKT signalling pathway. 
Representation of the main proteins, interactions and processes involved in the PI3K/AKT signalling pathway.  
Small yellow circles indicate phosphoryl groups.  
 
2.2 Regulation of PI3K  
The PI3K/AKT pathway is tightly regulated at various levels, but, even though the intensity of 
PI3K activation is regulated by a number of proteins, the phosphatase and tensin homolog 
deleted on chromosome ten (PTEN) is the main negative regulator of the pathway. PTEN is a 
lipid phosphatase with a lipid-binding domain that allows anchorage to the plasma membrane. 
Importantly, PTEN counteracts the activity of PI3K by converting PIP3 back to PI-4,5-PI2 
(Maehama and Dixon, 1998; Stambolic et al., 1998) (Figure 2). Downstream of PI3K, the 
activation of AKT is also negatively regulated by different proteins. While the 
dephosphorylation of the Thr308 residue is mediated by PP2A phosphatase (Padmanabhan et al., 
2009), PHLPP phosphatase dephosphorylates AKT at Ser473 (Gao et al., 2005). Furthermore, 
the pseudokinase tribbles homolog 3 (TRIB3) is able to bind and inhibit AKT in response to 
insulin stimulation (Du et al., 2003). In contrast, some members of the FOXO family can 
positively regulate the PI3K/AKT pathway, through the inhibition of the PP2A phosphatase (Ni 
et al., 2007) and transcriptional activation of some RTKs, including the insulin receptor, upon 
AKT inhibition (Chandarlapaty et al., 2011).  
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 PI3K is further controlled by downstream components of the pathway, thereby 
providing feedback regulation in response to extracellular signals. The most important negative 
feedback mechanism is the one driven by mTORC1 and S6K (Figure 2). First observations 
revealed that chronic insulin stimulation and consequent PI3K pathway hyperactivation lead to 
the phosphorylation and proteosomal degradation of the adaptor protein IRS1 (Haruta et al., 
2000; Qiao et al., 2002; Zhande et al., 2002). Later studies showed that S6K1 phosphorylated 
and inhibited IRS1 on Ser302 (Harrington et al., 2004) and Ser1101 (Tremblay et al., 2007), 
preventing its recruitment and binding to RTKs and leading to reduced PI3K signalling. 
Similarly, mTORC1 can phosphorylate IRS1 on Ser636/639 (Tzatsos and Kandror, 2006), 
thereby reducing its activity. Altogether, this explains why the hyperactivity of the pathway 
caused by chronic exposure to insulin results in the desensitization of the PI3K/AKT pathway 
and can lead to insulin resistance. 
 
2.3 Role of the PI3K pathway in cancer  
The role of the PI3K pathway in different diseases has been widely studied since its discovery. 
It is not surprising that, being a central mediator of survival and growth signals, aberrations in 
many of the members of the pathway have specially been associated with cancer as well as with 
various cancer susceptibility syndromes in humans.    
 The first direct link between PI3K activity and human cancer was established with the 
study of PTEN function which was found to be highly mutated and lost in several cancers (Li 
and Sun, 1997; Li et al., 1997; Steck et al., 1997). PTEN is considered one of the major tumour 
suppressor genes due to its ability to reduce PI3K signalling and, thereby, cell growth and 
survival. Mutations in the catalytic domain (Sansal and Sellers, 2004) or in ubiquitinylation 
sites (Trotman et al., 2007) correlate with the development and progression of cancer. In fact, 
PTEN is mutated in about 38% of the endometrial carcinomas, 21% of brain tumours, 17% of 
skin cancers, and 13% of colon carcinomas. Similarly, 25-37% of all the glioblastomas, 
melanoma and gastric and breast cancers present PTEN heterozygosity loss (Liu et al., 2009). 
Furthermore, germline mutations in the PTEN gene cause various inherited cancer 
predisposition syndromes such as Cowden’s syndrome, Lhermitte-Duclos and Bannayan-Riley-
Ruvalcaba’s syndrome (Eng, 2003). PI3K class IA is another member of the pathway that is 
frequently mutated and amplified in a wide variety of cancers (Samuels et al., 2004). Mutations 
in both, the catalytic p110! as well as the regulatory p85! subunit of PI3K, which lead to 
increased PI3K and AKT activity, are common alterations appearing in around 27% of breast 
cancers, 15% of colon cancers, 8% of pancreas cancers or 10% of glioblastomas (Liu et al., 
2009). Finally, amplification of the AKT (Liu et al., 2009) or PDK1 genes (Brugge et al., 2007), 
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have also been found in a number of different tumour types, and alterations in the TSC genes 
result in the development of an autosomal dominant disease called tuberous sclerosis, 
characterized by the formation of hamartomas in brain, heart, lung and kidney, 
angiomyolipomas and rhabdomyomas (Jozwiak et al., 2008). 
 
2.4  Role of the PI3K pathway in metabolic disorders 
As previously described, the PI3K/AKT pathway triggers a cascade of responses important for 
metabolic signals and glucose homeostasis.  
 Many studies in mouse models and the further support of clinical data have made clear 
that reduced PI3K activity plays a crucial role in insulin sensitivity and type II diabetes, among 
other metabolic disorders. In this context, p85, the regulatory subunit of PI3K IA, is involved in 
mediating insulin sensitivity. Despite being responsible for the stability of the catalytic subunit 
p110 (Yu et al., 1998) and for its recruitment to activated growth factor receptors or the adaptor 
protein IRS1 (Cantley, 2002), heterozygous deletion of p85! (Terauchi et al., 1999) and 
homozygous deletion of p85# in mouse  (Ueki et al., 2002), leads to improved insulin signalling 
and enhanced insulin-stimulated AKT activation. This apparent contradiction can be explained 
by the fact that monomeric p85, which appears in excess in many cell types, competes with p85-
p110 heterodimers for binding to and sequestering IRS1 in cytosolic protein complexes (Luo et 
al., 2005). Thus, reduced levels of monomeric p85 results in enhanced binding of p85-p110 
PI3K heterodimers to IRS and increased insulin sensitivity.  
 Furthermore, a great number of mouse studies suggest that PI3K plays an important role 
in setting the balance between nutrient storage and nutrient consumption, contributing in this 
manner to a differential fat accumulation. In general, overall reduction of PI3K signalling due to 
PTEN overexpression leads to enhanced energy expenditure and, thereby, to reduced body 
weight and enhanced metabolic damage protection (Figure 3) (Garcia-Cao et al., 2012; Ortega-
Molina et al., 2012). This increase in energy expenditure has been proposed to be mediated 
through two independent mechanisms. On the one hand, PI3K inhibition was shown to induce 
thermogenesis, and therefore energy expenditure, in the brown adipose tissue through the 
upregulation of ucp1 directly driven by FOXO1 (Ortega-Molina et al., 2012). On the other hand, 
it has been suggested that PTEN overexpression leads to increased mitochondrial oxidative 
phosphorylation together with reduced anaerobic glycolysis, which would eventually enhance 
energy expenditure (Garcia-Cao et al., 2012). Notably, PTEN-overexpressing mice are 
characterized by a cancer-protective state, improved insulin sensitivity and extended lifespan 
(Ortega-Molina et al., 2012). Further reinforcing this idea, inhibition of single PI3K isoforms 
also achieves similar metabolic effects. In particular, mice with systemic partial decreased 
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PI3K! signalling (Foukas et al., 2013), liver-specific complete loss of PI3K! (Chattopadhyay et 
al., 2011), total lack of PI3K% activity (Becattini et al., 2011; Kobayashi et al., 2011) or 
combined complete loss of PI3K% and PI3K# activities (Perino et al., 2014) are protected from 
obesity due to an enhanced energy expenditure. Also, S6K1-deficient mice exhibit enhanced 
lipolysis, reduced adipose tissue and HFD-induced metabolic damage protection (Um et al., 
2004) as well as extended lifespan (Selman et al., 2009). 
 Finally, data obtained from human patients further support a conserved role for this 
pathway in diabetes and obesity. For instance, p85 levels are increased in some patients with 
insulin resistance and AKT2 appears mutated in familiar insulin resistance. Furthermore, there 
is a strong association between hyperactive PI3K signalling due to germline PTEN 
haploinsufficiency and obesity (Pal et al., 2012).  
 
 
 
 
 
2.5  Targeting the PI3K/AKT/mTOR pathway 
Developing effective inhibitors that target PI3K and other key components of the pathway 
represents a major goal for the treatment of a number of diseases, including (but not 
exclusively) cancer types with increased PI3K activity. In fact, some of these compounds are 
already being tested in preclinical phase I-II trials for the treatment of a great variety of tumours 
(Liu et al., 2009). The first generation of PI3K inhibitors, wortmannin and LY294002, were 
broad-spectrum inhibitors with restricted selectivity for individual PI3K isoforms and 
significant toxicity associated (Knight and Shokat, 2007). However, new isoform-selective 
PI3K inhibitors (CAL-101, selective p110", and BYL-719, selective p110!) or dual PI3K-
mTOR inhibitors (SF1126 or BEZ235) are being introduced into preclinical trials for the 
treatment of advanced solid tumours and lymphomas showing more effective results (Liu et al., 
2009). 
 Another attractive target of the pathway, and probably the most studied one since the 
discovery of rapamycin, is mTORC1. Rapamycin is a bacterially derived product able to 
suppress mTOR-mediated S6K and 4EBP1 phosphorylation by forming a complex with 
FKBP12, which then binds directly to the mammalian TOR complex 1 (mTORC1) but not to 
mTORC2 (Benjamin et al., 2011; Sabatini, 2006). Originally used as an antifungal agent 
(Vézina et al., 1975), rapamycin was subsequently found to have important immunosuppressant 
functions in humans and is therefore used to prevent rejection in organ transplantation (Yatscoff 
Figure 3. Effects of genetic PI3K 
downregulation.  
Mice with reduced PI3K activity due to PTEN 
overexpression are characterized by cancer 
protection, increased energy expenditure, 
obesity protection, enhanced insulin 
sensitivity and extended longevity.  !
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et al., 1993). Even though rapamycin and rapamycin-related mTOR inhibitors present a low 
efficiency and response rate against tumour progression in some types of tumours, these have 
been approved for the treatment of renal cell carcinoma, soft-tissue and bone sarcomas and have 
also shown promising results for the treatment of TSC-associated symptoms (Faivre et al., 
2006). Of note, and as previously discussed, rapamycin treatment increases lifespan in a number 
of organisms including mice (Fontana et al., 2010). 
 Interestingly, and despite the numerous reports that suggest that reduced PI3K activity 
may protect against obesity and symptoms of the metabolic syndrome, there are currently no 
PI3K inhibitors approved for the use in obesity treatment. In this context, previous studies in 
our laboratory demonstrated that a synthetic PI3K inhibitor (CNIO-PI3Ki) is able to increase 
energy expenditure and hyperactivate the BAT of mice (Ortega-Molina et al., 2012). 
 
3. Pathophysiological implications of obesity 
In contrast to the beneficial effects of dietary restriction and reduced PI3K signalling, obesity is 
emerging as a major global public health problem due to the numerous pathologies associated to 
obesity such as type II diabetes, insulin resistance, hepatic steatosis and cancer (Figure 4). The 
worldwide prevalence of obesity has nearly doubled between 1980 and 2008 (Caballero, 2007) 
and the incidence in developing countries has risen 3-fold (Ellulu et al., 2014). As an example, 
in 2011-2012, it was estimated that over one-third of the US adult population was obese or 
overweight (Ogden et al., 2014).  
 Typically, obesity appears when nutrient intake exceeds nutrient consumption. Initially, 
this gain in net caloric intake, driven by hypercaloric or fat-rich diets combined with a lack of 
physical exercise, results in obesity due to the hypertrophy and hyperplasia of the adipose tissue. 
However, the continuous caloric overload finally leads to the aberrant accumulation of lipids in 
non-adipose tissues including liver and muscle (Van Der Klaauw and Farooqi, 2015).  
 Obesity is tightly associated with the metabolic syndrome; a pathophysiological 
condition characterized by the presence of at least three of the following medical signs 
occurring at the same time: abdominal obesity, hypertension, hyperglycemia, and dyslipidemia, 
which includes hypertriglyceridemia or low high-density lipoprotein (HDL) levels (Després and 
Lemieux, 2006). The metabolic syndrome, as well as obesity, is correlated with a higher risk of 
developing insulin resistance and type II diabetes (Figure 4). Insulin resistance is characterized 
by the presence of cells that are resistant to insulin action, thereby compromising glucose 
uptake in the tissues and increasing glucose production in the liver, which finally gives rise to 
hyperglycemia (Kahn et al., 2006). Although obesity triggers insulin resistance by diverse 
mechanisms, it is mostly accepted that elevated non-esterified fatty acids (NEFAs) arising from 
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adipocytes play a key role in two different ways. On the one hand, increased intracellular 
NEFAs result in competition with glucose for oxidation, which leads to the downregulation of 
glycolysis by inhibiting pyruvate dehydrogenase, phosphofructokinase and hexokinase II 
(Randle, 1998). On the other hand, high NEFA levels result in the inhibitory phosphorylation of 
IRS1 and IRS2 and eventual suppression of the downstream insulin signalling (Solinas et al., 
2006). The systemic increase in proinflammatory cytokines secreted by the adipose tissue also 
contributes to insulin resistance as TNF! (Zhang et al., 2002) and IL-6 (Yang et al., 2008) 
increase adipocyte lipolytic activity and thus, increase NEFA concentration, as well as mediate 
IRS1 and IRS2 inhibitory phosphorylation. Depending on pancreatic #-cell function, insulin 
resistance can progress to type II diabetes. In the context of healthy #-cells, elevated glucose 
levels lead to compensatory hyperinsulinemia and glucose tolerance through the increase of #-
cell function and growth. In contrast, susceptible pancreatic #-cells carrying genetic risk factors, 
result in #-cell dysfunction and apoptosis in response to increased glucose levels, leading to 
impaired glucose tolerance and followed by the development of type II diabetes (Kahn et al., 
2006).  
 Importantly, obesity is also considered a major risk factor not only for type II diabetes 
but also for other age-related pathologies including cardiovascular disease, neurodegenerative 
diseases and cancer (Haslam and James, 2005). In particular, several epidemiological studies 
have consistently shown a link between obesity and an elevated incidence of some cancer types 
such as colon, liver, pancreas, kidney and breast (Calle and Kaaks, 2004). Obesity increases the 
risk of developing cancer through a number of mechanisms and pathophysiological alterations 
that include changes in the production of hormones, adipokines and cytokines (Font-Burgada et 
al., 2016) (Figure 4). Obesity is characterized by systemic inflammation and a higher presence 
of pro-inflammatory M1 macrophages in the white adipose tissue that produce tumour-
promoting cytokines such as TNF and IL6 (McNelis and Olefsky, 2014). Both are able to 
induce survival, proliferation, DNA damage, stemness and invasiveness by activating NF-
$B/JNK and STAT3 respectively (Taniguchi and Karin, 2014; Yan et al., 2006). The altered 
secretion of adipokines, including low adiponectin and high leptin production, is another feature 
that can lead to tumourigenesis under obesity conditions. Whereas adiponectin is considered an 
inhibitor of tumour progression due to its ability to inhibit mTOR, activate AMPK and reduce 
inflammation (Dalamaga et al., 2012), leptin exerts a pro-tumourigenic effect by enhancing 
angiogenesis through the activation of STAT3 (Uddin et al., 2011). Furthermore, 
hyperinsulinemia and hypergylcemia are also two important tumour-promoting effectors 
derived from obesity-induced insulin resistance. Both, insulin and glucose exert an important 
cell survival, growth and proliferative promoting effect, especially in pre-neoplastic cells. 
Moreover, high glucose levels favour the increased survival of cancer cells under hypoxic 
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Figure 4. Pathophysiological implications of obesity.  
Obesity appears as a consequence of a positive energy 
balance that leads to visceral as well as aberrant fat 
accumulation in organs including liver and muscle. In 
a process in which the increased release of 
proinflammatory cytokines and NEFAs by the adipose 
tissue plays a determinant role, obesity is a major risk 
factor for the development of metabolic syndrome and 
conditions due to the activation of HIF1! (Catrina et al., 2004). Similarly, high-fat diet has been 
shown to increase stemness and tumourigenicity of intestinal stem and progenitor cells through 
a PPAR"-dependent mechanism (Beyaz et al., 2016). 
 As a consequence of the influence of obesity on tumourigenesis, it is considered that 
around 14% and 20% of all cancer deaths in men and women, respectively, are due in part to 
overweight and obesity. And, furthermore, it is estimated that the overall risk of death from 
cancer is around 1.5 fold higher in obese patients (Font-Burgada et al., 2016). However, despite 
the increasing number of obesity and overweight incidence worldwide and the important health 
implications, there are currently limited pharmacological treatments available to treat obesity. 
 
 
 
 
 
 
 
 
 
 
 
 
t   t  l t  t li  r   insulin resistance. In turn, insulin resistance can progress to 
type II diabetes in the context of susceptible pancreatic #-cells. Obesity is also considered an important risk factor for 
cancer. NEFA: non-esterified fatty acid, WAT: white adipose tissue. 
 
4. The fasting response 
DR is a potent intervention to extend healthy lifespan and longevity in a great number of 
organisms. In worms, flies and mice lifespan rises to a maximum as food intake is lowered but, 
with further reduction of food intake, longevity is rapidly reduced. Fasting is the most extreme 
form of DR and requires abstinence from all food, but not from water. Nevertheless, studies in 
experimental organisms as well as in humans indicate that fasting periods may provide effective 
strategies to delay ageing and improve healthspan (Longo and Mattson, 2014).  
 In lower organisms such as bacteria (Gonidakis et al., 2010), yeast (Wei et al., 2008) 
and worms (Kaeberlein et al., 2006) food deprivation causes a 2-fold lifespan extension as well 
as an increase in the resistance to multiple stresses mainly driven by the downregulation of the 
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TOR-S6K pathway and upregulation of FOXO transcriptional activity. In the case of mammals, 
fasting can be applied in a chronic manner as intermittent fasting. Several studies have shown 
that intermittent fasting can extend lifespan up to 30% (Goodrick et al., 1990) and promote 
protection against several age-associated diseases in rodents. In fact, intermittent fasting reduces 
the incidence of neurodegenerative diseases including Alzheimer, Parkinson and Huntington, by 
reducing inflammation and the accumulation of oxidatively damaged molecules, as well as by 
improving cellular bioenergetics, neurotrophic factor signalling, and increasing synaptic 
plasticity (Mattson, 2012). As in the case of DR, fasting can prevent and reverse all aspects of 
the metabolic syndrome, reduce obesity, inflammation and blood pressure and increase insulin 
sensitivity (Longo and Mattson, 2014). Importantly, alternative day fasting has been 
demonstrated to reduce cancer incidence (Varady and Hellerstein, 2007) and improve cancer 
treatment by selectively protecting normal cells, but not cancerous cells, from chemotherapeutic 
agents (Lee et al., 2012; Raffaghello et al., 2008). This effect, called differential stress 
resistance, has been demonstrated on different cancer cells and mouse models treated with 
chemotherapy. Differential stress resistance is based on the hypothesis that, in response to 
fasting, normal, healthy cells enter a state characterized by low proliferation and resistance to 
several stresses due to the downregulation of the PI3K/AKT signalling pathway among others. 
In contrast, activation of oncogenic pathways renders cancer cells insensitive to growth 
inhibitory signals and unable to switch to a stress resistance mode. Thus, upon fasting, 
chemotherapeutics that target actively proliferating cells retain their efficacy on malignant, 
cancer cells, without causing side effects on normal cells.  
 Furthermore, clinical and epidemiological data support the ability of fasting to delay 
aging and age-associated diseases in humans. Besides promoting a reduction of oxidative 
damage (Johnson et al., 2007), inflammation (Müller et al., 2001) and blood pressure (Varady et 
al., 2009), fasting has been shown to enhance insulin sensitivity (Harvie et al., 2011) and 
decrease chemotherapy-induced side effects (Raffaghello et al., 2010; Safdie et al., 2009) in 
patients. It is thought that the inhibition of mTOR and, specially, the reduction in circulating 
IGF1 levels, which induce FOXO, autophagy and improved mitochondrial function among 
others, account for the observed positive effects of fasting (Longo and Mattson, 2014).  
 
4.1  Physiological adaptations to fasting 
Throughout evolution, organisms have developed different behavioural, physiological, 
biochemical and molecular mechanisms to efficiently adapt to fluctuations in nutrient 
availability. In particular, fasting is signalled through highly conserved nutrient-sensing 
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pathways that promote the arrest of energy- and nutrient-consuming anabolic processes aimed 
to reduce energy consumption (Wang et al., 2006).  
 During the adaptive response to fasting, mammals go through four different metabolic 
stages that are essentially controlled by the liver (Cahill, 2006; Wang et al., 2006) (Figure 5): 
1. First, as glucose is consumed and cleared from the serum, hepatic glycogen serves as the 
main source of glucose. In a process called glycogenolysis, glucose, stored in the liver in the 
form of glycogen, is released again to the bloodstream to maintain constant blood glucose 
levels. Typically in humans, glucose from the diet is consumed within the first 4 hours. 
Glycogen becomes then the major glucose source for the next 4-16 hours, although glycogen 
stores last for more than 28 hours. In mice, glycogen stores are already completely consumed 
after 18-24 hours.  
2. After liver glycogen stores are depleted, gluconeogenesis becomes necessary to cover the 
energetic requirements of organs, especially the brain, by allowing the production of glucose 
from gluconeogenic substrates. Gluconeogenesis, which is a process that takes place mainly 
in the liver and partially covers the reverse steps of glycolysis, generates glucose from amino 
acids, lactate, glycerol and pyruvate generated in hepatocytes or delivered from extrahepatic 
tissues through the circulation. Gluconeogenesis becomes necessary in humans after ca. 16 
hours of fasting, turning into the main glucose supply for more than 24 days. In mouse, 
however, gluconeogenesis begins already 12 hours post-fasting.  
3. At the same time, glycerol and non-esterified fatty acids (NEFAs) are released by the 
adipose tissue into the bloodstream upon lipolysis of triglyceride stores. NEFAs become then 
the major energy source not only through their #-oxidation but also through their conversion 
to ketone bodies in the liver via ketogenesis. Ketone bodies, consisting of #-
hydroxybutyrate, acetoacetate and acetone, are produced in hepatocytes from the acetyl-CoA 
generated from the #-oxidation of fatty acids as well as from ketogenic amino acids (Iso, 
Phe, Tryp, Tyr and Thr). Ketone bodies, especially #-hydroxybutyrate, play an essential role 
in the adaptation to fasting as, unlike most tissues that can use fatty acids for energy, the 
brain relies on ketone bodies in addition to glucose for energy consumption. Ketogenesis 
starts to be indispensible in humans after the second day of fasting. In contrast, mice start to 
depend on ketone body formation already after 24 hours of fasting.   
4. Finally, with prolonged fasting, fat reserves are exhausted, leading to a rapid protein 
degradation in the muscle that is necessary to fuel gluconeogenesis in hepatocytes (Rui, 
2014; Wang et al., 2006). Normally, this process happens in human after 24 days of fasting 
and starts in mouse after 48 hours.   
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WAT: white adipose tissue, FAO: fatty acid #-oxidation, GNG: gluconeogenesis, TG: triglycerides, FA: fatty acids, 
NEFA: non-esterified fatty acids. 
 
 
4.2  Cellular and molecular adaptations to fasting 
Many of the molecular and cellular adaptations necessary for the adaptation to fasting are driven 
by insulin and glucagon, two hormones secreted by pancreatic #- and !-cells, respectively, in 
response to glucose availability. Under fasting conditions and hypoglycemia, reduced 
circulating insulin levels together with elevated glucagon levels promote a metabolic switch 
from an anabolic to a catabolic programme (Lempradl et al., 2015) (Figure 6). 
 The main functions of insulin, which acts by activating the PI3K/AKT pathway as 
previously described, is to increase glucose uptake in the tissues and promote the storage of 
substrates in fat, liver and muscle. Therefore, insulin is considered the primary regulator of 
blood glucose concentration. In the fasted state, reduced insulin levels are translated into 
multiple adaptations that are driven by the downregulation of the PI3K/AKT pathway by insulin. 
Low insulin promotes the release of glucose from glycogen liver stores in two different manners. 
First, reduced AKT activity leads to the activation of GSK3#, which in turn phosphorylates and 
inactivates glycogen synthase, thereby inhibiting glycogen synthesis (Cross et al., 1995). 
Second, by limiting the acetylation of glycogen phosphorylase, low insulin levels allow the 
phosphorylation and activation of glycogen phosphorylase, thereby promoting glycogenolysis 
(Zhang et al., 2012). Simultaneously, reduced insulin/PI3K/AKT signalling promotes 
gluconeogenesis in the liver through the increased activation of FOXO transcription factors that 
upregulate the expression of gluconeogenic genes such as PEPCK and G6Pc (Haeusler et al., 
2010; Puigserver et al., 2003). Additionally, FOXO transcription factors transcribe PDK4, an 
enzyme that inhibits the conversion of pyruvate to acetyl-CoA. This favours the use of pyruvate 
as gluconeogenic substrate and reduces the glycolytic activity of cells (Jeong et al., 2012). Low 
insulin levels further repress glycolysis by diminishing the activity of glucokinase and the 
kinase activity of the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphate 
(PFK-2/FBP-2) (Okar et al., 2001). Finally, insulin also participates in the metabolism of lipids 
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by stimulating the expression and activity of SREBP1, a key transcription factor that activates 
the expression of genes related to fatty acid and lipid synthesis. Thus, reduced insulin signalling 
results in the inhibition of lipogenesis by decreasing the expression of SREBP1 as well as by 
allowing the inhibitory binding of LIPIN1 to SREBP1. Of note, both processes are mediated 
through the reduction of mTORC1/S6K (Wan et al., 2011; Yecies et al., 2011).  
 At the same time, glucagon, which opposes the effects of insulin, is also responsible for 
many of the adaptations to fasting by activating the cAMP/PKA pathway. In response to low 
blood glucose levels, glucagon is secreted to the circulation by pancreatic !-cells and, when 
bound to GPCRs, it activates adenylate cyclase (AC). Active AC produces cAMP from ATP, 
which in turn triggers the activation of PKA (protein kinase A or cAMP-dependent protein 
kinase) and consequently the activation of a cascade of effectors including CREB (Altarejos and 
Montminy, 2011). Under fasting conditions, high glucagon levels promote glycogenolysis 
through different mechanisms mediated by PKA. First, PKA phosphorylates and activates 
glycogen phosphorylase directly or indirectly by inhibiting the acetylation of glycogen 
phosphorylase. PKA is also able to phosphorylate and activate phosphorylase kinase, which, in 
turn, triggers the activation of glycogen phosphorylase (Zhang et al., 2012). Glucagon also 
promotes hepatic gluconeogenesis by stimulating the expression of gluconeogenic genes such as 
PEPCK and G6Pc by CREB, which usually acts together with the coactivator CRTC2 (Herzig 
et al., 2001). PKA can further enhance gluconeogenesis by promoting the dephosphorylation of 
CRTC2, which avoids the degradation of CRTC2 (Wang et al., 2012); by stimulating the 
acetylation of CRTC2 via p300/CBP, which increases both the stability and gluconeogenic 
activity of CRTC2 (Liu et al., 2008); and by dephosphorylating and activating HDACs, which 
deacetylate and activate FOXO transcription factors and thereby FOXO-dependent transcription 
(Mihaylova et al., 2011). Moreover, glucagon supresses glycolysis by stimulating the PKA-
mediated phosphorylation of PFK-2/FBP-2, thereby enhancing its phosphatase activity (Okar et 
al., 2001) and by reducing the expression of the liver pyruvate kinase (L-PK), which suppresses 
the binding of ChREBP to its promoter region (Yamashita et al., 2001). In addition, the 
transcription factor ChREBP is phosphorylated at Ser196 by PKA in response to glucagon 
stimulation, resulting in cytoplasm retention and inactivation (Kawaguchi et al., 2001). On the 
contrary, ChREBP is strongly activated by glucose (Yamashita et al., 2001). Furthermore, 
decreased ChREBP activity not only supresses glycolysis but also lipogenesis due to the 
reduced expression of ChREBP-dependent lipogenic genes such as ACL, ACC, SCD1 and FAS 
(Iizuka et al., 2004).  
 Finally, glucagon is likewise involved in lipid metabolism by stimulating fatty acid#-
oxidation and ketogenesis in the liver. The peroxisome proliferator-activated receptor alpha 
(PPAR!), a nuclear receptor protein activated by fatty acids (Chakravarthy et al., 2009), is the 
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master regulator of both, fatty acid #-oxidation and ketogenesis, as its activity promotes the 
expression of genes involved in fatty acid transport and binding, peroxisomal and mitochondrial 
fatty acid #-oxidation and ketogenesis (Kersten et al., 1999; Pawlak et al., 2015; Wahli and 
Michalik, 2012). Glucagon, can directly induce the transcriptional activity of PPAR! by 
sequentially activating PKA, AMPK and p38 MAPK, leading to the dissociation from PPAR! 
from its repressor HSP90 (Longuet et al., 2008). Multiple PPAR! coactivators have been 
identified to promote PPAR!-dependent #-oxidation and ketogenesis. The peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC1!) is one of the best-
characterized PPAR! coactivators (Vega et al., 2000). PGC1! not only acts as PPAR! 
coactivator to promote fatty acid #-oxidation and ketogenesis, but is also able to activate 
gluconeogenesis by building a transcriptional complex with FOXO1 and HNF4 (Finck and 
Kelly, 2006; Yoon et al., 2001). Upon fasting, both, reduced insulin and high glucagon blood 
levels induce the expression of PGC1! through the stimulation of the transcriptional activity of 
FOXO (Daitoku et al., 2003) and CREB (Herzig et al., 2001), respectively. In addition, the 
absence of insulin increases the activity of PGC1! by reducing the inhibitory phosphorylation 
of PGC1! by AKT (Li et al., 2007).  
 Moreover, AMPK and SIRT1 are further considered important energy sensors, as a low 
energetic status is associated with high AMPK and SIRT1 activity. Activation of AMPK, which 
is triggered in response to low cellular energy (high AMP to ATP ratio), results in the 
repression of ATP-consuming anabolic processes such as lipogenesis, glycogenesis, 
gluconeogenesis and protein synthesis, and the activation of ATP-producing catabolic processes 
such as fatty acid #-oxidation, ketogenesis and glucose uptake (Fulco and Sartorelli, 2008). 
While AMPK controls glucose uptake by increasing GLUT4 expression and translocation in 
extrahepatic tissues (Fisher et al., 2002), in the liver, it blocks lipogenesis by phosphorylating 
(at Ser372) and inhibiting SREBP1 (Li et al., 2011). SIRT1 is a member of the sirtuin family of 
proteins that uses NAD+ as substrate and that exerts its functions through the deacetylation of 
target proteins such as histones, transcription factors and coactivators (Fulco and Sartorelli, 
2008). In turn, SIRT1 is able to promote fatty acid oxidation and gluconeogenesis by 
deacetylating PGC1! (Nemoto et al., 2005), thereby allowing its binding to HNF4 or PPAR!. 
Moreover, deacetylation of SREBP1 by SIRT1 leads to the inhibition of lipogenesis (Ponugoti 
et al., 2010). 
Finally, mTORC1 represents a main nutrient, stress and energy sensor as well. In a 
PI3K-independet manner, mTORC1 can also be directly regulated by nutrients, especially by 
amino acids (Sengupta et al., 2010). Amino acids have been proposed to activate mTORC1 
through the inhibition of TSC1/TSC2 (Gao et al., 2002), through the stimulation of Rheb (Long 
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et al., 2005) or via VPS34 class III PI3K signalling (Nobukuni et al., 2005). In particular, amino 
acid deprivation leads to rapid S6K1 and 4EBP1 dephosphorylation in an mTORC1-dependent 
manner. Moreover, mTORC1 senses the energy status of a cell through AMP-activated protein 
kinase (AMPK). Activated AMPK directly phosphorylates TSC2 leading to the inhibition of 
mTORC1 signalling and cell growth (Inoki et al., 2003b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Cellular and molecular adaptations to fasting. 
During fasting, reduced circulating insulin levels (synthesized in pancreatic #-cells) lead to the downregulation of the 
PI3K/AKT signalling pathway promoting gluconeogenesis, lipolysis, glycogenolysis and proteolysis and inhibiting 
glycolysis, lipogenesis and glycogen synthesis. At the same time, increased glucagon levels secreted by pancreatic !-
cells activate the AC/PKA signalling pathway whose effectors stimulate gluconeogenesis, glycogenolysis and 
PPAR! activity. PPAR!, which is activated by fatty acids, is the master regulator of fatty acid #-oxidation and 
ketogensis. AMPK, SIRT1 and mTORC1 are other important energy and nutrient sensors necessary for the 
adaptation to fasting. GR: glucagon receptor, IR: insulin receptor, FA: fatty acids. 
 
 
5. Role of tumour suppressor genes in stress signalling pathways 
Tumour suppressor genes are characterized by their ability to inhibit cell proliferation and 
tumour development. Many of them have a major role in the cellular response to a wide range 
of stress signals such as DNA damage, hypoxia or oncogenic activation, leading to DNA 
damage repair, cell cycle arrest, differentiation, senescence or apoptosis (Sherr, 2004; 
Vogelstein et al., 2000; Vurusaner et al., 2012). However, little is known about the possible 
effects that stress associated to nutrient deprivation could exert over tumour suppressors.  
 Previous researchers have identified p21 (also known as p21Cip1 or CDKN1A) as a 
fasting-induced factor (Tinkum et al., 2013), but, whereas its role in cell cycle regulation, 
senescence, apoptosis, DNA repair and transcriptional control has been widely studied, little is 
known about the relevance and involvement of p21 in metabolism or in the adaptation to fasting. 
In contrast, other tumour suppressor genes such as p53 have extensively been associated with 
the regulation of glucose metabolism (Kruiswijk et al., 2015; Puzio-Kuter, 2011). For instance, 
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p53 is phosphorylated and activated by AMPK, which leads to the induction of an important 
metabolic checkpoint and cell cycle arrest in response to glucose limitations (Jones et al., 2005). 
In addition, p53 has been implicated in modulating the balance between glycolytic and 
respiratory pathways. By promoting the activity of TIGAR (TP53-induced glycolysis and 
apoptosis regulator) (Bensaad et al., 2006) and downregulating PGM (phosphoglycerate 
mutase) (Kondoh et al., 2005) and GLUT4 (Zhang et al., 2013), p53 is able to limit glycolysis; 
whereas by inducing the expression of SCO2 (synthesis of cytochrome c oxidase 2) (Matoba et 
al., 2006), p53 stimulates mitochondrial respiration. Therefore, loss of p53 is associated with 
low oxygen consumption by mitochondrial respiration and enhanced glycolysis for the 
production of energy, thereby contributing to the Warburg effect. Finally, inhibition of p53 
activity in adipose tissue decreases the expression of pro-inflammatory cytokines and improves 
insulin resistance in mice (Minamino et al., 2009).  
 Given the reduced number of studies linking p21 to metabolism, and the evidence that 
p21 is a fasting-induced factor (Tinkum et al., 2013), we decided to further analyze the role of 
p21 in the fasting response. 
 
5.1  The tumour suppressor gene p21 
p21 belongs to the Cip and Kip family of cyclin-dependent kinase (CDK) inhibitors that include 
p27 and p57 as well. The first discovered and best-known function of p21 is mediating p53-
dependent cell cycle arrest by binding to and inhibiting the kinase activity of CDKs (El-Deiry et 
al., 1993; Harper et al., 1993) through the direct interaction with its N-terminal domain (Chen et 
al., 1995) (Figure 7). In particular, p21 contributes to G1 arrest by inhibiting the activity of 
CDK2, thereby not only suppressing the formation CDK2/cyclin E and CDK2/cyclin A 
complexes, but also inhibiting the CDK2-dependent retinoblastoma (RB) phosphorylation and 
the consequent release and activation of E2F transcriptional activity of genes involved in 
replication and cell progression (Zhu et al., 2005). In addition, p21 also inhibits the kinase 
activity of CDK2/cyclin A and CDK1/cyclin A, which are required for progression to S-phase 
and into G2, respectively (Dutto et al., 2014). Moreover, p21 induces DNA repair through the 
binding of its carboxy-terminal domain to PCNA (proliferative cell nuclear antigen) (Chen et al., 
1995), thus blocking DNA synthesis and S-phase progression  (Moldovan et al., 2007). Even 
though the activation of p21 by p53 in response to DNA-damage and oncogenic stress is the 
main and best-characterized p21-activating pathway that primarily mediates cell cycle arrest and 
p53-dependent apoptosis and senescence, multiple signals and factors have been shown to 
regulate p21. In a p53-independent manner, p21 can also be regulated by TGF#-activated 
SMAD complexes, E2F1, p300/CBP, HRAS, BRCA1, KLF4 and FOXO proteins (Abbas and 
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Dutta, 2009). Although best known for its growth-inhibitory functions, p21 also inhibits 
apoptosis in a p53-independent mechanism by interacting and inhibiting the activity of pro-
apoptotic proteins such as procaspase 3, caspase 8, caspase 10 and SAPKs (stress-activated 
protein kinases) (Gartel and Tyner, 2002). p21 can also modulate transcription acting as a co-
transcriptional factor by binding and suppressing  the transcriptional activity of E2F1 
(Delavaine and La Thangue, 1999), STAT3 (Coqueret and Gascan, 2000) and MYC (Kitaura et 
al., 2000) as well as by de-repressing and activating p300/CBP gene transcriptional activity 
(Snowden et al., 2000). p21 is further controlled at a post-transcriptional level by a number of 
protein kinases. Phosphorylation of p21 at Ser130 by CDK2/cyclin E promotes its binding to 
SKP2, leading to its ubiquitylation, proteolysis and consequent cellular progression (Bornstein 
et al., 2003). Furthermore, AKT phosphorylates p21 at Thr145 disrupting the binding with 
PCNA and preventing the nuclear translocation of p21 which promotes p21-dependent anti-
apoptotic activity and cell proliferation through assembly of CDK/cyclin complexes (Li et al., 
2002).       
Despite being downregulated in some human cancers such as head and neck, colorectal 
and small-cell lung cancer (Abbas and Dutta, 2009), loss-of-function mutations in p21 are 
extremely rare (Shiohara et al., 1994). In fact p21-deficient mice develop spontaneous tumours 
relatively late compared to mice lacking other tumour suppressor genes (Martin-Caballero et al., 
2001) such as Trp53 (Jacks et al., 1994), p16 (Serrano et al., 1996) or Arf (Kamijo et al., 1999). 
However, p21KO mice exhibit accelerated development of chemically-induced tumours 
(Philipp et al., 1999). Importantly, p21 has been attributed to have oncogenic capacity not only 
due to its anti-apoptotic function. This can further be explained by its ability to stimulate cell 
motility through the inhibition of Rho (Ras homolog family member A kinase), thereby 
contributing to tumour metastasis and invasion (Lee and Helfman, 2004), and by its ability to 
maintain self-renewal capacity and genomic stability in stem cells (Kippin et al., 2005). 
Moreover, p21 promotes G1 progression and proliferation by inducing the kinase activity of 
CDK4 or CDK6 in complex with cyclin D (Labaer et al., 1997). The theory that p21 may act as 
an oncogene is supported by the fact that p21 is overexpressed in a variety of human cancers 
such as prostate, cervical and breast (Abbas and Dutta, 2009) and that p21 deletion in mice 
suppresses the development of spontaneous lymphomas in p53-KO (De la Cueva et al., 2006) 
and ATM-KO mice (Wang et al., 1997). This dual, contradictory effect may be explained by the 
cellular localization of p21 as, whereas the growth-inhibitory functions of p21 are associated 
with its nuclear localization, the anti-apoptotic or oncogenic activities of p21 are frequently 
associated with its cytoplasmic accumulation. 
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Figure 7. The central role of p21 in sensing and responding to stimuli. 
Left, simplified representation of the stimuli that activate p21 and the different responses triggered either directly by 
p21 or mediated through the inhibition of CDK2 or PCNA. Right, regulation of p21 (p53-dependent and p53-
independent), main processes in which p21 is involved and principal interactions of p21 with proteins in the nucleus!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
 
 
 
 
 
 
 
! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
47 
 
1. Characterization of the pharmacological effects of PI3K inhibition on obesity.  
1.1 Study the in vivo effects of the treatment with PI3K inhibitors in obese mice and rhesus 
monkeys.  
1.2 Evaluate a possible use of PI3K inhibitors as anti-obesity treatment.  
 
2. Role of the tumour suppressor gene p21 in the fasting response. 
2.1 Analyse the role of p21 in the adaptive response to fasting.  
2.2 Characterize the fasting response in p21-deficient mice.  
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1. Caracterización de los efectos de la inhibición farmacológica de PI3K sobre la 
obesidad. 
1.1 Estudiar los efectos in vivo del tratamiento con inhibidores de PI3K en ratones y 
macacos rhesus obesos.  
1.2 Evaluar el posible uso de inhibidores de PI3K como tratamiento anti-obesidad. 
 
2. Análisis del papel del gen supresor de tumores p21 en la respuesta a ayuno.  
2.1 Analizar el papel de p21 en la respuesta de adaptación al ayuno.  
2.2 Caracterizar la respuesta a ayuno en ratones deficientes en p21.  
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MATERIALS & METHODS 
 
1. Mouse experimentation 
 
1.1  Animal housing 
All animal procedures done at the CNIO were approved by the CNIO-ISCIII Ethics Committee 
for Research and Animal Welfare (CEIyBA) and the Autonomous Community of Madrid, and 
conducted in accordance to the recommendations of the Federation of European Laboratory 
Animal Science Associations (FELASA). Wild type mice were originally obtained from Harlan 
Laboratories C57BL6/J-OlaHsd and housed at the specific pathogen-free (SPF) barrier area of 
the Spanish National Cancer Research Centre (CNIO), Madrid. Male mice were maintained at 
22°C, and with 12 hour dark/light cycles (light cycle from 8 am to 8 pm) having free access to 
water and standard chow diet (18% of fat-based calorie content, Harlan Teckland 2018). When 
indicated, mice were fed with a high fat diet (45% fat-based calorie content, Research Diets 
D12451) or fasted for 24 to 48 hours with ad libitum water access. Mice were observed on a 
daily basis and sacrificed when they showed signs of morbidity in accordance to the Guidelines 
for Humane Endpoints for Animals Used in Biomedical Research from the Council for 
International Organizations of Medical Sciences (CIOMS).  
 All animal procedures done at the National Institute on Aging (NIA-NIH) were 
approved in the study protocol 352-TGB-2016 by the Animal Care and Use Committee of the 
National Institute on Aging (Baltimore, MD). Male C57BL6 mice were obtained from the NIA 
Aging Colony (Charles River, Bethesda MD) at 8 weeks of age. They were aged in house until 
they reached 7 months of age.  
 
1.2  Transgenic mouse models 
Ob/Ob C57BL6/J male mice were purchased from Charles River Laboratories with 10 weeks of 
age and treated with 0.1 mg/ml of CNIO-PI3Ki dissolved in drinking water at 12 weeks of age.  
 Transgenic p21-/- (Brugarolas et al., 1995), p19ARF-/- (Kamijo et al., 1997) and Sirt-1+/- 
(Wang et al., 2008) male mice were maintained at the CNIO in a C57BL6 background and used 
for experimentation at 12 weeks of age. Mouse genotyping was performed by Transnetyx 
enterprise (Cordova, TN 38016).  
 Eµ-Myc mice (Adams et al., 1985) were kindly provided by Dr. Óscar Fernández-
Capetillo (CNIO) and genotyped by standard PCR procedures with the following primers that 
amplify a band of 850 base pairs: 
 Forward Primer: 5’ CAGCTGGCGTAATAGCGAAGAG 3’ 
Reverse Primer: 5’ CTGTGACTGGTGAGTACTCAACC 3’ 
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1.3  Administration of PI3K inhibitors  
For oral gavage administration, CNIO-PI3Ki, GDC-0941, BYL-719 and acalisib (all of them 
synthesized at the CNIO) were dissolved in 10% NMP (N-methyl-2-pyrrolidone, Sigma) - PEG-
300 (Polyethyleneglycol 300, Sigma). For administration in drinking water (CNIO, Madrid), 0.1 
mg/ml CNIO-PI3Ki was dissolved in 1.8% cyclodextrin (Sigma). For administration in food 
(NIA, Baltimore), CNIO-PI3Ki was incorporated into a high fat diet (60% calories from fat) 
purchased from Dyets, Inc. (Bethlehem, PA) at 0.17 g of drug per kg of food.  
 
1.4  Metabolic characterization 
 
1.4.1 Body composition 
At the CNIO, body composition (fat and lean content) was determined by Dual energy X-ray 
Absorptiometry (DXA) (Lunar PIXImus Densitometer, GE Medical Systems). Image 
acquisition lasted 5 minutes with mice under anesthesia by inhalation of 2% isofluorane in 
oxygen. Whole body fat and lean mass was determined excluding head region. 
 At the NIA, measurements of lean and fat mass were acquired by nuclear magnetic 
resonance (NMR) using the Minispec LF90 (Bruker Optics, Billerica, MA).  
 
1.4.2 Indirect calorimetry and activity studies 
At the CNIO (p21 project), indirect calorimetry was performed following standard methods 
using Oxylet System metabolic chambers (Panlab Harvard Apparatus) at the CNIO. 
Acclimatization of 12-13 weeks old WT and p21KO mice to the measurement cages was three 
days prior to data recording. Volume of consumed O2 (VO2) and eliminated CO2 (VCO2) was 
recorded in ad libitum fed mice for 48 hours. After that, food was withdrawn and data were 
recorded for the next 48 hours under fasting conditions with ad libitum water access. Room 
temperature was constantly kept at 21°C and light/dark cycles were of 12 hours. Respiratory 
Quotient (RQ) was calculated as RQ=VCO2/VO2 from volumes of consumed O2 (VO2) and 
eliminated CO2 (VCO2) recorded every 24 minutes (8 simultaneous metabolic chambers). 
Energy Expenditure (EE) was calculated as EE=(3.815+(1.232xRQ)) x VO2 x 1.44). Mouse 
activity was recorded in time intervals of 20 minutes during the whole measurement period. 
 At the NIA, metabolic rate of mice fed with HFD or HFD supplemented with CNIO-
PI3Ki was assessed by indirect calorimetry in open-circuit oxymax chambers using the 
Comprehensive Lab Animal Monitoring System (CLAMS; Columbus Instruments, Columbus, 
OH) as described previously (Mitchell et al., 2014). 
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1.4.3 Body temperature measurement 
At the CNIO, rectal temperature of ad libitum fed or 48 hours fasted WT and p21KO mice was 
measured using a rectal probe. 
 At the NIA, body temperature was established by thermoimaging. Mice were lightly 
anaesthetized with ketamine-xylazine, which was sufficient to induce anesthesia without a drop 
in respiration or body temperature. Rectal temperature was measured using a rectal probe prior 
to anaesthesia, once the mouse was asleep, and at the end of the imaging. Temperature remained 
consistent from the start to the end of the experiment. Mice were placed into a chamber 
maintained at 37ºC for the experiment. Thermal images of mice were captured every second for 
30 minutes for whole body and for the intrascapular area by the Seahorse Bioscience TSA 
ImagIR Thermal Imaging system (Seahorse Bioscience, N Billerica, Massachusetts, USA). 
 
1.4.4 Glucose and insulin tolerance test  
To perform the glucose tolerance test (GTT), mice were fasted overnight and i.p. injected with 
glucose 2 g/kg (Sigma). Tail blood glucose levels were measured 0, 15, 30, 60, 90 and 120 
minutes post-injection using a glucometer (Meranini Diagnosis). For the insulin tolerance test 
(ITT), mice were injected with 0.75 U/kg of insulin (Eli Lilly and Co., Humalog Insulin) and 
tail blood glucose levels were determined 0, 15, 30, 45, 60 and 90 minutes after insulin injection.  
 
1.4.5 Metabolic parameters in serum  
Blood was collected from the tail tip for the determination of glucose (Glucocard strips; A. 
Meranini Diagnosis) and insulin, or from post-mortem heart puncture for the rest of parameters. 
Serum insulin (Ultra Sensitive Mouse Insulin ELISA kit; Crystal Chem Inc.), Igf1 (Mouse/Rat 
IGF-1 ELISA; Demeditec), leptin (Crystal Chem Inc.) and adiponectin levels (Invitrogen) were 
measured by ELISA following the manufacturer’s instructions. Serum triglycerides (Serum 
Triglyceride Determination Kit; Sigma), free fatty acids (Wako NEFA C Kit; Wako Chemicals) 
and ketone bodies (Autokit 3-HB; Wako Chemicals) were quantified by colorimetric assay. 
ALT and cholesterol were determined by VetScan (mammalian liver profile; VetScan) or by 
ABX PENTRA 400 clinical chemical analyser (Horiba ABX Diagnostics). Insulin resistance 
was evaluated by the HOmeostatic Model Assessment index (HOMA-IR = [(fasting insulin, 
"U/ml) x (fasting glucose, mg/dl] / 405).  
 
1.4.6 Free fatty acids in liver 
Lipids were extracted from the liver as followed: 10-20 mg of tissues was homogenized with 
200 µl of Chloform/1% Triton. After centrifugation, lower, organic phase was collected and  
MATERIALS & METHODS 
58 
vacuum air dried at 50ºC to remove Chloroform. Afterwards, fatty acids were quantified using 
Wako NEFA C Kit (Wako Chemicals) and following the manufacturer’s instructions. 
 
1.4.7 Nuclear magnetic resonance 
Mice blood for serum isolation was collected by post-mortem heart puncture. After coagulation 
in ice, 100 µl of serum were mixed with 100 µl ice-cold 2X PBS buffer in deuterium oxide 
(D2O), centrifuged for 10 min at 16000 x g and transferred to a 3 mm NMR sample tube. NMR 
spectra were recorded at 20ºC in 9 mins on a Bruker Avance 700 MHz spectrometer. Metabolite 
levels in serum samples were determined from the integrals of the most resolved and largest 
signals of each metabolite (for example methyl groups of lactate, alanine and pyruvate, and H4 
proton of glucose) in 1D 1H NMR spectra acquired with a transversal relaxation filter (CPMG 
of 200 ms, t=0.4 ms) that attenuates the fast relaxing signals of macromolecules (proteins, lipids 
and lipoproteins) signals and optimises the NMR signals of low mass metabolites for their 
quantification (Beckonert et al., 2007). Thus, the obtained values of integrals are not absolute 
concentrations but relative concentrations in arbitrary units (AU).  
 
1.5  Histology and immunohistochemistry  
Tissues were fixed overnight in 10% buffered formalin (Sigma), embedded in paraffin blocks 
and sectioned at a thickness of 2.5 µm. Tissue sections were stained with hematoxylin/eosin 
(H&E), with anti-UCP1 (AbCam, #ab10983), anti-F4/80 (Monoclonal Antibodies Core Unit, 
CNIO #AM-D10 or ABD Serotec, #MCA497), Ki-67 (Master Diagnostica #0003110QD) or 
active-Caspase 3 (Cell Signaling #9661) following standard procedures. OCT frozen 10 µm 
liver sections were stained for Oil Red O (Sigma).   
 Senescence associated #-galactosidase staining (X-gal) in spleen of Eµ-Myc mice was 
performed following the manufacturer’s instructions (Senescence #-Galactosidase Staining Kit 
#9860; Cell Signaling). Shortly, tissues frozen in OCT tissue freezing medium (Leica) were 
sectioned at a thickness of 10 µm, fixed for 10 minutes, stained with X-Gal solution at 37ºC 
overnight and counter-stained with nuclear fast red.  
 
1.6  In situ hybridization 
Coronal mouse brain sections (16 "m) were probed with a specific oligonucleotide for AgRP 
(GenBank Accession Number: NM_007427; 5’-CGA CGC GGA GAA CGA GAC TCG CGG 
TTC TGT GGA TCT AGC ACC TCT GCC-3’), CART (GenBank Accession Number: 
NM_013732; 5’-ACA GTC ACA CAG CTT CCC GAT CCT GGC CCC TTT C-3’), NPY 
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(GenBank Accession Number: AF273768; 5’-GGG CGT TTT CTG TGC TTT CCT TCA TTA 
AGA GGT CTG-3’) and POMC (GenBank Accession Number: NM_008895; 5’-CTT GAT 
GAT GGC GTT CTT GAA GAG CGT CAC CAG GGG CGT CTG GCT CTT-3’) as 
previously published (López et al., 2008, 2010; Martínez De Morentin et al., 2014; Whittle et al., 
2012). Sections were scanned and the hybridization signal was quantified by densitometry using 
ImageJ-1.33 (NIH; Bethesda, MD, USA). We used between 12 sections for each animal (3 
slides with four sections per slide). The mean of these 12 values was used as the densitometry 
value for each animal. 
 
1.7  Immunophenotyping by flow cytometry 
Cells from ad libitum fed or 24 hour fasted WT and p21KO mice (12-16 weeks old, n=6) were 
isolated from spleen and liver by disaggregating tissues through a 70 µm or 100 µm strainer, 
respectively. Following erythrocyte lysis with Red Blood Cell Lysis Buffer (Qiagen), immune 
cells from the liver were further isolated using a 38-70% Percoll gradient (GE Healthcare). Cells 
were then blocked in Fc block (CD16/CD32, BD Biosciences #553141) diluted 1:400 on ice for 
30 minutes and incubated with the following conjugated antibodies for 1 hour at 4ºC in a 
rotating platform: CD8a-FITC (eBioscience #11-0081-82), CD4-PE (eBioscience #12-0041-82), 
CD45-PerCP (Biolegend #103130), CD11b-PerCP/Cy5.5 (eBioscience #45-0112-82), Gr1-
PECy7 (eBioscience #25-5931-82), NK1.1-PECy5 (Biolegend #108715), F4/80-AF647 
(eBioscience #12-0041-82), CD3-AF700 (eBioscience #56-0032-82), CD19-APC/EF780 
(eBioscience #47-0193-80) and B220-APC/EF780 (eBioscience #47-0452-82). Splenocytes 
were used as Fluorescence Minus One (FMO) to gate cell populations and commercial anti-
mouse or anti-rat IgG beads (BD Biosciences #552843 or # 552844) to compensate for 
fluorochrome spectral overlap. We used pulse processing to exclude cell aggregates and an 
amine reactive live/dead dye (Aqua, Invitrogen) to exclude dead cells. At least 10,000 cells 
from the CD45 gate were collected. Cells were analyzed in an LSR-Fortessa (BD Biosciences; 
FACS Diva software) and all data analyzed using FlowJo v9.6.2 software (Trestar, Oregon). 
 
2. Monkey experimentation 
 
2.1  Animal housing 
All procedures were approved by the Animal Care and Use Committee of the NIA Intramural 
Research Program. Rhesus monkeys (Macaca mulatta) were housed at the NIH Animal Center 
(Poolesville, MD, USA) in standard primate caging with controlled temperature and humidity 
and a 12-hour light cycle.  
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2.2  Preliminary study 
A preliminary study was performed to determine the appropriate dosing of the CNIO-PI3Ki 
compound for rhesus monkeys (Macaca mulatta) based on allometric scaling of the mouse 
dosing. Here, physiological parameters of six healthy monkeys (n=6; 3 males and 3 females) 
were monitored during dose escalation treatment of CNIO-PI3Ki administered intravenously 
under anesthesia. The test doses ranged from 0.2 mg/kg to 2.1 mg/kg. Animals were under 
anesthesia for 2 hours, while serum was collected at various time points. 
 
2.3  Long-term study 
For the 12-week study, subjects were 19 male and female rhesus monkeys aged 12 to 27 years 
(18 ± 5.4 years old) randomized into two groups: 9 control (5 females + 4 males) and 10 CNIO-
PI3Ki treated (6 females + 4 males). All monkeys were considered naturally obese with baseline 
body weights between 7 and 18 (11.8 ± 2.5) kilograms and body fat > 27% (Hansen et al., 2013). 
Monkeys were fed commercially prepared monkey chow that was distributed twice daily along 
with daily food enrichment, and water was available ad libitum. Additionally, study animals 
were supplemented with 5 or 6 PRIMA-treat® wafers (Bio-Serv®, assorted fruit flavors, F0345; 
each wafer weighs 5 g with 3.28 kcal/gr). The PRIMA-treat wafers were used as vehicle for 
CNIO-PI3Ki. Individually weighed doses of CNIO-PI3Ki were reconstituted in water and then 
distributed, via syringe, onto the PRIMA-treats. Once absorbed, they were fed to the animals. 
Drug administration continued daily (weekends included) for 12 weeks. 
 Monkeys were anesthetized at baseline to measure body weight, blood pressure, heart 
rate, temperature, to collect anthropometric measures (i.e., abdominal circumference and crown-
rump length), and to extract blood samples. These parameters were subsequently evaluated 
every one to two weeks during the study. In addition, food consumption data were collected 
daily for three to five days at baseline and again at weeks 3, 6, 8, and 11.  
 
2.4  Metabolic parameters 
Fasting blood samples were obtained by venipuncture of the femoral artery after anesthesia with 
intramuscular ketamine (7-10 mg/kg) and sent to Antech Diagnostics for chemistry panel and 
complete blood count testing. The following measurements were performed: glucose, total 
protein, albumin, globulin, alkaline phosphatase, gamma guanine triphosphate, alanine and 
aspartate transaminases, bilirubin, BUN, creatinine, phosphorus, calcium, magnesium, sodium, 
potassium, chloride, cholesterol, triglycerides, amylase, lipase, creatining phosphokinase, white 
blood cells, red blood cells, hemoglobin, hematocrit, MCV, MCH, MCHC, neutrophils, 
platelets, lymphocytes, monocytes, eosinophils, and basophils.  
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 Trunk body composition (fat and lean content) was determined by Dual energy X-ray 
Absorptiometry (DXA) using the GE Lunar Prodigy® (GE Healthcare, Wauwatosa, WI).  
 At baseline and week 10, monkeys were fasted overnight and anesthetized for two-hour 
Intravenous Glucose Tolerance Test (IVGTT). During each test, serial blood samples were 
collected following a dose of 300 mg/kg of 50% dextrose administered IV through the 
saphenous vein. Glucose values were promptly measured in whole blood using an Ascensia® 
Breeze 2 blood glucose monitoring system (Bayer HealthCare LLC., Mishawaka, IN). Samples 
were then centrifuged and serum samples were aliquoted and stored at -80°C for subsequent 
analysis using a commercially available Insulin ELISA (Mercodia, Inc., Uppsala, Sweden).  
Insulin resistance was evaluated by the HOmeostatic Model Assessment index (HOMA-IR = 
[(fasting insulin, "U/ml) x (fasting glucose, mg/dl] / 405).  
 
3. Characterization of the CNIO-PI3K inhibitor 
The low molecular weight compound CNIO-PI3Ki is described in patent WO2010/119264 
(files available at the World Intellectual Property Organization, 
http://www.wipo.int/pctdb/en/wo.jsp?WO=2010119264).  
 
3.1  PI3K inhibitory assay 
The kinase activity of PI3K isoforms was measured by using the commercial PI3kinase (h) 
HTRF™ assay available from Millipore, following the manufacturer´s recommendations. 
PI3K! (p110!/p85!) and PI3K" (p110"/p85!) were used at 100 pM; PI3K! (p110#/p85!) and 
PI3K# isoforms (p110#) at 500 pM and 4 nM respectively. ATP concentration was 50 times 
KMATP: 200 mM for PI3K! and PI3K", 250 mM for PI3K# and 100 mM for PI3K#. PIP2 was 
held at 10 mM. Values were normalized against the control activity included for each enzyme 
(i.e, 100% PI3K activity, without compound). These values were plotted against the inhibitor 
concentration and were fitted to a sigmoidal dose-response (variable slope) curve by using 
GraphPad Software. The obtained IC50 were converted to kiapp according to Cheng-Prusoff 
equation for competitive inhibitors (Cheng and Prusoff, 1973).  
 Mammalian target of rapamycin (mTOR) was assayed by monitoring phosporylation of 
GFP-4EBP using a LanthaScreen™ kinase activity assay (Invitrogen). The enzyme and reagents 
were purchased from Invitrogen. Reaction conditions used were those recommended by the 
manufacturer. Values were plotted against the inhibitor concentration and fitted to a sigmoid 
dose-response curve by using GraphPad Prism version 5.03 (GraphPad Software CA, USA).  
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3.2  Pharmacokinetics 
Male C57BL6 mice (n=3) were treated intravenously with 2 mg/kg or orally with 10 mg/kg 
CNIO-PI3Ki. Drug concentration was measured by mass spectrometry. Pharmacokinetic 
parameters were estimated by fitting the experimental data to a bicompartmental model using 
WinNonlin software for pharmacokinetic analysis.  
 
4. In vitro procedures  
 
4.1  Cell culture 
Primary large-T immortalized pre-brown adipocyte cell lines were kindly provided by Dr. 
Ángela Martínez-Valverde (IIB-Madrid) and obtained from the interscapular BAT of 3-5 day-
old neonates as previously described (Fasshauer et al., 2000; Lorenzo et al., 1993). Primary 
large-T immortalized WT and p21KO hepatocytes were also provided by Dr. Ángela Martínez-
Valverde (IIB-Madrid) and obtained from the liver of 3-5 day-old neonates as previously 
described (Gonzalez-Rodriguez et al., 2007). HepG2 cells (human hepatocellular carcinoma) 
were obtained from ATCC® (HB-8065) (Knowles et al., 1980).  
 All cell lines were cultured in DMEM (Dulbecco’s Modified Eagle’s Medium; Gibco) 
supplemented with 10% heat inactivated FBS (Fetal Bovine Serum; Gibco) and 1% 
antibiotic/antimycotic (Gibco) if not otherwise specified. Cells were incubated in 20% O2 and 
5% CO2 at 37ºC.  
 
4.2  Lentiviral transduction 
Lentiviral supernatants were produced in HEK293T cells (ATCC® number CRL-11268TM) 
plated at 2.5 x 106 cells per 100 mm-diameter dish and transfected with the packaging plasmids 
pLP1 (1.95 µg), pLP2 (1.3 µg), pLP/VSVG (1.65 µg) (Invitrogen), and one of the following 
lentiviral constructs (5 µg) expressing shRNAs against PIK3C! (pLKO.1; Thermo Scientific 
TRCN0000025615), PIK3C$ (pLKO.1; Thermo Scientific TRCN0000024793), PIK3C# 
(pLKO.1; Thermo Scientific TRCN0000024569) and PIK3C% (pLKO.1; Thermo Scientific 
TRCN0000024644). Transfections were performed using Fugene HD transfection reagent 
(Promega) according to the manufacturer’s instructions. Supernatants from HEK293T cells used 
for infection of pre brown-adipocytes were collected 48, 56 and 72 hours after transfection. 
Primary immortalized pre-brown adipocytes were plated (8 x 105 per 100 mm-diameter dish) 
the day prior to infection and selected with puromycin (2 mg/ml, Sigma) after 48 hours. 
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4.3  Treatments  
Primary immortalized pre-brown adipocytes were stimulated with DMSO (Dimethyl Sulfoxide, 
Sigma) or forskolin 10 µM (Sigma) for 4 hours. HepG2 and primary immortalized hepatocytes 
(plated at 5 x 105 cells per 6-well plate the previous day) were washed twice with PBS 
(Phosphate Buffer Saline, Gibco) and nutrient starved in starvation medium consisting of 
glucose-free DMEM (Gibco #11966025) without FBS supplementation for 24 or 48 hours. 
When indicated, cells were stimulated with forskolin 10µM (Sigma) or CNIO-PI3Ki 10 µM, 
both dissolved in DMSO, for 5 hours.   
 
4.4  Crystal violet staining 
For crystal violet staining, cells cultured for 48h in complete or starvation medium were fixed in 
1% glutaraldehyde (Sigma) for 10 minutes and stained with 0.1% crystal violet (Sigma) for 30 
minutes. After washing with distilled H2O, plates were scanned.  
 
5. Biochemical assays 
 
5.1  DNA extraction 
For the genotyping of Eµ-Myc mice, DNA was extracted from mouse-tail. After overnight 
incubation with proteinase K (0.4 mg/ml; Roche), DNA was isolated following standard 
phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma) extraction protocol and performing 
genotyping PCR as specified in section 1.2.  
 
5.2  RNA extraction and qRT-PCR 
Total RNA from tissues or cells was isolated using TRIZOL (Invitrogen), chloroform and 
isopropanol standard extraction protocol. RNA extraction of monkey biopsies was optimized as 
followed: tissue was homogenized using an Omni Polytron Homogenizer and aqueous phase 
isolated with the help of Phase Lock Gel Tubes (5PRIME). RNA was precipitated overnight at -
20ºC and pelleted by centrifugation at 20000 g, at 4ºC, during 30 minutes. DNA synthesis was 
performed with 1-2 µg of RNA using iScript First Strand cDNA synthesis kit (BioRad #170-
8891) according to the manufacturer’s instructions. Quantitative real time-PCR (qRT-PCR) was 
carried out using GoTaq Q-PCR Master Mix (Promega) in a 7500 Fast Real-Time PCR System 
(Applied Biosystems). Reactions were performed in triplicate, normalized to "-actin or Gapdh 
in the case of muscle, and calculations were made using the &&Ct method as described (Yuan et 
al., 2006).  
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Primer sequences used for mouse, monkey and human transcripts are described below:  
PCR primers for mouse transcripts 
Primer Forward sequence 5’ ! 3’ Reverse sequence 5’ ! 3’ 
"-Actin GGCACCACACCTTCTACAATG GTGGTGGTGAAGCTGTAGCC 
Gapdh TTCACCACCATGGAGAAGGC CCCTTTTGGCTCCACCCT 
CD68 TGTCTGATCTTGCTAGGACCG GAGAGTAACGGCCTTTTTGTGA 
Emr1 TGACTCACCTTGTGGTCCTAA CTTCCCAGAATCCAGTCTTTCC 
IL-6 AGTTGCCTTCTTGGGACTGA TCCACGATTTCCCAGAGAAC 
Ucp1 ACTGCCACACCTCCAGTCATT CTTTGCCTCACTCAGGATTGG 
G6pc ACTGTGGGCATCAATCTCCT AGGTGACAGGGAACTGCTTT 
Pgc1! GGGTTATCTTGGTTGGCTTTATG AAGTGTGGAACTCTCTGGAACTG 
PI3K! AAAGTGTGTGGCTGTGACGA CTTTCTTTGGCCATCAGCAT 
PI3K" TACAGGTCAGTGGGAGAGTG GAAGTGGGGCAGGGTTCTAT 
PI3K# CGAAACCATTGGAATCATCTT CCAGAGATTCAGTCTCCCAAA 
PI3K$ CAGGGGTCTACTTGAACTTCC CTGAGCATGTGGAAGAGTGG 
Tnni1 GCCTCCACAACACCAGAGAG GCCAGACATAGCCTCCACAT 
Myh2 GCAAACACGAGAGACGAGTG CAGCTTGTTGACCTGGGACT 
Myh4 AACCTGATGCAGGCTGAGAT TCCTGCTCCTTCTTCAGCTC 
p21Cip1 GTGGGTCTGACTCCAGCCC CCTTCTCGTGAGACGCTTAC 
p16Ink4a TACCCCGATTCAGGTGAT TTGAGCAGAAGAGCTGCTACGT 
p19ARF GCCGCACCGGAATCCT TTGAGCAGAAGAGCTGCTACGT 
p27Kip1 TCAAACGTGAGAGTGTCTAACG CCGGGCCGAAGAGATTTCTG 
p53 GCGTAAACGCTTCGAGATGTT TTTTTATGGCGGGAAGTAGACTG 
Fgf21 GTGTCAAAGCCTCTAGGTTTCTT GGTACACATTGTAACCGTCCTC 
CD36 ATGGGCTGTGATCGGAACTG TTTGCCACGTCATCTGGGTTT 
Abcd2 TGTGGAGCAGCTGTGGACTA ATCAGCTCCAGAGGCCAGTA 
Saa3 TAAAGTCATCAGCGATGCCAGAG CAACCCAGTAGTTGCTCCTCTTC 
Acacb GTATCCGCAAGGCTGAGAGT GTTCTGGGCCAGCTTCATTA 
Srebp1 TAGAGCATATCCCCCAGGTG GGTACGGGCCACAAGAAGTA 
Gyk TGAAGAAAGCGAAATCCGTTACT CCCAAAGGCAGACTACAGAAG 
Cpt1a TCAATCGGACCCTAGACACC CTTTCGACCCGAGAAGACCT 
Acot1 TGCACGAGCGTCACTTCTT GATACTCCAGAAGGCCACCTC 
Acot3 GCACGAGCGTCACTTCAT CGATACTCCAGAAGGCCACT 
Ppar! AGCCTCAGCCAAGTTGAAGT TGGGGAGAGAGGACAGATGG 
Ppar# TGGCCACCTCTTTGCTCTGCTC AGGCCGAGAAGGAGAAGCTGTTG 
Ppar$ ACCAGAACACACGCTTCCTT TTGCGGTTCTTCTTCTGGAT 
Itgal CCAGACTTTTGCTACTGGGAC GCTTGTTCGGCAGTGATAGAG 
Icam TCCGCTACCATCACCGTGTAT TAGCCAGCACCGTGAATGTG 
Tlr1 TGTGAATGCAGTTGGTGAAGA CATTCCTGAGGTCCCTGCTA 
Ccl3 CTCCCAGCCAGGTGTCATTTT CTTGGACCCAGGTCTCTTTGG 
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Rantes GCTGCTTTGCCTACCTCTCC TCGAGTGACAAACACGACTGC 
Ifn#r1 GTGGAGCTTTGACGAGCACT TTCCCAGCATACGACAGGGT 
IL-5 CTCTGTTGACAAGCAATGAGACG TCTTCAGTATGTCTAGCCCCTG 
IP10 CCAAGTGCTGCCGTCATTTTC GGCTCGCAGGGATGATTTCAA 
Mig GGAGTTCGAGGAACCCTAGTG GGGATTTGTAGTGGATCGTGC 
Nos2 AATCTTGGAGCGAGTTGTGG CAGGAAGTAGGTGAGGGCTTG 
CD301 TGAGAAAGGCTTTAAGAACTGGG GACCACCTGTAGTGATGTGGG 
CD163 TCCACACGTCCAGAACAGTC CCTTGGAAACAGAGACAGGC 
 
PCR primers for rhesus monkey transcripts 
Primer Forward sequence 5’ ! 3’ Reverse sequence 5’ ! 3’ 
Ipo8 GCTCCTTCCTGATTCCTCCTATT CATCCACGTTGTCATGGTTTG 
Tnni1 GGTTCCAAGCACAAGGTGTC AAGTGAGTGAGCTGGGTTGG 
Myh2 TGACAAGATCGAGGACATGG CTGTCACCACCTCAGGGTTA 
Myh4 GTTCATTGACTTCGGGATGG GGAGGTATCTGTTGCCTTGG 
Pgc1! GCTGACAGATGGAGACGTGA CCACTGCATTCATTATAACTTAGCTG 
Pck1 GCTCTCAGGATAGCCAGTCG AAATGCAGCTGCCAGGTACT 
Adiponect. CGAGAAGGGTGAGAAAGGAGA CATGTTGGGGACAGTAACGTAG 
Ucp1 GTGTGCCCAACTGTGCAAT TGCCTTGACTTTGACAGTTCTC 
Prdm16 CCTGGCTGAGGAGCTCAAG- GGCACTGGTCGCATTTGTA 
Emr1 CTTCCTGGAGAGCGTGGA CTGCCAAGCTCAAGTTCACA 
CD68 CTCGACCTGCTCTCCCTGAG TGATGAGAGGCAGCAAGATG 
CD11c TTGATGCTCTGAAAGATATTCAAAA CTGCGCCATCTCCAATTC 
CD206 ACAAGGGATCGGGTTTATGG GGCGTTGCCCAGTAGTGTAT 
 
PCR primers for human transcripts 
Primer Forward sequence 5’ ! 3’ Reverse sequence 5’ ! 3’ 
"-Actin CAAGGCCAACCGCGAGAAGAT CCAGAGGCGTACAGGGATAGCAC 
p21Cip1 TGTCCGTCAGAACCCATG TGCCTCCTCCCAACTCATC 
 
5.3  Mitochondrial content 
Mitochondrial content in monkeys was analysed as previously described (Lagouge et al., 2006). 
Shortly, DNA was extracted from muscle biopsies by overnight incubation with proteinase K 
(0.4 mg/ml; Roche), followed by standard phenol:chloroform:isoamyl alcohol (25:24:1) 
extraction protocol. PCR was performed in a 7500 Fast Real-Time PCR System (Applied 
Biosystems) in triplicate and expression of the mitochondrial gene Cox2 was normalized to the 
expression of the nuclear gene Mrsp18a using the following primers:  
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Cox2 Forward Primer: 5’ TAGCATCACAGATGCCCAAG 3’ 
Cox2 Reverse Primer: 5’ CCCGTAGTCCGTGTATTCGT 3’ 
Mrps18a Forward Primer: 5’ GCTGGAACAAGGTGTGCAT 3’ 
Mrps18a Reverse Primer: 5’ GGGCTTATGAGTGTGCCTCT 3’ 
 
5.4  RNA-seq based transcriptional profiling 
Livers of ad libitum fed or 24 hours fasted WT and p21KO mice (n=2-3 per group) were snap-
frozen in liquid nitrogen and RNA was prepared using Trizol (Invitrogen) and further purified 
with RNeasy Mini kit (Qiagen) following the manufacturer’s instructions. RNA Integrity 
Number (RIN) was in the range of 9.1-9.5 (Agilent 2100 Bionalyzer). 2–8 ng of total RNA was 
used to synthesize the cDNA (SMARTer Ultra Low Input RNA Kit, version 3, Clontech 
#634848). After amplification with SeqAmp DNA Polymerase (Clontech), 10 ng of cDNA was 
used to prepare the adaptor-ligated library following the ‘‘TruSeq DNA sample preparation 
guide’’ (part #15005180). The resulting cDNA libraries were sequenced for 50 bases in a 
single-read format (Illumina HiSeq2000). Reads were aligned to the mouse genome 
(GRCm38/mm10) with TopHat-2.0.10 (Trapnell et al., 2012) using Bowtie 1.0.0 (Langmead et 
al., 2009) and Samtools 0.1.19 (Li et al., 2009), allowing two mismatches and five multihits. 
Transcripts assembly, estimation of their abundances and differential expression were calculated 
with Cufflinks 2.2.1 (Trapnell et al., 2012), using the mouse genome annotation data set 
RCm38/mm10 from the UCSC Genome Browser. Gene Set Enrichment Analysis (GSEA) was 
performed using annotations from the KEGG, Reactome and NCI databases. Genes were ranked 
using the t statistic. After Kolmogorov-Smirnoff correction for multiple testing, only those 
pathways bearing a FDR<0.25 were considered significant. Enrichment plots were also obtained 
with GSEA and ranked according to their enrichment score (ES). 
 
5.5  Protein extraction and immunoblots  
Protein lysates were prepared using lysis buffer (150 mM NaCl, 10 mM Tris pH 7.2, 0.1% SDS, 
1% Triton X-100, 1% deoxycholate, 5 mM EDTA, protease inhibitors). In the case of tissue 
extracts, lysates were homogenized using a Precellys 24 tissue homogenizer (Bertin 
Technologies). Immunoblot analyses were performed according to standard procedures. 
Membranes were stained with antibodies anti-P-Ser473-AKT (Cell Signaling, #4058), anti-P-
Thr24/Thr32-FOXO1/3 (Cell Signaling, #9464), anti-total-AKT1 (Millipore, #07-416), anti-
UCP1 (AbCam, #ab10983), anti-P-Thr1462-TSC2 (Cell Signaling, #3616), anti-TSC2 (Cell 
Signaling, #3612), anti-P-Thr389-p70S6K (Cell Signaling, #9206), anti-P-Ser240/Ser244-S6 
(Cell Signaling, #5364), anti-P-Ser65-4EBP1 (Cell Signaling, #9451), anti-4EBP1 (Cell 
Signaling, #9644), anti-$-actin (Sigma, #AC-15), and anti-%-tubulin (Sigma, #T6557). 
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6. Statistical analysis 
Data are expressed as mean ± s.d. or mean ± s.e.m. and differences are considered significant 
with P value < 0.05 (* p<0.05, ** p<0.01, *** p<0.001). Statistical significance between two 
groups was assessed using the two-tailed unpaired Student's t test. In the longitudinal fat and 
lean content measurement in the monkey study statistical significance was determined using the 
paired Student's t test, as specified in the figure. For survival curves, we used the Log-rank 
(Mantel-Cox) test. These statistical analyses were performed using GraphPad Prism software.  
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PART1. EFFECT OF PHARMACOLOGICAL PI3K INHIBITION ON 
METABOLIC SYNDROME AND OBESITY 
 
Various research lines focussed on longevity, dietary restriction, obesity and metabolic 
syndrome have converged on the concept that a partial downregulation of PI3K signalling 
activity has the potential to improve health and provide protection from obesity and its 
associated pathologies. PI3K inhibitors have recently entered clinical use for cancer treatment, 
but, likewise, it is of great importance to determine the potential beneficial effects of 
pharmacological PI3K inhibition on obesity and healthspan.  
 
1.1  Effects of CNIO-PI3Ki on cellular and glucose homeostasis  
For our studies, we took advantage of CNIO-PI3Ki, a PI3K inhibitor developed by the 
Experimental Therapeutics Programme at the Spanish National Cancer Research Centre (CNIO), 
characterized by high PI3K! (IC50 2.4 nM), PI3K% (IC50 2.5 nM) and modest PI3K# (IC50 44 
nM) inhibitor activity (Figure 8A); no relevant or modest inhibitory activity against other 284 
tested kinases (data not shown) including mTOR (Figure 8A); minimal access to the brain 
(Figure 8B); and a good pharmacokinetic profile in mice (Figure 8C). To compare the effects 
and efficiency of our compound, we also used the well-characterized PI3K inhibitor GDC-0941 
(also called pictisilib) that shows inhibitory activity restricted to PI3K! (IC50 3 nM), PI3K% 
(IC50 3 nM), PI3K$ (IC50 33nM) and PI3K# (IC50 75 nM), little access to the brain and a good 
pharmacokinetic profile as well (Salphati et al., 2012; Workman et al., 2010).   
 
Figure 8. Pharmacological characterization of CNIO-PI3Ki. 
(A) Inhibitory activity (IC50) of CNIO-PI3Ki towards the four PI3K isoforms and mTOR. All assays were performed 
in triplicates (n=3). (B) CNIO-PI3Ki concentration in serum and brain of mice after 1-hour i.v. (2 mg/kg) or oral (10 
mg/kg) CNIO-PI3Ki administration. All values correspond to average ± s.d. n=3, except for brain where CNIO-PI3Ki 
after i.v. was detectable only in one sample. (C) Pharmacokinetic data of CNIO-PI3Ki upon i.v. (2 mg/kg) or oral (10 
mg/kg) administration. Measured parameters are: bioavailability (F); maximum plasmatic concentration (Cmax); time 
for maximum plasmatic concentration (Tmax); area under the curve (AUC); plasmatic half-life of the product (T &); 
plasmatic clearance (Cl) and volume of distribution (Vd). Values correspond to average ± s.d. n=3.  
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 As a first step to use CNIO-PI3Ki in mice, we began by measuring its serum levels by 
mass spectrometry. After a single oral dose of 15 mg/kg, the drug reached a serum 
concentration of 2-3 µg/ml (4-6 µM) 1 to 6 hours post-administration, being completely cleared 
after 24 hours (Figure 9A). Given the direct role of PI3K in insulin signalling and glucose 
homeostasis (Crouthamel et al., 2009), we next examined the effect of CNIO-PI3Ki on glucose 
levels of overnight fasted mice treated with a dose of 15 mg/kg. We observed a glucose peak of 
about 150 mg/dl 30 minutes to 2 hours post-administration (Figure 9B). Importantly, these 
glucose levels are comparable to those of ad libitum-fed mice (Figure 9B).  
 
 
 
 
 
 
Figure 9. Effects of PI3K inhibition on glucose homeostasis. 
(A) Detection of CNIO-PI3Ki in serum by mass spectrometry at the indicated times. Mice (C57BL6 males n=4 per 
group, 3-4 months old) were orally administered with CNIO-PI3Ki (15 mg/kg). Dots correspond to individual values 
and blue line to average. (B) Left panel, glucose serum levels at the indicated times after CNIO-PI3Ki (15 mg/kg) 
orally administered by gavage. Mice (C57BL6 males n=8-9 per group, 4 months old) were fasted overnight prior to 
gavage and maintained under fasting. Values correspond to average ± s.d. Right panel, glucose serum levels of ad 
libitum-fed mice (C57BL6 males n=16, 3 months old). Dots correspond to individual values and blue line to average. 
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
From a molecular point of view, both PI3Kis, GDC-0941 (75 mg/kg) and CNIO-PI3Ki 
(15 mg/kg), significantly reduced phosphorylated AKT (P-Ser473-AKT) (Figure 10A) and 
phosphorylated FOXO1, FOXO3 (P-Thr24/Thr32-FOXO1/3) and 4EBP1 (P-Ser65-4EBP1) 
levels in the liver and, especially, in the interscapular brown adipose tissue (iBAT) of mice 1 
hour after treatment (Figure 10B). Inhibition of P-AKT was still detectable, although less 
notably, in both tissues 6 h post-administration (Figure 10A). Similarly, PI3K inhibition 
resulted in remarkable upregulation of the hepatic gluconeogenic transcriptional programme 
(measured by G6pc mRNA) 1 hour post-treatment, although G6pc levels returned close to basal 
after 6 hours (Figure 10C). Hence, we conclude that, at the administered dose, PI3K inhibitors 
produce a transient glycemic response within physiological range and a measurable 
downregulation of the PI3K/AKT signalling. 
 
 
RESULTS 
73 
Figure 10. In vivo effects of 
PI3K inhibition. 
(A) and (B) immunoblot 
analyses of the indicated proteins 
of liver and iBAT extracts, 1 or 6 
h after oral gavage of vehicle, 
GDC-0941 (75 mg/kg), or 
CNIO-PI3Ki (15 mg/kg). (C) 
Expression of G6pc relative to !-
actin in the liver of mice treated 
by gavage with vehicle, GDC-
0941 (75 mg/kg), or CNIO-
PI3Ki (15 mg/kg) 1 or 6 hours 
post-administration. In (A) and 
(C), mice were fed ad libitum 
during the whole assay. In (B), 
mice were fasted overnight, fed 
for 1 hour ad libitum, food 
removed and dosed by gavage. 
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Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
 In agreement with our previous data (Ortega-Molina et al., 2012), CNIO-PI3Ki 
treatment led to increased UCP1 protein levels in the BAT after 6 h administration, together 
with reduced P-AKT and P-FOXO1 (Figure 11A). After 24 h, and despite normalized P-AKT 
and P-FOXO1 levels and cleared serum PI3K inhibitor, UCP1 levels were still elevated (Figure 
11A). Also, extending our previous findings on the ability of CNIO-PI3Ki to promote brown-
like features within white adipose depots (Ortega-Molina et al., 2012), we also observed 
increased Ucp1 expression in subcutaneous inguinal white adipose tissue (iWAT) and in 
visceral epididymal (eWAT) and perirenal white adipose tissue (rWAT) 6 hours after treatment 
(Figure 11B).  
 
 
 
Figure 11. Effects of CNIO-PI3Ki on UCP1 
expression in brown and white adipose 
tissue.   
(A) Immunoblot analyses of the indicated 
proteins in iBAT lysates after treatment with 
vehicle or CNIO-PI3Ki (15 mg/kg) at the 
indicated times. (B) Ucp1 expression in 
inguinal (iWAT), epididymal (eWAT), and 
perirenal (rWAT) white adipose tissue of mice 
(C57BL6 males n=4 per group, 12 weeks old) 
treated orally by gavage with vehicle or CNIO-
PI3Ki (15 mg/kg) at the indicated times. Data 
are expressed as mean ± s.d.  
Mice were fed ad libitum during the whole 
experiment. Statistical significance was 
determined by the two-tailed Student’s t test: *p 
< 0.05. 
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 As already shown, both PI3K inhibitors have limited access to the brain (Figure 8B), 
but still, the arcuate nucleus of the hypothalamus (ARC), a master regulator of metabolism 
(Sohn et al., 2013; Yeo and Heisler, 2012), is exposed to peripheral circulation through the 
median eminence, a circumventricular organ lacking brain-blood barrier (Cone et al., 2001). 
Thanks to the collaboration established with Dr. Miguel López from de CIMUS (Santiago de 
Compostela), we were able to verify unaltered expression of the main orexigenic (NPY and 
AgRP) and anorexigenic (CART and POMC) neuropeptides by in situ hybridization in the 
arcuate nucleus after oral PI3K inhibitor administration (Figure 12). These results indicate lack 
of hypothalamic effects, at least at the level of the ARC, and represent an important safety 
feature of both PI3K inhibitors.  
 As a conclusion, we show that PI3K inhibitors produce a transient cellular and 
molecular response accompanied by a glycemic peak within physiological range and without 
detectable effects on the hypothalamus.  
 
Figure 12. Hypothalamic effects of PI3K inhibition. 
Effects of oral administration of vehicle, GDC-0941 (75 mg/kg) and CNIO-PI3Ki (15 mg/kg) on NPY, AgRP, POMC 
and CART mRNA expression measured by in situ hybridization in the arcuate nucleus of the hypothalamus (ARC) of 
mice. Data are expressed as mean ± SEM, n=4 per group (male C57BL6). No statistical significant differences were 
observed relative to vehicle by two-tailed Student’s t-test. 
 
 
1.2  PI3K inhibition reduces obesity, visceral fat and hepatic steatosis in mice 
In order to test whether pharmacological PI3K inhibition could reduce obesity in mice, we 
started by performing a 10 days short-term treatment protocol, in which obese mice that had 
been on a HFD for 8 months were daily treated with 10 or 15 mg/kg CNIO-PI3Ki or 10 or 75 
mg/kg GDC-0941 by gavage (Figure 13A). These diet-induced obese mice did not only weight 
around 44% more than control animals on a SD, but also presented insulin resistance and 
elevated levels of leptin (data not shown). Interestingly, mice significantly decreased their body 
weight upon treatment with PI3K inhibitors (Figure 13B) despite continuing on a HFD and 
maintaining their food intake constant (Figure 13C). In the most efficient case (15 mg/kg 
CNIO-PI3Ki), mice lost more than 20% body weight within the 10-day treatment and even 
reached the same weight as lean SD-fed mice (Figure 13B). Although to a lesser extent, 
treatment with 10 mg/kg CNIO-PI3Ki and 75 mg/kg GDC-0941 significantly reduced body 
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weight, too (Figure 13B). In all cases, mice displayed ad libitum glucose levels similar to 
vehicle treated mice 3 days after the end of the treatment (Figure 13D), meaning that glucose 
homeostasis had completely been restored. We also performed dual-energy X-ray 
absorptiometry (DXA) before, during and after treatment, which allowed us to follow fat and 
lean mass content of mice as well as distinguish the tissue responsible for the observed body 
weight loss. Importantly, this loss was exclusively due to a reduction in adiposity, while lean 
mass content remained stable throughout the whole experiment (Figure 13E).  
 
 
 
 
 
 
 
Figure 13. Body weight reduction and decreased adiposity after PI3Ki treatment. 
(A) Schematic diagram showing administration regime of vehicle or PI3K inhibitors by gavage at the indicated days 
(grey boxes) to diet-induced obese mice (C57BL6/CBA males, n=4-7 per group, 10 months old). (B) Body weight 
change relative to day 0 (left) or to the last day of treatment (day 10) (right). For reference, right panel includes a 
dotted red line corresponding to the relative body weight of control male mice fed SD. (C) Average food intake per 
day during treatment. (D) Ad libitum glucose serum levels at the end of the treatment (day 13) with PI3K inhibitors. 
(E) Adiposity (top) and lean mass (bottom) at the indicated times measured by DXA. Adiposity values correspond to 
the fat percentage relative to the sum of lean and fat masses. For reference, graphs include dotted red lines 
corresponding to adiposity and lean mass of control male mice fed with SD. Right panel, representative DXA images 
at the indicated days of two mice treated with vehicle or CNIO-PI3Ki (15 mg/kg), respectively.   
All values correspond to average ± s.d. All panels follow colour code as in (A). Statistical significance was 
determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
 Examination of a number of tissues at the end of the treatment revealed important 
macroscopical as well as histological differences between groups. Whereas vehicle treated mice 
showed a pale coloured liver characteristic of obese animals and a great amount of fat 
surrounding the heart (pericardial fat), 15 mg/kg CNIO-PI3Ki treated mice exhibited normal, 
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healthy liver coloration and almost absent pericardial fat (Figure 14A). Both features seemed to 
be partially improved in 10 mg/kg CNIO-PI3Ki or 75 mg/kg GDC-0941 treated mice compared 
to controls (Figure 14A). Furthermore, histological analyses revealed reduced lipid 
accumulation in liver as well as reduced adipocyte size in eWAT, iBAT and perirenal and 
pericardial fat of CNIO-PI3Ki (15 and 10 mg/kg) and 75 mg/kg GDC-0941 treated mice 
(Figure 14B). Also, some browning areas (Wu et al., 2013), characterized by the presence of 
brown-like adipocytes interspersed in the eWAT, were also distinguishable, especially in the 
case of 15 mg/kg CNIO-PI3Ki-treated mice (Figure 14B). 
 Altogether, these data indicate that pharmacological PI3K inhibition reduces adiposity, 
lipid accumulation and induces browning within the white adipose tissue, thereby reducing 
body weight in diet-induced obese mice.  
 
 
 
Figure 14. Reduced liver steatosis and increased browning after acute CNIO-PI3Ki treatment. 
(A) Representative pictures of liver and fat surrounding lung and heart (perivascular fat) in vehicle- and PI3Ki-treated 
mice at day 13. Bars correspond to 0.5 cm. (B) Representative pictures of H&E-stained sections of the indicated 
tissues at day 13. eWAT is epididymal WAT and iBAT interscapular BAT. In perirenal fat K indicates kidney; in 
perivascular fat L indicates lung and H heart. Bars correspond to 0.5 mm with the exception of the perivascular 
picture, where it corresponds to 2 mm. All high-magnification insets correspond to 50 µm.   
Mice are the same as in Figure 13.  
 
  
1.3  Improved metabolic syndrome after long-term CNIO-PI3Ki treatment 
A desirable feature for an anti-obesity treatment is to retain activity at low doses, which would 
allow its administration during prolonged periods of time and would lead to a gradual, 
controllable weight loss. Bearing this in mind, we formulated the CNIO-PI3Ki for 
administration in drinking water at a concentration of 0.1 mg/ml, which corresponds to a daily-
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accumulated dose of approximately 10 mg/kg. For this experiment, diet-induced obese HFD-fed 
and lean SD-fed mice were either treated with vehicle or CNIO-PI3Ki for 2.5 months. Due to ad 
libitum and, consequently, heterogeneous water access of mice, the administered dose resulted 
in detectable but variable (63 ± 54 ng/ml) CNIO-PI3Ki levels in serum with almost no signs of 
accumulation in iWAT, iBAT and liver (Figure 15A). At this point, it is worth mentioning that 
the mean CNIO-PI3Ki serum concentration in this assay is about 40-fold lower than the drug’s 
peak obtained after 1-6 hours CNIO-PI3Ki at 15 mg/kg given by gavage (Figure 9A).  
 Soon after the beginning of the treatment, obese HFD-fed mice treated with CNIO-
PI3Ki showed a progressive body weight loss (Figure 15B) despite continuing on a HFD and 
maintaining their food and water intake unaltered (Figure 15C). This loss represented a 20% 
body weight reduction compared to HFD vehicle-treated mice and takes places during the first 
50 days of treatment, as body weight stabilizes after this time point (Figure 15B). This 
behaviour supports the idea that CNIO-PI3Ki increases energy expenditure, and, thereby, 
lowers body weight until mice reach a new energetic balance. Also, the fact that CNIO-PI3Ki 
treatment is only effective in HFD-fed mice and not in lean SD-fed animals suggests that the 
inhibitor may selectively act on energy expenditure induced by nutritional overload and 
represents a relevant safety feature as well.  
 
 
Figure 15. Obesity reduction upon long-term CNIO-PI3Ki treatment.    
(A) CNIO-PI3Ki concentration measured by mass spectrometry in serum, iWAT, iBAT and liver of long-term CNIO-
PI3Ki (0.1 mg/ml in drinking water) treated mice fed on a standard diet (SD, n=2-5 depending on tissue) or high fat 
diet (HFD, n=7). Dots and squares correspond to individual values and blue bars to average. (B) Left, body weight 
curves during 2.5 months vehicle or CNIO-PI3Ki (0.1 mg/ml) treatment in drinking water. HFD, mice fed high-fat 
diet since 2 months of age and throughout the whole assay; SD, mice fed SD. C57BL6 males, n=5-7 per group; 11 
months at the beginning of the treatment. Right, body weights relative to SD-fed, vehicle-treated mice at the end of 
the treatment. Significant weight difference between groups maintained on a HFD started at day 23 (p < 0.05) and 
lasted until the end of the assay (p < 0.001). (C) Absolute (left) and relative (right) food and water intake during 
vehicle/CNIO-PI3Ki treatment of HFD-fed mice. Intake was measured in periods of 3 days in a total of 4 periods, 
distributed throughout the entire assay. 
Values correspond to average ± s.d in (B) or average ± SEM in (C). Statistical significance was determined by the 
two-tailed Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001.  
 
 
We confirmed again that the observed body weight loss after CNIO-PI3Ki treatment 
was exclusively due to a reduction in adiposity %, as lean mass content was unaltered (Figure 
16A). Verifying this data, we found reduced relative weight of eWAT and iWAT as well as 
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Figure 16. Adipose content is 
reduced upon long-term CNIO-
PI3Ki treatment.    
(A) Adiposity (left) and lean mass 
(right) measured by DXA at the 
indicated times. Adiposity values 
correspond to the percentage of 
fat relative to the sum of lean and 
fat masses. (B) Left, weight of 
liver, eWAT and iWAT relative 
to body weight (BW) at the end of 
vehicle or CNIO-PI3Ki long-term 
treatment. SD, n=5 in both 
decreased pericardial and perirenal fat accumulation (Figure 16B), lower leptin serum levels 
(Figure 16C) and a tendency towards reduced serum triglycerides (Figure 16D) in CNIO-
PI3Ki treated mice compared to vehicles at the end of the treatment. In contrast, cholesterol 
serum levels did not change (Figure 16E).  
 
 
 
 
 
 
  
 
 
 
treatment. SD, n=5 in both groups; HFD, n=6 for vehicle and n=7 for CNIO-PI3Ki. Right, representative
macroscopic pictures of pericardial and perirenal fat of vehicle or CNIO-PI3Ki treated mice. (C) Ad libitum leptin 
serum levels, (D) ad libitum triglycerides serum levels and (E) ad libitum cholesterol serum levels at the end of the 
long-term vehicle/CNIO-PI3Ki treatment.  
Values correspond to average ± s.d in (A) and (B). In (C), (D), and (E) dots correspond to individual values and blue 
bars to average. Mice are the same as in Figure 15. 
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001.  
 
 
 We next wanted to address if the CNIO-PI3Ki treatment had improved some of the 
pathological signs associated to obesity. For example, PI3K inhibition was able to revert liver 
steatosis by reducing fat accumulation in liver (Figure 17A). Other markers of liver injury such 
as circulating alanine aminotransferase (ALT) levels (Figure 17B) or Il-6 mRNA expression in 
liver, indicative of chronic inflammatory reaction (Figure 17C), were also reduced in CNIO-
PI3Ki treated mice. Regarding the adipose tissues of HFD-fed mice, iBAT as well as 
epididymal WAT (eWAT) of CNIO-PI3Ki-treated mice showed a clear decrease in lipid 
droplets compared with vehicle-treated mice (Figure 17A). In contrast to the previous 
experiment, in which CNIO-PI3Ki was administered acutely by gavage at a higher dose (15 
mg/kg), we were not able to detect any browning areas in the eWAT of CNIO-PI3Ki-treated 
animals (Figure 17A). We hypothesize that a possible reason for this finding is precisely the 
low CNIO-PI3Ki dose administered in drinking water, which leads to a 40-fold lower serum 
concentration compared to the peak of drug achieved by gavage. Another feature of insulin 
resistance associated with obesity is the infiltration of macrophages into the white adipose tissue 
(Strissel et al., 2007). Interestingly, staining with macrophage-restricted glycoprotein F4/80 
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revealed reduced infiltration of macrophages in HFD CNIO-PI3Ki-treated mice compared with 
vehicle-treated (Figure 17A). Measurement of macrophage mRNA markers such as Emr1 and 
Cd68 in the eWAT showed a similar tendency (Figure 17D). Of note, no differences could be 
established in SD-fed mice treated or not with CNIO-PI3Ki in any of the analysed parameters.  
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Reduced hepatic steatosis and inflammation after CNIO-PI3Ki treatment. 
(A) Representative pictures of liver sections stained with H&E or oil red O (upper panel), interscapular BAT (iBAT) 
sections stained with H&E or anti-UCP1 (middle panel) and epididymal WAT (eWAT) sections stained with H&E or 
anti-F4/80 (lower panel). Bars in low-magnification pictures correspond to 200 µm; bars in high magnification insets 
correspond to 50 µm. (B) Ad libitum alanine aminotransferase (ALT) serum levels at the end of the long-term 
vehicle/CNIO-PI3Ki treatment. Dots correspond to individual values and blue bar to average. (C) Il-6 expression 
relative to "-actin in liver. (D) Emr1 and Cd68 mRNA levels relative to "-actin in eWAT. Values correspond to 
average ± s.d. Mice in this figure are the same as in Figure 15.  
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05. 
  
 
 Next, we wondered whether 2.5 months CNIO-PI3Ki treatment had possibly 
ameliorated glucose homeostasis. However, none of the tested parameters including glucose 
tolerance (Figure 18A), insulin tolerance (Figure 18B), glycemia, insulinemia, and insulin 
resistance (quantified by the HOMA-IR index) (Figure 18C) showed any difference between 
HFD vehicle or CNIO-PI3Ki treated mice. Taking into account that the mice used for this assay 
had been for more than 8 months on a HFD and are presumable profoundly diabetic, we 
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Figure 18. Glucose homeostasis 
after 2.5 and 5 months CNIO-PI3Ki 
treatment.  
(A) Area under the curve (AUC) of 
GTT and (B) AUC of ITT at the end 
of 2.5 months treatment with vehicle 
of CNIO-PI3Ki. SD n=4-5 per group; 
HFD, n=4-7 per group. (C) Overnight 
fasting glucose serum levels (left), 
fasting insulin serum levels (middle), 
and derived insulin resistance index 
HOMA-IR (right) at the end of 2.5 
reasoned that 2.5 months treatment would not be enough to improve glucose homeostasis. 
Therefore, we performed a new experiment in which diet-induced obese mice (that had been for 
8 months on a HFD previously) were subjected to vehicle or 0.1 mg/ml CNIO-Pi3Ki in their 
drinking water and under continuous HFD conditions for 5 months. Again, obese mice treated 
with the CNIO-PI3K inhibitor reduced their body weight about a 20% compared to vehicle-
treated mice during the first 50 days of treatment and, afterwards, stabilized their weight for the 
next 100 days (Figure 18D). This observation points out to the fact that the treatment does not 
cause any drug resistance, as mice do not spontaneously gain weight again. Of note, body 
weight is only maintained as long as the treatment is present, as PI3Ki withdrawal from the 
drinking water promotes rapid body weight gain (Figure 18D), thereby indicating that the 
treatment does not cause any irreversible changes in the organism and normal homeostasis can 
rapidly be restored. Regarding glucose homeostasis, we were able to detect normalized fasting 
glucose levels, comparable to those of SD fed mice, in HFD-fed mice that had been treated for 5 
months with the CNIO-PI3Ki and then released from the drug for the next month (Figure 18E). 
 In conclusion, we have demonstrated that long-term low-dose CNIO-PI3Ki treatment 
progressively reduces body weight by decreasing fat accumulation only in the context of 
nutritional overload and improves hepatic steatosis, chronic inflammation and fasting glucose 
levels, thereby ameliorating some of the signs of the metabolic syndrome. Furthermore, CNIO-
PI3Ki treatment is reversible and does not cause resistance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
HOMA-IR (right) at the end of 2.5 months. (D) Body weight change relative to day 0. 10-month-old mic  (C57BL6 
male, n=9-10 per group) fed with HFD for 8 months were treated with vehicle or CNIO-PI3Ki (0.1 mg/ml) in 
drinking water during 5 months. At day 155, treatment was removed from the water for the rest of the experiment. 
Mice were fed with HFD during the entire assay. Significant weight difference between groups lasted from day 7 to 
day 180. (E) Fasting glucose levels of HFD-fed mice at the end of the procedure (5 months vehicle/CNIO-PI3Ki 
treatment and 48 days treatment-free) compared to SD-fed control mice.  
In (A), (B) and (C) dots correspond to individual values and blue lines to average. In (E) values correspond to 
average ± s.d. Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01. 
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1.4 CNIO-PI3Ki protects against obesity and induces energy expenditure 
We also asked whether CNIO-PI3Ki treatment would prevent obesity in lean mice subjected to 
de novo HFD. Thus, we designed two new assays in which lean SD-fed mice were switched to 
high fat diet together with the administration of the CNIO-PI3Ki either in the drinking water at 
a concentration of 0.1 mg/ml and performed at the CNIO (Madrid), or mixed with food pellets 
using a concentration of 0.17 g/kg and performed by the group of Dr. Rafael de Cabo at the 
National Institute on Aging (NIA, Baltimore). The approximate accumulated daily dose was 10 
mg/kg and HFD food as well as water was available ad libitum in both cases. Importantly, 
CNIO-PI3Ki treatment clearly slowed down the rate of body weight gain despite unaffected 
food intake (Figure 19A). While vehicle treated mice increased their body weight around 50% 
in 80 days, CNIO-PI3Ki-treated had only gained about 25% body weight (Figure 19A). 
Moreover, mice treated with the inhibitor in their food (NIA experiment) showed improved 
fasting glucose levels (Figure 19B) suggesting that the CNIO-PI3K inhibitor treatment not only 
protects against obesity onset but also prevents glucose intolerance.  
These observations underline the efficacy of our compound, which works in drinking 
water as well as mixed with food in two different and independent laboratories. On the other 
hand, they indicate that the beneficial effects of PI3K inhibition appear as soon as high-fat 
feeding starts in lean, healthy mice.  
 
 
 
Figure 19. CNIO-PI3Ki treatment prevents obesity onset.  
(A) Left, performed at the CNIO, body weight change relative to day 0. 2-months-old mice (C57BL6 male, n=8-10 
per group) were put simultaneously on a HFD with CNIO-PI3Ki (0.1 mg/ml) or vehicle in drinking water for 20 
weeks. Significant weight difference starts at day 3. Middle, performed at the NIA, body weight change relative to 
day 0. 28-weeks-old SD-fed mice (C57BL6 male, n=18-24 per group) were put on HFD or HFD supplemented with 
CNIO-PI3Ki (0.17 g/kg) for 12 weeks. Significant weight difference observed after first weight measurement. Right, 
food intake of mice fed with HFD or HFD supplemented with CNIO-PI3Ki. Intake was measured in periods of 2 
days for a total of 3 periods at weeks 2, 4 and 8 of treatment. Mice are the same as in the middle panel. (B) Fasting 
glucose level of mice after 12 weeks with or without CNIO-PI3Ki treatment in their HFD food. Animals (control n=8, 
CNIO-PI3Ki n=8) are from assay (A) performed at the NIA. 
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05. 
 
 
We have previously shown that CNIO-PI3Ki (15 mg/kg via oral gavage) enhances 
energy expenditure, at least in part, by activating thermogenesis in brown adipocytes, both in 
vivo and in vitro (Ortega-Molina et al., 2012). To validate whether continuous, low-dose CNIO-
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PI3Ki treatment via food pellets (NIA) had a measurable impact on energy expenditure, we 
performed indirect calorimetry assay which revealed higher constitutive energy expenditure 
(Figure 20A), oxygen consumption and CO2 consumption (Figure 20B and 20C) together with 
higher locomotor activity (Figure 20D). Still, it remains debatable to what extent increased 
locomotor activity translates into increased total energy expenditure (Virtue et al., 2012). In 
order to evaluate iBAT thermogenesis, we also measured whole-body and shoulder temperature 
using a thermogenic camera. Although body temperature progressively dropped due to the 
administered anaesthesia, only shoulder temperature was consistently higher in HFD CNIO-
PI3Ki compared to both, HFD vehicle and weight-matched SD-fed control mice (Figure 20E).  
 In summary, PI3K inhibition protects against obesity and glucose resistance onset in 
lean mice subjected to de novo HFD and elevates energy expenditure at the administered low-
dose.  
 
 
 
 
 
 
 
 
 
 
 
(n=6-9 per group). Temperature was recorded every second for 10 min. All these assays were performed at the NIA, 
and mice are the same as in Figure 12, middle panel (NIA). Values correspond to average ± s.d. Statistical 
significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01. 
 
 
1.5  CNIO-PI3Ki treatment reduces obesity in hyperphagic mice  
We next wanted to test if our inhibitor was also able to induce body weight loss in a model of 
obesity independent of high fat intake. Hence, we used the leptin deficient, hyperphagic, ob/ob 
mouse model, which constitutes a relevant model of obesity induced by a high intake of 
standard diet. Importantly, three months administration of CNIO-PI3Ki in the drinking water 
using again an accumulative daily dose of 10 mg/kg resulted in a very pronounced body weight 
loss compared to vehicle-treated mice (Figure 21A). Taking into account that CNIO-PI3Ki 
ob/ob mice were more hyperphagic than vehicle-treated mice (Figure 21B), this weight 
Figure 20. CNIO-PI3Ki treatment enhances 
energy expenditure. 
(A) Energy expenditure (EE) recorded during 80 h 
(left) and mean energy expenditure (right) measured 
during light and dark period of control and CNIO-
PI3Ki-treated mice. (B) Mean VO2, (C) VCO2 
consumption and (D) activity, measured as total 
counts, during light and dark period of mice treated 
during 84 days with HFD in the absence (control, 
n=7) or presence (n=8) of PI3Ki. (E) Whole-body 
and shoulder area temperature of mice on HFD with 
or without PI3Ki, and of control lean mice on SD 
second for 10 min.  
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difference is even more striking. Reaffirming our previous data, PI3Ki-treated ob/ob mice 
showed reduced liver damage measured by ALT levels in serum (Figure 21C), reduced hepatic 
steatosis and decreased adipocyte size in perirenal, pericardial and iBAT (Figure 21D). 
However, no differences were observed regarding glucose homeostasis (Figure 21E), 
reinforcing the idea that only longer treatments, such as 5 month treatments, are able to affect 
glucose tolerance.  
These results prove that CNIO-PI3Ki treatment is also effective in obese hyperphagic 
ob/ob mice, and therefore, that CNIO-PI3Ki protects against obesity not only induced by high-
fat diets but also caused from an excessive intake of a normal diet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. CNIO-PI3Ki treatment reduces obesity of hyperphagic, leptin deficient ob/ob mice.    
(A) Body weight change relative to day 0, and representative picture of CNIO-PI3Ki or vehicle treated mice at the 
end of the treatment. Hyperphagic ob/ob male mice (12 weeks old) fed with SD and treated with vehicle or CNIO-
PI3Ki (0.1 mg/ml) in drinking water during 16 weeks. C57BL6 males ob/ob mice, n=10 per group. Significant weight 
difference between groups starts at day 3. (B) Absolute (left) and relative to body weight (right) food intake of ob/ob 
mice treated with vehicle or CNIO-PI3Ki. Intake was measured in periods of 4 days, in a total of two periods, 
distributed in the middle of the treatment. (C) Alanine aminotransferase (ALT) levels in serum of ob/ob mice after 
105 day of vehicle (n=6) or CNIO-PI3Ki (n=5) treatment. (D) Representative microscopic pictures of liver, perirenal 
and pericardial fat sections stained with H&E, and BAT stained with anti-UCP1 of ob/ob mice at the end of the 
treatment. Bars in low magnification pictures correspond to 200 µm, and bars in high magnification insets to 50 µm. 
(E) Ad libitum (ad lib) and fasting serum insulin (left) and glucose (middle) level in ob/ob mice at the end of the 
treatment. Right, insulin resistance of ob/ob mice measured by the HOMA-IR index. Dots correspond to individual 
values and blue line to average.  
Values correspond to average ± s.d. Statistical significance was determined by the two-tailed Student’s t test: *p < 
0.05, **p<0.01. 
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1.6  PI3K! inhibition promotes Ucp1 activity and causes body weight loss 
The beneficial metabolic effects of overall PI3K signalling reduction have been attributed to an 
increase in energy expenditure (Becattini et al., 2011; Garcia-Cao et al., 2012; Ortega-Molina et 
al., 2012; Perino et al., 2014) and thereby to an attenuation of nutrient storage in favour of 
nutrient consumption. We have previously shown that GDC-0941 and CNIO-PI3Ki increase 
Ucp1 expression and thermogenesis in cultured brown adipocytes (Ortega-Molina et al., 2012). 
Dealing with two compounds that inhibit several PI3K isoforms (in both cases principally ! and 
" together with %, in a lesser extent; and # only in the case of GDC-0941), we next wanted to 
identify the isoform responsible for the regulation of the thermogenic activity in brown 
adipocytes in vitro. Individual inhibition of the predominantly expressed catalytic p110-!, p110-
$ and p110-% subunits in brown adipocytes using shRNA revealed that only PI3K!, but none of 
the other PI3Ks, resulted in enhanced Ucp1 and Pgc1! expression in forskolin-stimulated 
brown adipocytes (Figure 22). This result reinforces the concept that PI3K! inhibition is a 
relevant mediator of the link between PI3K and metabolism (Foukas et al., 2013; Ortega-Molina 
et al., 2012). Nevertheless, it does not exclude other mechanisms through which PI3K! 
inhibition may induce energy expenditure nor alternative mechanisms independent of brown 
adipocyte thermogenesis by which inhibition of other PI3K isoforms may increase energy 
expenditure (Becattini et al., 2011; Perino et al., 2014).  
 
 
 
 
 
 
Figure 22. PI3K! inhibition induces Ucp1 and Pgc1! expression in vitro.  
(A) Left, relative mRNA level of the different PI3K isoforms PI3K!, PI3K", PI3K$ and PI3K# in pre-brown 
adipocytes. Middle, validation of PI3K shRNAs. p110!, p110" and p110$ mRNA expression in pre-brown 
adipocytes after sh-scramble, sh-p110!, sh-p110$ and sh-p110% lentiviral transduction. Right, relative Ucp1 and 
Pgc1! expression in pre-brown adipocytes transduced with the indicated shRNAs and after 4h DMSO or forskolin 10 
µM stimulation. mRNA levels were normalized to "-actin. Stimulation was performed twice with similar results and 
each experiment was done in triplicate. Values correspond to average ± s.d. of one experiment, n=3.  
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p<0.01. 
 
 
 Furthermore, we next wanted to verify whether PI3K! inhibition was responsible for 
the described body weight loss in vivo as well. Thus, we decided to treat 20 weeks old obese 
ob/ob mice daily by gavage, and during 16 days, either with vehicle or with three different PI3K 
inhibitors: CNIO-PI3Ki at 5 mg/kg and 1 mg/kg, BYL-719 (also called alpelisib) and acalisib, 
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both at 10 mg/kg and 5 mg/kg. BYL-719 (Furet et al., 2013) is a selective PI3K! inhibitor (IC50 
of 5 nM) currently in phase I and II clinical trials to treat various tumour types such as breast or 
pancreas cancer. Acalisib (Shugg et al., 2013) is mainly a % subunit inhibitor (IC50 of 12.7 nM) 
used for mouse studies and closely related to idelalisib, which has been already approved for the 
treatment of chronic lymphocytic leukemia. Initially, we checked the physiological response on 
glucose homeostasis by following for 24 hours the glucose levels of ad libitum fed ob/ob mice 
given a single dose of the different inhibitors by gavage. A prolonged hyperglycemic peak was 
observed during the first 6 hours after CNIO-PI3Ki and BYL-719 treatment, while acalisib and 
vehicle did not have any significant effects on glucose levels (Figure 23A). Importantly, 
homeostasis was re-established after 24 hours.   
 Soon after daily exposure to CNIO-PI3Ki and BYL-719 (only at the dose of 10 mg/kg), 
ob/ob mice started losing weight (Figure 23B) despite maintaining their food intake constant or 
even more elevated than controls (Figure 23C). This weight loss only continued during the first 
10 days of treatment and, afterwards, body weight stabilized until the end of the assay. 
Compared to vehicle-treated mice, CNIO-PI3Ki (1 mg/kg) and BYL-719 (5 mg/kg) treatment 
produced a significant 6-7% reduction in body weight, and CNIO-PI3Ki (5 mg/kg) and BYL-
719 (10 mg/kg) resulted in a significant 10% body weight reduction (Figure 23B). Moreover, 
acalisib-treated mice showed a small, non-significant, body weight reduction compared to 
vehicle-treated animals (Figure 23B). Again, seven days after the beginning of the treatment, 
physiological glucose levels were confirmed 24 hours post-PI3Ki dosing (Figure 23D). Of note, 
PI3Ki-treated ob/ob mice, in particular those treated with BYL-719 (10 mg/kg) and CNIO-
PI3Ki (5 mg/kg), showed a very important increase in water intake (Figure 23C), probably 
resulting as a mechanism to counteract the detected hyperglycaemic peak. In this context, it is 
relevant to mention that, at later time points (between day 9 to 16), around 20% of the mice 
treated with CNIO-PI3Ki and BYL-719, at both doses, had to be sacrificed due to their inability 
to re-establish normal glucose homeostasis.  
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Figure 23. Effects of PI3K! and PI3K" inhibition in ob/ob mice. 
(A) Glucose serum levels at the indicated times after vehicle, BYL-719 (only PI3K!-inhibitor), acalisib (mainly 
PI3K%-inhibitor) or CNIO-PI3Ki (PI3K! and PI3K% inhibitor) orally administered by gavage at the specified doses. 
ob/ob male mice n=10 per group; 20 weeks old. (B) Left, body weight change relative to day 0, or right, relative to 
the last day of treatment (d16). For reference, the right panel includes a dotted black line corresponding to the initial 
weight. (C) Relative food and water intake during vehicle and PI3K inhibitor treatment. Intake was measured for 5 
days, in the middle of the assay. (D) Ad libitum glucose serum levels, measured before new dosing, after 7 days 
treatment. 
Values correspond to average ± s.d. Statistical significance was determined by the two-tailed Student’s t test: *p < 
0.05, **p<0.01, ***p<0.001. 
 
 
 Additionally, we analysed various metabolic parameters in serum at the end of the assay. 
Probably, as a sign of low fat absorption by the adipose tissue, we detected higher circulating 
triglycerides (Figure 24A) and free fatty acid levels (Figure 24B) in BYL-719 (10 and 5 
mg/kg) and CNIO-PI3Ki-treated (5 mg/kg) ob/ob mice. Similarly, cholesterol serum levels 
appeared elevated in mice treated with BYL-719 (Figure 24A). Interestingly, CNIO-PI3Ki-
treated ob/ob mice presented reduced lactate serum levels compared to vehicle-treated controls 
(Figure 24A). As previously reported in Tg-PTEN mice (Garcia-Cao et al., 2012) reduced 
lactate levels can be considered an indicator of increased mitochondrial activity since pyruvate, 
generated from glucose catabolism, can be reduced to lactic acid (anaerobic glycolysis) or 
further metabolized by the mitochondria (oxidative phosphorylation). Consequently, this 
suggests that an increased mitochondrial oxidative phosphorylation may also be contributing to 
the described body weight loss.  
                       
  
 
   
 
 
 
Figure 24. PI3K! and PI3K" inhibition in ob/ob mice.  
(A) Ad libitum serum triglycerides, lactate and cholesterol level; and (B) free fatty acids serum levels at the end of the 
treatment (day 16). n=6-8 per group. Values correspond to average ± s.d.  
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p<0.01, ***p<0.001. 
 
 
 Aiming to determine whether the used PI3K inhibitors were having an impact on energy 
expenditure that could explain the different outcomes observed on body weight, we decided to 
perform indirect calorimetry. Therefore, we treated lean mice orally with 15 mg/kg of CNIO-
PI3Ki, BYL-719 or acalisib and recorded for 6 hours (starting one hour after gavage) oxygen 
and CO2 consumption. To minimize the effects of body weight on energy expenditure, we 
selected a cohort of mice with homogenous weights (29.5 ± 1.25 g) for this experiment. As 
expected, administration of CNIO-PI3Ki and BYL-719 significantly induced energy 
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expenditure in mice compared to controls (Figure 25) whereas acalisib treatment did not have 
any effect on energy expenditure.   
 Altogether, these data point out to the fact that PI3K! inhibition, and not PI3K%, is the 
key event leading to enhanced energy expenditure and body weight reduction. Likewise, and 
taking into account the different concentrations used, CNIO-PI3Ki appears more potent and 
efficient than BYL-719 in reducing obesity. 
 
 
 
 
Figure 25. Energy expenditure after PI3K inhibitor administration.   
Left, energy expenditure (EE) of lean mice after administration of 15 mg/kg of CNIO-PI3Ki, BYL-719 or acalisib. 
Animals were orally treated by gavage and EE recoded from 1 to 6 hours post-gavage. n=6-8 males, 20 weeks old. 
Middle, mean EE and right, area under the curve (AUC) after PI3K inhibitor treatment. Values correspond to average 
± s.e.m.  
Statistical significance compared to vehicle was determined by the two-tailed Student’s t test: *p < 0.05, **p<0.01.  
 
 
1.7 CNIO-PI3Ki treatment reduces adiposity in rhesus monkeys 
Having validated that the CNIO-PI3K inhibitor treatment is able to revert obesity by reducing 
fat accumulation in different obesity mouse models, as well as improve some of the signs of the 
metabolic syndrome such hepatic steatosis and fasting glucose levels together with reduced 
inflammation, we next decided to examine the effects of CNIO-PI3Ki on rhesus monkeys 
(Macaca mulatta) thanks to the collaboration established with Dr. Rafael de Cabo at the 
National Institute on Aging (NIA, Baltimore) and performed at the Animal Centre (Poolesville).   
 Initially, we performed a preliminary study in which we tried to determine the best and 
safest CNIO-PI3Ki dose for rhesus monkeys. Therefore, we monitored the response of 6 
animals (3 females and 3 males) after intravenous administration with increasing concentrations 
of the compound, ranging from 0.2 to 2.1 mg/kg and calculated upon allometric scaling of the 
mouse dosing. We confirmed that 2.1 mg/kg CNIO-PI3Ki resulted in a detectable PI3Ki serum 
concentration of 400 ± 224 ng/ml 2 hours post-dosing (Figure 26A) that was comparable to the 
one achieved in mice 1-6 hours post oral administration and that was well tolerated, as it did not 
have any harmful effects on glycemia (Figure 26B) or heart rate (Figure 26C).  
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Figure 26. Preliminary dose-response study in rhesus monkeys.  
(A) CNIO-PI3Ki concentration measured by mass spectrometry in serum of rhesus monkeys (n=5-6) 2h after i.v. 
injection of 0.2 mg/kg, 0.7 mg/kg, 1.4 mg/kg and 2.1 mg/kg CNIO-PI3Ki. Dots correspond to single individuals and 
blue lines to dose-specific averages. (B) Serum glucose values measured at specific intervals after i.v. administration 
of the indicated CNIO-PI3Ki doses. (C) Heart rate of monkeys i.v. injected with the indicated CNIO-PI3Ki doses; 
same colour code as (B).  
All measurements performed throughout the preliminary dose-response study (n=5-6). No statistical significant 
differences were detected. 
 
 
Once established that 2.1 mg/kg CNIO-PI3Ki was the highest and safest tolerated dose, 
a group of 19 naturally obese monkeys was selected for the study. Monkeys, aged between 12 to 
27 years (18 ± 5.4 years) and considered naturally obese based on high body weight (11.8 ± 2.5 
kg) and a body fat index ' 27% (Hansen et al., 2013), were randomized into control group (n=9; 
5 females and 4 males) and CNIO-PI3Ki-treated group (n=10; 6 females and 4 males), and were 
followed during 12 weeks of treatment in a longitudinal study. Drug treatment consisted of a 
daily oral administration of 2.1 mg/kg CNIO-PI3Ki that led to PI3Ki serum levels of 35 ± 20 
ng/ml (Figure 27A), around 2-fold lower than the observed in mice allowed to ad libitum 
access to 0.1 mg/ml in drinking water. During the whole assay, obese monkeys did not change 
their standard chow intake (Figure 27B) but received, however, a daily tasty treat that 
facilitated the dosing of the drug (control monkeys received the same treat without compound). 
Of note, the treat represents a 16% increase in total caloric intake (Figure 27B). Unfortunately, 
no differences were detected in total body weight in any of the two groups throughout the whole 
study (Figure 27C). Nevertheless, these additional calories from the diet resulted in a 4% trunk 
adiposity increase measured by DXA in the control group at the end of the 12-week experiment 
(Figure 27D). Interestingly, in contrast to the control group, CNIO-PI3Ki-treated macaques had 
maintained or even reduced their adiposity content (Figure 27D), leading to a significant 7% 
relative adiposity difference between both groups at the end of the 3 months treatment (Figure 
27D).  
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Figure 27. CNIO-PI3Ki reduces adiposity of obese rhesus monkeys.  
(A) CNIO-PI3Ki concentration in serum of control (n=9) and drug-treated monkeys (n=10). Serum samples were 
collected 2 hours post oral administration of 2.1 mg/kg PI3Ki treatment and analyzed by mass spectrometry. Dots 
correspond to individual values and blue line to average. (B) Relative calorie intake of control (n=9) and CNIO-
PI3Ki-treated (n=10) monkeys at baseline and again after 11 weeks of daily drug treatment. Values with or without 
vehicle (treat) are included. (C) Body weight of control and experimental rhesus monkeys treated with 2.1 mg/kg 
CNIO-PI3Ki after 4, 8 and 12 weeks treatment. Values correspond to average ± s.d.  (D) Left, trunk adiposity 
evolution measured by DXA in control monkeys at baseline and after 12 weeks vehicle-treatment. Middle, 
progression of trunk adiposity in CNIO-PI3Ki-treated monkeys at baseline and after 12 weeks PI3Ki-treatment. Right, 
fold change trunk adiposity, calculated for each monkey as adiposity at week 12 relative to baseline adiposity. As a 
reference, dotted line represents mean adiposity at baseline.  
Statistical significance was determined by the two-tailed Student’s t test, except for (F), left and middle panel 
(longitudinal analysis) that was determined by the paired Student’s t test: *p < 0.05, **p<0.01. 
 
 
 Metabolic and welfare parameters associated to respiration, pulse, blood pressure or 
temperature as well as complete blood biochemistry were measured before, during and after the 
trial. Importantly, a tendency towards decreased relative fasting glucose levels was observed in 
the CNIO-PI3Ki-treated monkeys compared to controls (Figure 28A). Whereas fasting glucose 
levels did not change after 10 weeks vehicle treatment compared to baseline in control monkeys 
(Figure 28A), CNIO-PI3Ki macaques showed significantly improved glucose levels after drug 
treatment (Figure 28A). Nevertheless, no changes were found in the intravenous glucose 
tolerance test (IVGTT) (Figure 28B), fasting insulin levels (Figure 28C) or in the insulin 
resistance index HOMA-IR (Figure 28D). Of note, CNIO-PI3Ki did not affect any of the other 
metabolic and blood chemistry parameters tested including temperature, heart rate, total proteins, 
ALT, bilirubin, creatinine, calcium, sodium, potassium, cholesterol, triglycerides, white and red 
blood cells, hemoglobin, hematocrit, MCV, MCH, lymphocytes and platelets, thereby indicating 
that the CNIO-PI3Ki is a safe treatment with no associated toxicities at the specified dose in 
monkeys. 
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Figure 28. Effects of CNIO-PI3Ki on obese rhesus monkeys.  
(A) Left, fasting glucose level evolution for each control monkey at baseline and after 10 weeks vehicle-treatment. 
Middle, progression of fasting glucose levels in CNIO-PI3Ki-treated monkeys at baseline and after 10 weeks PI3Ki-
treatment. Right, fold change fasting glucose level for each monkey calculated as fasting glucose level at week 10 
relative to baseline level. As a reference, dotted line represents mean fasting glucose level at baseline. (B) IVGTT 
performed at baseline and after 10 weeks vehicle (n=9) or 2.1 mg/kg CNIO-PI3Ki (n=10) treatment. Animals were 
administered glucose intravenously and blood samples collected at the indicated times. Bars represent the area under 
the curve (AUC) at baseline and after 10 weeks treatment (average ± s.d.). (C) Fasting insulin values measured at 
baseline and after 12 weeks vehicle or CNIO-PI3Ki treatment. (D) Insulin resistance, measured by the HOMA-IR 
index, at baseline and at the end of the treatment. In (C) and (D), dots correspond to individual values and black bar 
to average.  
Statistical significance was determined by the two-tailed Student’s t test except for (A), left and middle panel, that 
was determined by the paired Student’s t test: *p < 0.05, **p<0.01. 
 
 
In order to have a deeper look into possible genetic alterations induced by the treatment, 
liver, muscle and subcutaneous WAT (scWAT) biopsies taken at baseline and after 12 weeks 
treatment were used for gene expression analysis by Q-PCR. However, no overall significant 
differences could be established between CNIO-PI3Ki-treated macaques and controls: no 
changes were detected in markers of slow- (Tnni1) and fast- twitch fibers (Myh2 and Myh4) as 
well as in mitochondrial content in muscle (Figure 29A); no signs of altered gene expression 
was evident in the liver (Figure 29B); and, expression of markers of browning (Ucp1, Prdm16 
and Pgc1!) and immune related genes (Emr1, CD68, CD11c and CD206) remained stable in the 
white adipose tissue (Figure 29C). These results emphasize the fact that CNIO-PI3Ki treatment 
does not cause long-lasting changes, given that biopsies were performed (24 hours after the last 
CNIO-PI3Ki dosing, and thereby constitute another important safety aspect.  
 We conclude from this assay that CNIO-PI3Ki is able to reduce adiposity and may also 
decrease serum glucose levels in obese rhesus monkeys without any detectable toxic effects 
after 12 weeks of daily treatment.    
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Figure 29. Effects of CNIO-PI3Ki on gene expression of obese rhesus monkeys. 
(A) Left, relative mRNA levels in muscle of rhesus monkeys treated with or without the CNIO-PI3Ki at baseline 
(control n=4; PI3Ki n=7) and after 12 weeks (control n=6; PI3Ki n=7). Right, mitochondrial content in muscle of 
monkeys measured as Cox2 expression relative to Rsp18.  (F) Relative expression in liver of rhesus monkeys before 
(control n=5; PI3Ki n=10) and after 12 weeks (control n=8; PI3Ki n=6) treatment. (G) Relative mRNA levels of 
genes related to brown-adipocyte function (left) or inflammation (right), in subcutaneous WAT (scWAT) of rhesus 
monkeys at baseline (control n=7; PI3Ki n=8) and after 12 weeks (control n=8; PI3Ki n=8).  
All mRNA levels were normalized with Ipo8. Values correspond to average ± s.d.  
Statistical significance was determined by the two-tailed Student’s t test:*p < 0.05, **p<0.01. 
 
 
Altogether we conclude that the pharmacological inhibition of PI3K reduces body 
adiposity and some signs of the metabolic syndrome, such as hepatic steatosis and high fasting 
glucose levels, in obese mice and monkeys.    
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PART 2. ROLE OF THE TUMOUR SUPPRESSOR GENE p21 IN THE 
FASTING RESPONSE 
 
For decades, dietary restriction has been known to protect against cancer and expand lifespan in 
a great variety of organisms including worms, flies and mice. Similarly, alternative fasting 
periods have been demonstrated to improve healthspan and delay ageing onset. The positive 
effects exerted by both, calorie restriction and alternative fasting periods, are thought to be 
partially mediated by the reduction of circulating insulin, Igf1 and cytokine levels which, 
among others, lead to decreased growth factor signalling and mTOR activity, improved 
mitochondrial function and decreased inflammation. Nevertheless, the underlying mechanisms 
are still poorly understood. 
  
2.1  Characterization of fasting-induced p21 upregulation 
Previous reports have described that p21 mRNA is induced in many tissues upon fasting 
through a mechanism that is independent of p53 and partly mediated by FOXO1 (Tinkum et al., 
2013). Aiming to confirm and further explore the role of p21 in the fasting response, we decided 
to start by fasting WT mice for 48 hours and analyse the expression of a panel of different cell 
cycle inhibitors and tumour suppressor genes in the liver. Interestingly, only p21Cip1 mRNA was 
strongly upregulated upon fasting whereas the expression of p16Ink4a, p19Arf, p27Kip1, or p53 
remained unchanged (Figure 30A). Continuing our analysis, we detected induced p21 levels 
upon fasting not only in liver, but also in a great variety of organs and tissues, such as the 
epididymal white adipose tissue (eWAT), brown adipose tissue (BAT), intestine, muscle, lung 
and spleen (Figure 30B). Confirming previous data (Tinkum et al., 2013), we also found that 
fasting-induced p21 upregulation was independent of the p19Arf/p53 pathway, as we found 
elevated p21 mRNA levels in fasted p19Arf KO as well as in p53KO mice (Figure 30C and 
30D). The sirtuin SIRT1 is involved in many responses to nutrient deprivation (Dominy et al., 
2010), but, still, p21 upregulation by fasting was not affected in Sirt1-heterozygous mice 
(Figure 30D). As a reference for comparison, the induction of p21 mRNA in the liver was of 
higher magnitude (>10 fold) than that of Pgc1! (<5 fold) (Figure 30D). 
 Thus, we show that p21 is induced in several tissues upon fasting in a p53 independent 
manner.  
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forskolin 10 µM or PI3Ki 10 µM. Experiment was performed twice with similar results and each time in triplicate. Data 
represent one experiment (n=3) and are expressed as mean ± s.d. mRNA levels are relative to !-actin.  
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01, *** p < 0.001. 
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Figure 30. p21 is highly 
induced after fasting. 
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p21 and Pgc1! in the liver of 48 h fasted or ad libitum fed p19ARF-/- and SIRT-1+/- mice. n=4, 12 weeks old male. 
Data are expressed as mean ± s.d. mRNA levels are relative to "-actin, except for gastrocnemius and soleous that are 
relative to Gapdh. Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01. 
 
 
 The induction of p21 by nutrient deprivation was also recapitulated in cultured cells. In 
particular, p21 was significantly induced when human hepatocellular carcinoma HepG2 cells or 
mouse immortalized primary hepatocytes were starved in glucose- and serum-free medium for 
24 hours (Figure 31). In general, nutrient deprivation, among many other effects, decreases 
PI3K activity and elevates cAMP, both being important for metabolic adaptation (Lempradl et 
al., 2015). To explore the contribution of these pathways to the upregulation of p21, cells were 
treated with a pharmacological inhibitor of PI3K or with forskolin, which is a compound that 
increases cAMP levels. Interestingly, forskolin, but not PI3K inhibition, further enhanced the 
upregulation of p21 by nutrient deprivation in cells (Figure 31). This suggests that p21 
upregulation is positively regulated by PKA, and it is not further affected by PI3K inhibition. 
 Together, these observations reinforce the concept that p21Cip1 is a sensor of nutrient 
deprivation both in vivo and in vitro. 
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2.2  Impaired adaptation to prolonged fasting in p21Cip1 deficient mice 
In order to address the role of p21 in the metabolic adaptation to fasting and test whether its 
induction upon fasting is of physiological significance, p21KO mice were starved for up to 48 
hours.  
 Consistent with previous reports, we did not detect any obvious differences after 24 
hours of fasting (Tinkum et al., 2013). However, after 48 hours fasting, p21 deficient mice 
presented dramatic differences compared to WT controls. From a behavioural point of view, 
p21KO mice were either extremely stressed or lethargic, even though their weight loss was 
comparable to that of WT mice (Figure 32A). Upon necropsy, we observed conserved white 
adipose tissue (WAT) and interscapular brown adipose tissue (BAT) in WT mice (Figure 32B), 
while p21KO mice had only remnants of WAT and BAT (Figure 32B). Additionally, 
histological analysis of eWAT and BAT sections confirmed a clear reduction in lipid droplet 
size in fasted p21 deficient mice compared to controls (Figure 32C).  
 
 
 
Figure 32. p21KO mice are unable to adapt to 48 hours fasting. 
(A) Relative weight loss of 12 weeks old WT and p21KO mice after 24 and 48 hours fasting. (B) Representative 
pictures of epididymal white adipose tissue (eWAT) and interscapular brown adipose tissue (BAT) of WT and 
p21KO mice after 48 hours fasting. (C) Representative pictures of H&E-stained sections of eWAT and BAT of ad 
libitum fed or 48 hours fasted WT and p21KO mice. Bars correspond to 0.2 mm. High magnification insets 
correspond to 50 µm.  
 
 
 To further characterize the phenotype of 48 hours fasted p21KO mice, we continued by 
measuring a subset of parameters that highlighted their misadaptation to fasting. Mice deficient 
in p21 showed a dramatic drop in body temperature (rectal) that reached 25ºC upon fasting 
(Figure 33A). Moreover, a number of metabolic adaptations were significantly altered in fasted 
p21KO mice (Figure 33B, 33C, 33D and 33E). In particular, circulating serum free fatty acids 
(FFA), triglycerides (TG) and ketone bodies (KB) were strongly reduced compared to WT mice, 
which suggests that p21KO mice exhaust lipid stores prematurely compared to WT mice. 
Similarly, metabolic related hormones such as insulin, IGF1 and leptin were also significantly 
decreased in 48h fasted p21KO mice compared to controls, indicating a severe state of energy 
depletion. In contrast, no differences were detected in adiponectin serum levels. Serum glucose 
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levels were highly variable among fasted p21KO mice, as some individual p21KO mice had 
relatively high levels of glucose, which could reflect their profound decrease in insulin and 
IGF1 levels. Regarding serum amino acids, fasted p21KO mice presented significantly higher 
levels of phenylalanine, tyrosine, alanine, leucine and valine (Figure 33E), indicative of an 
enhanced proteolytic adaptation that may partially compensate for the loss of lipid stores. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Altered metabolic profile in 48h fasted p21-deficient mice. 
(A) Temperature of fed and 48 hours fasted WT and p21KO mice. Temperature was measured with a rectal 
thermometer. n=4-6 males, 12 weeks old. Values correspond to average ± s.d. (B) Relative glucose (GLUC.), free 
fatty acids (FFA), ketone bodies (KB), triglycerides (TG), insulin, IGF1, leptin and alanine aminotransferase (ALT) 
serum levels in WT and p21KO mice after 48 hours fasting or ad libitum feeding. Values correspond to average ± s.d 
(C) Temperature and level of the indicated metabolites in serum. *represents significant difference with ad libitum 
controls and # represents significant difference with WT controls (D) Relative level of ketones bodies (acetoacetate 
and $-hydroxybutyrate) and (E) of the indicated amino acids in the serum of WT and p21KO mice after ad libitum 
feeding, or after 24 hours or 48 hours fasting. Measurement performed by NMR. Values correspond to average ± s.d. 
n=4-5 male mice, 12 weeks old.  
Data are expressed as mean ± s.d. Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, 
**p < 0.01, ***p<0.001. 
 
 
 Finally, all the above alterations were accompanied by hepatic damage, as reflected, by 
increased serum alanine aminotransferase (ALT) levels (Figure 33B) and apoptosis measured 
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apoptosis in the liver of 
fasted 21KO mice. 
(A) Left, representative 
pictures of active 
caspase-3 stained liver 
sections of WT and 
p21KO mice under 
feeding conditions, and 
after 24 hours or 48 
hours fasting. Bars 
correspond to 25 µm. 
Right, quantification of 
positive active-caspase 3 
nuclei per area. (B) Left, 
representative pictures of 
Ki67 stained liver 
sections of WT and 
p21KO mice under 
feeding conditions, and 
after 24 or 48 hours!
fasting. Bars correspond 
by active-caspase3 staining in the liver (Figure 34A). Of note, proliferation levels, measured by 
Ki67 immunohistochemistry, were moderately, but significantly, higher in 48 hours fasted 
p21KO livers compared to WT controls (Figure 34B). 
 Altogether, these data demonstrate that in the absence of p21, nutrient and energy stores 
are prematurely exhausted upon fasting. They also support a relevant role for p21 in the 
adaptation to nutrient starvation, as p21KO mice are unable to efficiently adapt to prolonged 
fasting periods of 48 hours. 
 
 
 
 
  
 
 
 
 
 
 
 
fasting. Bars correspond to 25 µm. Right, quantification of positive Ki67 nuclei per area. In (A) and (B) 10-15 similar 
areas were selected per animal in a total of 3 representative mice per group. Values correspond to average ± s.d.  
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01, ***p<0.001. 
 
 
2.3  Enhanced energy expenditure and activity in p21KO mice during fasting 
All the previous observations suggest that p21KO mice suffer a premature exhaustion of 
energetic reserves during fasting.  
 To directly evaluate this, we measured energy expenditure (EE), performing indirect 
calorimetry, in WT and p21KO mice during 48 hours of fasting as well as under standard 
feeding conditions (Figure 35A). Of note, p21KO mice presented higher EE levels during the 
first dark and second light fasting periods, resulting in an overall increased EE during the total 
fasting period. In contrast, no significant differences in EE were observed under normal ad 
libitum feeding conditions (Figure 35B).  
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Figure 35. Enhanced energy expenditure in p21KO mice during fasting. 
(A) Left, energy expenditure (EE) of WT and p21KO mice during 48 hours of fasting. Right, mean EE of WT and 
p21KO at the indicated period during fasting. (B) Left, Energy Expenditure (EE) of WT and p21KO mice under ad 
libitum feeding conditions. Right, mean EE of WT and p21KO at the indicated period. n=8 C57BL6 males, 12 weeks 
old. Data are expressed as mean ± s.e.m.  
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01. 
 
 
 Fasting induces stress and behavioural changes that reflect in elevated locomotor 
activity (Chen et al., 2005). Interestingly, p21KO mice showed a significant increase in activity 
during the entire 48 hours of fasting (Figure 36A), while no significant differences could be 
established under feeding conditions (Figure 36B).  
Together, we conclude that in the absence of p21, mice do not adapt efficiently to 
energy deprivation and nutrient stores are prematurely exhausted. 
 
 
 
 
 
 
 
 
 
 
Figure 36. Enhanced activity in p21KO mice during fasting. 
(A) Left, activity of WT and p21KO mice during 48 hours of fasting. Right, mean activity of WT and p21KO at the 
indicated period during fasting. (B) Left, activity of WT and p21KO mice under ad libitum feeding conditions. Right, 
mean activity of WT and p21KO at the indicated period. n=8 C57BL6 males, 12 weeks old. Data are expressed as 
mean ± s.e.m. Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p < 0.01. 
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Figure 37. Global transcription 
changes in p21Cip1 deficient mice.  
(A) Venn diagram of differentially 
expressed genes (DEG) in the liver of 
p21KO compared to WT mice under 
ad libitum feeding conditions and 
upon 24 hours fasting. Data were 
obtained from RNA-seq analysis of 2-
3 male mice per group. Red circles 
correspond to upregulated and green 
circles to downregulated genes. 
Values were considered significant 
when FRD value was q<0.05. (B) 
Heat map of significantly altered 
pathways (KEGG) in the liver of 
p21KO mice compared to WT 
controls under feeding conditions or 
upon 24 hours fasting. Results were 
considered significant when 
FDR<0.25. 
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2.4  Global transcriptome changes in p21Cip1 deficient mice 
Aiming to gain insight into the mechanisms responsible for the defective adaptation of p21KO 
mice to prolonged fasting, we obtained the liver RNA-seq profiles of WT and p21KO mice 
under standard feeding conditions and after 24 hours fasting (n=2-3 per condition and genotype). 
We chose 24 hours of fasting to capture early defects in p21KO mice, prior to the severe 
phenotype observed at 48 hours.  
 A total of 451 genes (128 UP and 323 DOWN)!were differentially expressed (FDR q< 
0.05) between p21KO and WT livers after 24 hours fasting; 96 of these genes (8 UP and 88 
DOWN) were already differentially expressed under ad libitum feeding conditions (Figure 37A 
and Supplementary Figure S1). Gene-set enrichment analysis (GSEA) of KEGG pathways 
indicated a reduced number of altered pathways in p21KO livers compared to WT under ad 
libitum feeding conditions (Figure 37B). In contrast, fasted p21KO livers presented a great 
number of downregulated pathways, mostly related to inflammation and metabolism, compared 
to controls (Figure 37B and Supplementary Figure S2). Of note, no upregulated pathway was 
found in the liver of fasted p21KO mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5  Decreased immune response in 24 hours fasted p21 deficient mice 
One of the major consequences of starvation and dietary restriction is a general decrease in the 
number of infiltrating leukocytes and markers of inflammation (Mitchell et al., 2010; Robertson 
and Mitchell, 2013; Sokolovi) et al., 2013). The reduction in gene sets related to immune 
function and inflammation observed in 24 h fasted p21KO mice (Figure 38A) suggests that the 
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effects of fasting appear prematurely in p21KO mice compared to WT controls. We supported 
the GSEA data by first confirming a general reduction in the mRNA levels of genes related to 
the immune system in the liver of p21KO fasted mice compared to controls (Figure 38B).  
 Moreover, this was further substantiated by quantifying infiltrating leukocytes (CD45+ 
cells) in the liver, which showed a significant reduction in fasted p21KO livers compared to 
fasted WT controls (Figure 38C). Consequently, this was translated into a reduction of all the 
analysed immune system populations, without affecting their relative distribution within the 
tissue (Figure 38D). Finally, F4/80 staining revealed reduced macrophage infiltration in the 
liver of p21KO fasted mice compared to controls (Figure 38E). 
 We interpret this reduction in leukocyte population and transcriptional level of markers 
related to immune function as indicative of the accelerated physiological effects of fasting in 
p21KO mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Decreased immune response in fasted p21KO mice. 
(A) Representative GSEA plots of immune-related pathways downregulated in 24 hours fasted p21KO mice 
compared to 24 hours fasted controls. FDR<0.25 (B) Relative expression of the indicated genes related to 
inflammation in the liver of WT and p21KO mice under ad libitum feeding conditions or 24 hours fasting. mRNA 
levels were normalized to "-actin. n=6, C57BL6 males, 12 weeks old. (C) CD45+ immune cells relative to total 
events and (D) percentage of the indicated immune cell populations relative to CD45+ leukocytes in the liver of ad 
libitum fed or 24 hours fasted WT and p21KO mice. n=6 males, 12-16 weeks. (E) Representative pictures of F4/80 
stained liver sections of WT and p21KO mice under feeding conditions, 24 hours and 48 hours fasting. Bars 
correspond to 50 µm. 
Values correspond to average ± s.d. Statistical significance was determined by the two-tailed Student’s t test: *p < 
0.05, **p < 0.01. 
 
 
2.6  Decreased PPAR! activity in the liver of p21KO mice 
We took note of the fact that “PPAR signalling” was one of the pathways downregulated in 
fasted p21KO mice compared to WT mice (Figure 39A). PPAR! is a critical hepatic 
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transcription factor activated by fatty acids in response to nutrient deprivation that plays a key 
role in promoting fatty acid #-oxidation and ketogenesis. Notably, PPAR! is required for the 
adaptation to fasting as shown in PPAR!-KO mice (Kersten et al., 1999; Leone et al., 1999).   
 We first validated RNA-seq data by directly measuring the mRNA of PPAR!, -# and -$ 
isoforms together with some well-established PPAR! transcriptional targets in the liver of fed 
and fasted p21KO and WT mice. Interestingly, PPAR% and some of the PPAR! target genes 
such as Cd36, Abcd2, Saa3, Gyk, Acot1 and Acot3 were significantly downregulated in 24h 
fasted p21KO livers (Figure 39B). One of the main characteristics of PPAR!-KO mice is the 
accumulation of fatty acids in the liver upon fasting due to their inability to undergo ketogenesis 
(Kersten et al., 1999; Leone et al., 1999). Even though we could not establish significant 
differences after 24 or 28 hours fasting, we were able to observe a tendency towards increased 
FFAs in the liver of p21KO mice compared to controls after 48 hours fasting (Figure 39C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p<0.01, ***p<0.001. Only 
significant differences between WT and p21KO fasted samples are represented. 
 
 To explore a possible mechanistic link between p21 and PPAR!, we first tested if p21 
plays a cell-autonomous role in hepatocytes upon nutrient deprivation. Interestingly, after 48 
hours of serum and glucose starvation, cultured immortalized p21KO primary hepatocytes 
underwent massive cell death, whereas WT control hepatocytes remained largely viable (Figure 
40A). Afterwards, we compared the induction of PPAR! target genes in WT and p21KO 
hepatocytes. Remarkably, the induction of PPAR! targets after 24 hours nutrient starvation 
(Figure 40B) or with PPAR! agonist WY-14,643 treatment (Figure 40C) was completely 
blunted or significantly reduced in p21KO hepatocytes. These data indicate that p21 is an 
important positive regulator of PPAR!.  
Figure 39. Decreased PPAR signalling in p21KO mice. 
(A) GSEA plot of the “PPAR Signalling Pathway” downregulated 
in the liver of 24 hours fasted p21KO mice compared to 24 hours 
fasted WT mice. FDR<0.25. (B) Relative mRNA levels of PPAR 
isoforms and PPAR! target genes expressed in the liver of WT and 
p21KO mice under ad libitum feeding conditions and upon 24 hours 
fasting. n=6 per group, 12 weeks old male mice. Levels of mRNA 
were normalized to !-actin. Values correspond to average ± s.d. (C) 
free fatty acids in the liver of WT and p21KO mice after ad libitum 
feeding, 24 and 48 hours fasting. n=6-7 male mice, 12 weeks old. 
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 Altogether, our data demonstrate that p21 is a fasting-induced factor necessary for the 
efficient adaptation to fasting. Mice deficient in p21 present severe adaptational abnormalities to 
fasting including premature energy exhaustion, and molecular analysis indicate that p21 is a 
positive regulator of the activity of PPAR!, a master regulator of fasting adaptation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. Decreased PPAR!  activity in p21KO mice. 
(A) Left panel, representative pictures of WT and p21KO large-T immortalized primary hepatocytes cultured for 48 
hours in complete medium (DMEM + 10% FBS) or starvation medium (glucose-free DMEM). Right, representative 
pictures of WT and p21KO immortalized primary hepatocytes stained with crystal violet after 48 hours culturing in 
starvation medium. Experiment was repeated three times in triplicate. (B) Relative mRNA levels of PPAR! target 
genes expressed in WT and p21KO immortalized primary hepatocytes after culturing in complete (DMEM + 10% 
FBS) or starvation medium (glucose-free DMEM) for 24 hours. Experiment was performed twice with similar results 
in duplicate or triplicate. n=5-6. (C) Relative expression of PPAR! target genes in WT and p21KO immortalized 
primary hepatocytes cultured in complete medium and treated with DMSO or 10 µM of the PPAR! agonist WY-
14,643 for 24 hours. Experiment was performed twice in triplicate with similar results. One experiment is represented, 
n=3. mRNA levels were normalized to "-actin. Values correspond to average ± s.d.  
Statistical significance was determined by the two-tailed Student’s t test: *p < 0.05, **p<0.01, ***p<0.001. Only 
significant differences between WT and p21KO samples are represented. 
 
 
2.7  Fasting induces senescence in combination with a low oncogenic stress 
Activated oncogenes induce compensatory tumour-suppressive mechanisms, such as cellular 
senescence and apoptosis. In particular, senescence leads to a persistent growth arrest that is 
principally characterized by a complex pro-inflammatory response, known as senescence-
associated secretory phenotype (SASP); the activation of the CDKN2A locus, which encodes 
p16 and ARF; and the activation of the p53-pathway, together with the induction of p15, p21, 
p27 and Rb (Campisi and d’Adda di Fagagna, 2007; Collado et al., 2007; Muñoz-Espín and 
Serrano, 2014).  
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 Importantly, oncogene-induced senescence has been shown to diminish cancer 
development in vivo by inducing a stable growth arrest (Collado et al., 2005; Michaloglou et al., 
2005). Initially, it was thought that cells could only undergo senescence under high oncogenic 
stress conditions. However, a low oncogenic stress in combination with CDK2 (Campaner et al., 
2010) or CDK4 (Puyol et al., 2010) deletion can also induce a full senescence response. Given 
the fact that fasting greatly upregulates p21 levels, and, consequently, inhibits CDK2 activity, 
we hypothesized that fasting could also induce a senescence response in the context of low 
oncogenic stress.  
 Therefore, we decided to fast Eµ-Myc mice for 48 hours at 10 weeks of age, when 
moderate oncogenic c-Myc activity is present and mice do not exhibit yet signs of lymphoma or 
other associated malignancies (pre-tumoural stage). Interestingly, senescence associated-# 
galactosidase (SA-# gal) staining revealed positively stained areas in the pre-tumoural spleen of 
48h fasted Eµ-Myc mice, but not in fed E"-Myc mice (Figure 41A). However, the degree of 
senescence was highly variable between individuals. Quantification of SA-# gal positive areas 
allowed us to distinguish highly, medium and low senescent spleens. In contrast, standard fed 
Eµ-Myc or WT littermate controls barely presented any SA-# gal staining (Figure 41A). 
Besides SA-# gal activity, senescent cells present important gene expression alterations. In 
particular, we confirmed induced expression of the senescence markers p16, p19 and p21 in 
fasted Eµ-Myc spleens compared to controls (Figure 41B), which further supports a senescence 
response. Remarkably, higher p16, p19 and p21 mRNA levels positively correlate with high 
SA-# gal staining.  
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Figure 42. Survival of Eµ-Myc 
mice upon 48h fasting.  
(A) Kaplan-Meier survival curve of 
control Eµ-Myc mice or Eµ-Myc 
mice fasted for 48 hours at 10 weeks 
of age. n=11-13, males. Statistical 
significance was determined by the 
log-rank (Mantel Cox) test. (B) 
Maximal survival of control or 48h 
fasted (at the age of 10 w) Eµ-Myc 
mice. Values correspond to average ± 
s.d. n=11-13, males. Statistical 
significance was determined by the 
two-tailed Student’s t test. 
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Figure 41. Fasting-induced senescence in pre-tumoural Eµ-Myc spleens. 
(A) Left, SA-# Gal staining in spleen OCT sections of ad libitum fed or 48 hours fasted WT and Eµ-Myc mice at 10 
weeks of age. Right, quantification of positive SA-# Gal cells per field. 10-15 similar areas were selected per animal. 
According to the number of positive cells, animals were divided into high, medium and low senescent. Picture of 
fasted Eµ-Myc spleen corresponds to a high senescent case. (B) Relative expression of p16INK4A, p19ARF and p21Cip1 
in the spleen of ad libitum fed or 48h fasted WT and Eµ-Myc mice. Mice were adjudged to high, medium and low 
SA-#Gal positive staining. mRNA levels were normalized to "-actin. Dots correspond to individual mice and black 
line to averages. In (A) and (B) n=3-6 male mice, 10 weeks old, mixed background. 
 
Senescence is a tumour-suppressive response that prevents the proliferation of 
cancerous cells by inducing a stable cell cycle arrest. Therefore, we next wanted to address if 
the observed fasting-induced senescence response would be translated into an improved 
tumour-free survival of Eµ-Myc mice. Unfortunately, a single 48 hours fasting period at 10 
weeks of age did not significantly affect overall survival of fasted Eµ-Myc mice compared to 
controls (Figure 42A). Nevertheless, we observed a non-significant trend towards extended 
maximal survival that suggests that repeated fasting periods could possibly delay tumorigenesis 
(Figure 42B). 
 
 
 
 
 
 
 
 
Altogether, these results show that, in the context of a low oncogenic stress, fasting is able 
to promote senescence in the pre-tumoural spleen of Eµ-Myc mice.  
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PART1. EFFECT OF PHARMACOLOGICAL PI3K INHIBITION ON 
METABOLIC SYNDROME AND OBESITY 
 
The PI3K/AKT signalling pathway is one of the main regulators of proliferation, growth, 
survival and metabolism. In particular, PI3K activity has been shown to play an important role 
in insulin sensitivity and glucose homeostasis (Carracedo and Pandolfi, 2008) and PI3K 
downregulation, either by genetic PTEN overexpression or treatment with a synthetic PI3K 
inhibitor (CNIO-PI3Ki), enhances energy expenditure and thermogenesis (Ortega-Molina et al., 
2012). Importantly, boosting energy expenditure is considered a promising therapeutic strategy 
to fight obesity; an increasing public health problem and a major risk factor for the development 
of type II diabetes and metabolic syndrome, as well as of cancer and cardiovascular diseases 
(Haslam and James, 2005). Despite great efforts to develop efficient and safe anti-obesity drugs, 
there are currently a reduced number of pharmacological treatments available, as most of them 
show limited efficacy or have been withdrawn from the market due to substantial adverse side 
effects that included cardiovascular effects, central nervous system toxicity, hypertension, 
memory impairment and psychiatric effects (Giordano et al., 2016). Therefore, it is of great 
importance to develop new therapeutic options. Numerous independent studies have reported 
the beneficial effects of PI3K signalling pathway downregulation, including PTEN upregulation 
(Garcia-Cao et al., 2012; Ortega-Molina et al., 2012), deletion of single PI3K isoforms 
(Becattini et al., 2011; Chattopadhyay et al., 2011; Foukas et al., 2013) and deletion of the 
PI3K-downstream substrate AKT1 (Wan et al., 2012). Based on these evidences, we 
hypothesized that the pharmacological inhibition of PI3K could be an effective treatment 
against obesity and the metabolic syndrome.  
 
1.1 PI3K inhibitors as anti-obesity treatment in obese mice 
As a first step to assess the possible use of PI3K inhibitors in the treatment against obesity, we 
began by determining whether the pharmacological inhibition of PI3K produced evident 
changes in vivo. Given the relevant role of PI3K in insulin signal transduction and glucose 
homeostasis, we decided to evaluate the effects of a single oral dose of PI3K inhibitor treatment. 
We therefore measured the acute effects of CNIO-PI3Ki treatment on fasting glycemia, initially. 
As expected, oral CNIO-PI3Ki administration (15 mg/kg) resulted in a high, but transient, 
serum glucose peak that was maintained within physiological ranges and that was comparable 
to a normal post-prandial glycemia. Importantly, this glucose peak was rapidly reversed 6 hours 
post-PI3Ki administration, reflecting a quick glucose homeostasis recovery. Supporting this fast 
homeostatic readjustment, CNIO-PI3Ki administration led to detectable serum drug levels only 
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1 to 6 hours after dosing, being completely eliminated after 24 hours. As a consequence of the 
inhibition of PI3K, we detected reduced AKT and FOXO1 phosphorylation in the liver and 
BAT of treated mice. The liver is responsible for the production of glucose during fasting 
through the transcriptional activation of genes involved in gluconeogenesis upon PI3K/AKT 
downregulation and consequent FOXO activity. Indeed, after PI3Ki treatment, we observed 
elevated expression of the gluconeogenic gene G6Pc in the liver of treated mice. In turn, the 
adipose tissue is another relevant target of PI3K inhibition (Ortega-Molina et al., 2012) and, 
accordingly, CNIO-PI3Ki and GDC-0941 treatment led to enhanced expression of UCP1, both 
at a protein level in the BAT and at a transcriptional level in white adipose depots. Together, 
this suggests an increased thermogenic activity in the BAT as well as in the brown adipocytes 
(known as brite or beige adipocytes) interspersed within the WAT (Wu et al., 2013). Thus, 
pharmacological PI3K inhibition produces a transient glycemic peak, within physiological 
range, together with increased UCP1 expression.  
 In order to test the anti-obesity capacity of pharmacological PI3K inhibition, we have 
compared in parallel the activity of two PI3K inhibitors, CNIO-PI3Ki (developed at the CNIO) 
and GDC-0941, in diet-induced obese mice. Both PI3K inhibitors are highly specific class IA 
PI3Ks p110! and p110% inhibitors, show similar inhibitory capacity in vitro, and do not cross 
the blood-brain barrier (Ortega-Molina et al., 2012; Workman et al., 2010). Additionally, we 
have demonstrated that they do not affect the arcuate nucleus of the hypothalamus; a master 
regulator of metabolism that is exposed to peripheral circulation and releases, among others, 
important orexigenic and anorexigenic hormones (Sohn et al., 2013; Yeo and Heisler, 2012). 
The lack of hypothalamic effects of these PI3K inhibitors constitutes a relevant safety feature to 
take into account for a future anti-obesity use. Importantly, treatment with both PI3K inhibitors 
reduced the weight of obese mice in a short period of 10 days, despite maintaining their high-fat 
food intake constant. Even though the weight loss of mice happened in a dose-depend manner, 
it is worth mentioning that GDC-0941 treatment had to be administered at a higher dose (75 
mg/kg) than CNIO-PI3Ki (10 mg/kg) to achieve similar results. Notably, the reduction in body 
weight was entirely due to the loss of adiposity, without affecting lean mass content. This was 
particularly striking in the pericardial fat, as well as reflected by a reduction in liver steatosis. 
Moreover, in the case of the highest dose of CNIO-PI3Ki (15 mg/kg), there were evident 
browning areas in the epididymal, pericardial, and perirenal fat depots.  
 To simulate a hypothetical clinical application, we tested the effects of long-term 
treatment with a low dose of CNIO-PI3Ki administered through the drinking water that resulted 
in 40-fold lower serum drug levels compared to the peak of drug achieved 1-6 hours post-oral 
gavage. Nonetheless, the daily accumulative dose of the drug was calculated for 10 mg/kg, 
which is sufficient to partially inhibit the pathway. As expected, dietary-induced obese mice 
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treated with CNIO-PI3Ki through the drinking water lost weight while maintaining their 
average high-fat food intake unaltered. Notably, this weight loss happened in a progressive 
manner and only during a period of 50 days. Afterwards, treated mice stabilized their body 
weight at a set point 20% below non-treated obese mice and as long as the treatment was 
administered. This effect can be explained by the fact that mice under chronic CNIO-PI3Ki 
treatment present enhanced energy expenditure, which may lead to a resetting of energy balance 
at a lower body weight. The long-lasting stability of this new energetic balance also suggests 
that chronic PI3Ki treatment does not elicit compensatory changes to defend body weight, nor 
causes drug resistance. The body weight loss was due to a reduction in adiposity, as lean mass 
content remained stable throughout the entire treatment. Together, these are desirable features 
for an anti-obesity treatment in humans because a slow, progressive and controlled weight loss 
would allow better medical supervision.  
 Long-term treatment with CNIO-PI3Ki produced a range of beneficial effects beyond 
body weight and adiposity loss. In particular, the liver of treated mice presented decreased 
steatosis and reduced hepatic damage measured by serum ALT levels. Also, expression of the 
pro-inflammatory cytokine Il6 in the liver as well as the infiltration of macrophages and 
expression of inflammation-related genes in the eWAT was reduced in treated mice, thereby 
confirming a decrease in obesity-associated inflammation. In contrast to the previous short-term, 
high-dose assay, and despite reduced adipocyte size and fat accumulation, we could not observe 
browning areas in the WAT of low-dose treated mice. To explain this difference we could argue 
that either the browning of the WAT or the induction of UCP1 are below detection level; that 
the activation of UCP1 may be happening in a transient manner; or that the administered dose is 
too low to have a detectable impact on UCP1 expression. While glucose homeostasis and 
insulin resistance did not improve after 2.5 months treatment, mice treated for 5 months showed 
normalized serum fasting glucose levels. We reason that dealing with extremely insulin resistant 
mice after 8 months under continuous high-fat feeding, 2.5 months treatment may not be 
sufficient to improve glucose homeostasis. In general, these data demonstrate that long-term 
CNIO-PI3Ki treatment improves some of the symptoms associated with the metabolic 
syndrome such as fat accumulation and hyperglycemia. 
 Interestingly, the effects of CNIO-PI3Ki on body weight were reversible upon 
withdrawal of the treatment, as mice rapidly readjusted their body weight to the same level as 
control high-fat fed mice in the absence of drug. This reversibility indicates that long-term 
exposure to CNIO-PI3Ki does not cause irreversible metabolic alterations that may compromise 
tissue functioning. In line with this, we did not detect any evidence of toxic effects in mice even 
after 5 months of continuous treatment with CNIO-PI3Ki.   
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 Besides reducing body weight and adiposity in obese high-fat fed mice, CNIO-PI3Ki 
treatment was also effective in hyperphagic, standard-diet fed ob/ob mice, suggesting that the 
treatment is active against obesity produced by nutritional overload, independently of the fat 
content of the diet. In contrast, CNIO-PI3Ki treatment did not have any effect on healthy, lean 
mice under standard diet. Nevertheless, when healthy lean mice were put de novo on a high-fat 
diet, CNIO-PI3Ki treatment significantly delayed body weight gain as well as glucose 
intolerance onset, indicating that the treatment is effective as soon as high-fat food is present, 
even without a pre-existing context of obesity or high-fat food intake. It is well known that in 
response to overnutrition, the WAT can expand via both an increase in adipocyte size 
(hypertrophy) and adipocyte number (hyperplasia), thereby leading to obesity (Steinberg et al., 
1962; Peckham et al., 1962). Importantly, newly published reports demonstrate that de novo 
adult adipogenesis (only in the visceral eWAT) and adipocyte hypertrophy (in both, visceral 
eWAT and subcutaneous iWAT) induced by high-fat diet depends on PI3K/AKT2 activity 
(Jeffery et al., 2015). This is consistent with our data and suggests that PI3K inhibition may be 
limiting both processes, and thereby delaying obesity onset. Altogether, these scenarios 
(efficacy on ob/ob mice, lack of effect on mice with standard diet, and efficacy upon de novo 
high-fat feeding) point to nutritional overload as a key requisite for the anti-obesity activity of 
PI3K inhibition. This constitutes another important and attractive safety feature for a 
hypothetical use in humans because PI3Ki would presumably be effective only on people under 
nutritional overload, but not on lean people with an energetically balanced diet. 
 In summary, we have demonstrated that CNIO-PI3Ki treatment is an efficient and safe 
anti-obesity intervention in obese mice that improves some of the signs of the metabolic 
syndrome such as adiposity and hyperglycemia, and reduces obesity-associated symptoms 
including liver steatosis and inflammation.  
 
1.2  p110! in the regulation of energy homeostasis  
CNIO-PI3Ki is a specific class IA PI3K! (catalytic subunit p110!) and PI3K" (catalytic 
subunit p110") inhibitor that induces Ucp1 expression and thermogenesis in vivo, as well as in 
cultured brown adipocytes (Ortega-Molina et al., 2012). Whereas p110! is ubiquitously 
expressed, p110" is principally expressed in leukocytes and plays a key role in antigen receptor 
and cytokine-mediated B and T cell development, differentiation and function (Hawkins and 
Stephens, 2015). Reinforcing the idea that p110!, but not p110", is the key mediator of the 
metabolic responses of PI3K (Foukas et al., 2013; Vanhaesebroeck et al., 2010), we first 
confirmed that p110! downregulation in brown adipocytes led to significantly increased levels 
of the thermogenic-related genes Ucp1 and Pgc1!  compared to controls upon forskolin 
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stimulation. In contrast, p110# and p110" downregulation did not elicit transcriptional changes 
in thermogenic genes, further supporting a specific role of PI3K! in the regulation of 
thermogenesis.   
 Additionally, we validated the metabolic role of p110! in vivo by treating obese, 
hyperphagic ob/ob mice with three different PI3K inhibitors: CNIO-PI3Ki (! and " inhibitor), 
BYL-719 (selective ! inhibitor) and acalisib (selective " inhibitor). With the intention to imitate 
the intake of a pill, treatments were administered daily by oral gavage and during 15-16 days. 
Interestingly, while acalisib treatment did not affect body weight, CNIO-PI3Ki and BYL-719 
significantly reduced body weight of mice throughout the assay. In particular, ob/ob mice 
showed a body weight reduction of 7% and 10% compared to vehicle controls after treatment 
with 1 mg/kg and 5 mg/kg CNIO-PI3Ki, respectively. In the case of BYL-719, treatment with 
10 mg/kg resulted in 10% body weight reduction. Treatment with CNIO-PI3Ki and BYL-719 
produced an important, dose-dependent hyperglycemic peak that was cleared after 24 hours. 
Presumably, the detected increase in water intake contributes to the normalization of glycemia. 
Nevertheless, it is important to bear in mind that, starting at day 9, some mice had to be 
sacrificed due to their inability to re-establish normal glucose homeostasis. This difference with 
previous assays can be explained, at least in part, by the aggressive model that we are using 
(ob/ob mice are profoundly insulin resistant) combined with the treatment dosing (one single, 
full-concentration dose). Therefore, this is a critical fact to consider when designing a 
hypothetical use in humans, as dosing and timing of the treatment should be tightly supervised. 
As a result, we have confirmed that the inhibition of PI3K! alone (BYL-719) or in combination 
with PI3K" (CNIO-PI3Ki) reduces body weight in obese mice and causes an increase in glucose 
levels upon administration, while single PI3K" downregulation (acalisib) does not have major 
effects on weight or glycemia.   
 Finally, we have demonstrated that CNIO-PI3Ki and BYL-719, but not acalisib (all of 
them administered at a dose of 15 mg/kg), lead to increased energy expenditure in lean, WT 
mice during the next 7 hours after drug administration. This result further emphasizes the role of 
PI3K! in thermogenesis and energy expenditure control. Nevertheless, and even though all our 
data indicate that PI3K! inhibition is responsible for the increased thermogenic program, and 
consequently, of the elevated energy expenditure and body weight reduction, we cannot exclude 
that PI3K" may be also contributing to the improvement of obesity or some of its associated-
symptoms. During obesity, the adipose tissue exhibits an altered immune infiltration profile 
characterized by abundant pro-inflammatory M1 macrophages (McNelis and Olefsky, 2014) 
and deregulated IKK-NF*B and JNK-AP1 signalling pathways (Solinas et al., 2007) that give 
rise to elevated IL6 and TNF serum levels (Weisberg et al., 2003). In fact, pharmacological 
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inhibition of the TBK1 and IKK' kinases has been shown to produce body weight loss due to 
enhanced energy expenditure, together with improved insulin sensitivity and decreased hepatic 
steatosis in obese mice (Reilly et al., 2012). Taking this into account, the predominant role of 
PI3K" in hematopoietic cells and the fact that PI3K" is a main target of CNIO-PI3Ki, it is 
conceivable that inhibition of PI3K" could also explain some of the beneficial effects of PI3K 
inhibition by reducing obesity-related inflammatory responses.    
 Therefore, we conclude that p110!  is the critical mediator of the positive effects on 
body weight, thermogenesis and energy expenditure of PI3K inhibition, and that inhibition of 
p110" alone does not impact on weight, thermogenesis or energy regulation.  
 
1.3 PI3K, energy expenditure and obesity 
In this thesis, we have demonstrated that PI3K! inhibition elevates thermogenesis, energy 
expenditure (EE) and, thereby, reduces obesity in mice. Typically, thermogenesis is induced 
through the activation of the uncoupling protein UCP1 in the BAT, in a process driven by the 
release of epinephrine by the sympathetic nervous system (SNS) in response to cold or 
overfeeding (Lowell and Spiegelman, 2000). In turn, UCP1 is able to dissociate oxidative 
phosphorylation from ATP synthesis, thereby dissipating energy as heat and increasing EE 
(Cannon and Nedergaard, 2004). However, this main switch commanded by the SNS can be 
modulated via PI3K, as reduced PI3K levels, and increased FOXO1 and PGC1! activity, 
additionally stimulate thermogenesis by inducing Ucp1 expression (Ortega-Molina et al., 2012). 
Although the presence and relevance of BAT in human thermogenesis was controversial, 
physiologically active BAT was clearly identified in adult humans 7 years ago (Cypess et al., 
2009; van Marken Lichtenbelt et al., 2009; Virtanen et al., 2009). These findings have generated 
a growing interest in BAT activation as a promising target for the treatment of obesity and offer 
a potential translational use of the CNIO-PI3Ki treatment for human obesity treatment. 
Supporting the idea that suppressed PI3K activity positively regulates thermogenesis, CNIO-
PI3Ki treatment by oral gavage led to elevated UCP1 levels in the brown and white adipose 
tissue of obese mice; higher temperature around the BAT and shoulder area and to enhanced EE. 
However, we could not detect an increase in browning or Ucp1 expression neither in the long-
term CNIO-PI3Ki treatment nor in the ob/ob mice assay, thereby suggesting that other 
mechanisms may be stimulating EE as well.  
In general, EE results from the sum of the resting metabolic rate (obligatory and stable 
EE required to perform cellular and organ functions), physical activity and adaptive 
thermogenesis. As already discussed, adaptive thermogenesis can be increased by, first, 
activating the BAT, for example through the inhibition of PI3K (Ortega-Molina et al., 2012) or 
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through the use of #3-adrenergic signalling mimetics (Clapham and Arch, 2007); or, secondly, 
by stimulating the differentiation of brown adipocytes. Similarly, resting metabolic rate and EE 
can be boosted by inhibiting anaerobic glycolysis in favour of oxidative phosphorylation 
(García-Cao et al., 2012). Providing evidence for this possible mechanism, we detected lower 
lactate levels, indicative of increased oxidative phosphorylation, in ob/ob mice treated by 
gavage with CNIO-PI3Ki. Finally, alternative strategies to induce energy expenditure consider 
the use of physical activity mimetics that provide similar benefits for those individuals with 
physical or time limitations (Himms-Hagen, 2004; Goodyear, 2008); compounds that increase 
thermogenic activity in the skeletal muscle; or drugs that stimulate mitochondrial uncoupling. In 
this regard, various drugs including resveratrol, which activates SIRT1 (Lagouge et al., 2006), 
the AMPK activator AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) (Koh et al., 
2008) or DNP (2,4-dinitrophenol) (Colman, 2007) have been extensively studied, although, in 
general, they have shown limited efficacy or toxic side effects.  
Besides the induction of energy expenditure, other potential anti-obesity approaches 
primarily focus on either reducing appetite and food intake by amplifying inhibitory effects of 
anorexigenic signals or by blocking orexigenic factors, or on blocking nutrient absorption in the 
gut (Bray and Tartaglia, 2000). Similarly, several methods that promote nutrient turnover, 
stimulate adipocyte apoptosis, or that inhibit lipid synthesis could be effective strategies to 
reduce fat and protein storage (Bray and Tartaglia, 2000). In this context, PI3K inhibition could 
also be preventing fat storage by limiting adipocyte hypertrophy and hyperplasia since 
PI3K/AKT2 signalling has been demonstrated to be essential for both processes under high-fat 
diet conditions (Jeffery et al., 2015). 
Thus, our data suggest that PI3K inhibition reduces obesity by promoting energy 
expenditure through various mechanisms that include the induction of thermogenesis, the 
stimulation of oxidative phosphorylation and, possibly, the prevention of adipogenesis and 
adipocyte hypertrophy.  
 
1.4  CNIO-PI3Ki treatment in obese rhesus monkeys 
We have extended the use of the CNIO-PI3Ki treatment to rhesus monkeys. For this purpose, 
we treated naturally obese monkeys for 3 months with a single daily oral dose of CNIO-PI3Ki. 
Of note, the administered dose resulted in relatively low serum drug concentrations, considering 
that the levels achieved 2 hours post-dosing (35 ng/ml) are about two times lower than the 
levels reached in the long-term assay in mice (63 ng/ml). Interestingly, treatment with CNIO-
PI3Ki caused a modest, but significant, decrease in adiposity (7.6% reduction) and a trend 
towards reduced fasting glucose in monkeys. Although food intake was similar between the 
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CNIO-PI3Ki treated and control group, it is necessary to point out that both groups received a 
daily extra-treat in which the drug was administered. This treat represents a 16% increase in the 
total caloric intake and can be considered as a high-fat diet mimetic. The fact that CNIO-PI3Ki 
treatment reduces adiposity in the presence of a greater caloric intake further supports the idea 
that CNIO-PI3Ki works in the context of nutritional overload. Although the observed adiposity 
reduction was not translated into a reduction in body weight, we believe that either a longer 
treatment or a higher dose of the CNIO-PI3Ki could conceivably produce an eventual decrease 
in body weight.  
 Remarkably, no toxic secondary side effects associated to respiration, blood pressure, 
pulse, temperature or complete blood biochemistry were detected in any of the treated animals, 
indicating that the CNIO-PI3Ki is a safety treatment at the specified dose in rhesus monkeys as 
well. Moreover, transcriptional analysis of the liver and adipose tissue revealed no long-lasting 
gene expression changes after 3 months CNIO-PI3Ki treatment, demonstrating that the drug 
does not cause major or irreversible metabolic alterations.   
 
1.5 Concluding remarks 
Based on the evidence presented here, we propose that moderate pharmacological inhibition of 
PI3K could be an effective and safe therapeutic strategy against human obesity and metabolic 
syndrome in the future. Furthermore, we propose a model in which PI3K promotes anabolism 
and nutrient storage in the context of nutritional overload, which eventually promotes obesity, 
liver steatosis and hyperglycemia. Nevertheless, a partial reduction of PI3K activity 
(specifically of p110!) by CNIO-PI3Ki treatment induces energy expenditure through several 
mechanisms that may include the stimulation of thermogenesis in the brown and white adipose 
tissue, the induction of oxidative phosphorylation, and the reduction of adipocyte hyperthrophy 
and adipogenesis. In this manner, CNIO-PI3Ki treatment reduces adiposity, liver steatosis and 
inflammation, as well as promotes normoglycemia in obese mice, thereby improving some 
symptoms of the metabolic syndrome (Figure 41). Likewise, CNIO-PI3Ki treatment reduces 
adiposity and glucose levels in obese monkeys, thereby highlighting a translational potential use 
in humans.  
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Figure 41: Positive effects of pharmacological PI3K inhibition.  
Under nutritional excess, PI3K activity promotes obesity, liver steatosis and hyperglycemia by stimulating anabolism 
and nutrient storage. However, the pharmacological inhibition of PI3K! leads to induced energy and thereby, to 
reduced adiposity, liver steatosis, inflammation and normoglycemia in obese mice and, partly, in obese monkeys.  
 
 
 
 
PART 2. ROLE OF p21 IN THE FASTING RESPONSE 
 
Fasting is the most extreme form of dietary restriction because it requires complete abstinence 
from food, but not from water. Although long-term fasting periods are only sustainable and 
advantageous in lower organisms such as yeast and worms, mammals can also benefit from 
alternative fasting cycles. Indeed, intermittent fasting cycles have been shown to promote 
healthy lifespan and delay the onset of age-associated diseases such as type II diabetes, 
metabolic syndrome, cardiovascular disease and cancer (Longo and Mattson, 2014). Some of 
the mechanisms responsible for these positive effects include improved mitochondrial function, 
insulin sensitivity and glucose homeostasis; increased stress and cancer resistance; enhanced 
autophagy, regenerative capacity and DNA repair; and reduced inflammation, proliferation and 
oxidative damage. However, the underlying molecular pathways are still poorly understood.  
Here, we have addressed a general question regarding the involvement of tumour 
suppressor genes in the response to fasting with the idea that they could be mediating some of 
the reported beneficial effects of starvation. Some of the most important tumour suppressors are 
activated in response to cellular stresses such as DNA damage and oxidative or oncogenic stress, 
and participate in signalling pathways that prevent proliferation as well as stimulate DNA repair 
under these stressful conditions (Sherr, 2004; Vogelstein et al., 2000; Vurusaner et al., 2012). At 
the same time, fasting is a physiological stress that triggers complex metabolic, cellular and 
molecular adaptations (Cahill, 2006; Lempradl et al., 2015; Wang et al., 2006). But still, 
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nothing is known about the possible role that stress-responsive tumour suppressors may play 
during fasting.  
 
2.1  p21 is a fasting-inducible factor  
In order to investigate whether tumour suppressor genes play a role in the adaptation to fasting, 
we began by asking if their expression was affected in response to starvation. Interestingly, p21 
was highly induced in multiple tissues including liver, adipose depots, muscle, and lung upon 
48 hours fasting, whereas none of the other tested tumour suppressors including p16, p19, p27 
and p53 altered their expression. This observation confirms previous reports that demonstrate an 
important upregulation of p21 mRNA levels, in a process that is independent of the p53 activity 
and is partly mediated through the activation of FOXO1 (Tinkum et al., 2013). Confirming this 
result, we extended these observations by ruling out the participation of p53, which is the main 
activator of p21 transcription in response to DNA damage and oncogenic stress (Abbas and 
Dutta, 2009), and of p19 and Sirt1. Besides FOXO1 (Seoane et al., 2004; Tinkum et al., 2013), 
whose activity is enhanced by reduced insulin levels, CREB is activated by glucagon in 
response to fasting and it is another transcriptional activator of p21 upon nutrient shortage 
(Everett et al., 2013). 
 p21 is an important tumour suppressor gene involved in cell cycle regulation, 
senescence, apoptosis, DNA repair and transcriptional control (Abbas and Dutta, 2009). 
However, the role of p21 in metabolism has remained largely unexplored and controversial 
since p21 loss has been associated with both, adipose tissue hyperplasia and obesity (Naaz et al., 
2004) as well as with reduced adipocyte size and impaired adipocyte differentiation (Inoue et 
al., 2008). Given the reduced number of studies linking p21 to metabolism, and the important 
p21 induction observed after 48 hours of fasting in various tissues, we decided to further 
analyze the role of p21 in the fasting response.  
 
2.2 p21 enables efficient adaptation to fasting 
To study whether the upregulation of p21 is of physiological significance, we decided to fast 
mice lacking p21. As already reported (Tinkum et al., 2013), p21KO mice did not present any 
obvious differences regarding appearance, fat accumulation or metabolic adaptation markers 
after 24 hours fasting. However, after 48 hours of fasting, p21KO mice manifested profound 
defects in the adaptation to fasting and became severely morbid showing clear signs of energy 
exhaustion as reflected by the almost complete lack of adipose tissue upon necropsy. One of the 
main adaptations to fasting consists in the release of triglycerides and free fatty acids as well as 
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fat-derived ketone bodies to the bloodstream by the adipose tissue and liver, respectively, that 
meet the energy-demanding needs of tissues, especially the brain (Wang et al., 2006). 
Interestingly, 48 hours fasted p21KO mice presented low serum triglycerides, free fatty acids, 
and ketone bodies levels compared to fasted WT mice. This was accompanied by a greater 
reduction of IGF1, insulin and leptin levels compared to WT controls. Together with these 
deficiencies, p21KO mice showed a dramatic body temperature drop, probably as a 
consequence of the absence of BAT. In an advanced stage of the metabolic adaptations to 
fasting, proteins are rapidly degraded in the muscle and released to the bloodstream in order to 
boost gluconeogenesis in the liver. In the case of p21KO mice, we detected increased 
circulating amino acids in the serum indicative of an enhanced proteolytic adaptation that may 
partially compensate the premature loss of lipid stores. In addition, there was evidence of 
hepatic damage, based on the elevated serum alanine aminotransferase (ALT) levels and 
apoptotic hepatocytes.  
To detect energetic adaptive differences, we performed calorimetry analyses during a 
period of 48 hours under ad libitum feeding conditions followed by 48 hours fasting. 
Importantly, we observed that p21KO mice presented higher energy expenditure than WT 
controls during the first 36 hours of fasting, which could explain the premature exhaustion of 
nutrient stores. Also, this was accompanied by an increase in locomotor activity that can be 
interpreted as an enhanced foraging. At the same time, it may also constitute an additional 
expense of energy that aggravates the observed premature energy depletion (Westerterp, 2013). 
As a reference, no differences were observed in energy expenditure and activity under standard 
feeding conditions.  
 Additionally, in vitro studies also pointed to a role of p21 in the fasting response. First, 
cultured human hepatocellular carcinoma HepG2 cells and immortalized hepatocytes presented 
upregulated p21 expression upon nutrient starvation. Remarkably, recapitulating the in vivo 
effects of p21-deficiency, p21KO hepatocytes underwent massive cell death after 48 hours of 
nutrient starvation, unlike WT hepatocytes that remained largely viable.  
Thus, we show that p21 deficiency leads to enhanced energy expenditure, premature 
energy depletion and inability to efficiently adapt to long fasting periods.  
 
2.3  p21 deficiency and transcriptional changes 
To get a better insight into the mechanisms that could explain the inability of p21KO mice to 
properly adapt to fasting, we performed unbiased examination of the liver transcriptome by 
RNA-seq of WT and p21KO mice upon 24 hours fasting, when the severe defects of fasting 
have not been manifested yet. This analysis revealed important differences between WT and 
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p21KO mice. Of note, gene set enrichment analysis (GSEA) revealed a great number of 
downregulated pathways associated to metabolism or related to different immune-related 
responses in the liver of fasted p21KO mice.  
 Regarding the involvement of immune-related pathways, we confirmed by diverse 
techniques that fasting produces a greater and more profound decrease of immune-related 
responses in p21KO livers compared to controls. Fasting consistently reduces the number of 
tissue infiltrating leukocytes and inflammatory-associated processes in the liver of normal mice 
(Mitchell et al., 2010; Robertson and Mitchell, 2013; Sokolovi) et al., 2013). In the case of 
p21KO, this reduction was significantly more pronounced than in WT mice, which we interpret 
as a further indication that the absence of p21 results in an accelerated onset of the effects of 
fasting.  
 Furthermore, within the metabolic-related group, RNA-seq analysis also pointed out to 
a defective activation of the “PPAR signalling pathway” in fasted p21KO livers. This is 
particularly interesting because PPAR! is known to be a critical factor expressed in hepatocytes 
and necessary for the correct adaptation to fasting (Contreras et al., 2013). PPAR!  is a member 
of the nuclear hormone receptor superfamily of transcription factors and it is involved in the 
regulation of a variety of processes, ranging from inflammation to glucose, lipid and amino acid 
metabolism, energy homeostasis and hepatocyte proliferation (Rakhshandehroo et al., 2010). 
Under fasting conditions, PPAR! is activated by fatty acids and stimulates fatty acid #-
oxidation as well as ketogenesis in the liver. In fact, PPAR!-deficient mice present an abnormal 
response to fasting that renders them unable to efficiently adapt, thereby demonstrating the 
relevance of PPAR! activity during nutrient deprivation.   
 Therefore, we decided to study the PPAR! response in depth and focused first on the 
regulation of PPAR! transcriptional targets. Interestingly, the liver of p21KO fasted mice 
showed impaired upregulation of a subset of PPAR! transcriptional targets. Moreover, p21KO 
hepatocytes showed a blunted or reduced activation of some of the transcriptional PPAR! target 
genes upon 24 hours nutrient starvation or treatment with the PPAR! agonist WY-14,643, 
further supporting a cell-autonomous function of p21 in the fasting response. The mechanistic 
basis for the regulation of PPAR! by p21 remains to be established. One possible mechanistic 
link could be provided by the histone acetyltransferase coactivators p300/CBP, since the 
interaction of p21 with p300/CBP (Snowden et al., 2000) and p300/CBP with PPAR! (Dowell 
et al., 1997) have already been described. In fact, we have been able to reproduce the interaction 
of p21 with CBP. Still, and most likely due to various technical problems associated with the 
lack of an adequate cellular model (expressing high p21 and PPAR! levels) and of a good 
PPAR! antibody available in the lab, we have not been able to detect CBP-PPAR! and p21-
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PPAR! interactions. Another possible mechanism linking p21 with PPAR! could be mediated 
through cyclin-dependent kinases (CDKs). In this regard, it is known that CDK4 directly binds 
and activates PPAR%, a related peroxisome proliferator-activated receptor that is mainly 
expressed in adipocytes, and, thereby, stimulates lipid uptake and adipogenesis in the adipose 
tissue (Abella et al., 2005). Even though our data indicate an effect over PPAR!, it is 
conceivable that other CDKs could be binding different members of the PPAR family.  
 Similar to p21KO mice, PPAR!-deficient mice present low body temperature as well as 
reduced serum glucose and ketone bodies after 48 hours fasting, although no major differences 
regarding plasma free fatty acids and triglycerides (Kersten et al., 1999; Leone et al., 1999). Of 
note, they are also characterized by the accumulation of triglycerides and fatty acids in the liver 
upon fasting due to their inability to undergo ketogenesis. In the case of p21KO mice, it seems 
clear that, in the WAT, lipolysis and the release of free fatty acids to the bloodstream is 
correctly working. However, when fatty acids reach the liver, they may not be efficiently 
converted into ketone bodies. This could explain that the WAT is required to foster lipolysis and 
that, therefore, lipid stores are prematurely exhausted. An open remaining question would be: 
what is then happening to the released fatty acids? One possible explanation could be that, as in 
the case of PPAR!-KO mice, fasted p21KO animals accumulate them in the liver. Nevertheless, 
quantification of hepatic free fatty acids showed no significant differences between p21KO 
livers and controls (although a tendency towards higher levels in p21KO mice after 48 hours 
fasting). Other potential explanations could be that ketogenesis and ketone body formation is 
diminished, but not absolutely blocked, as a consequence of the impaired PPAR! activation, or 
finally, that fatty acids may be excreted without entering the liver. 
 
 Altogether, we conclude that the tumour suppressor p21 is a fasting-induced factor that 
contributes to fasting adaptation (Figure 42). Mechanistically, our data suggest that p21 is a 
positive regulator of PPAR!, which, in turn, is a critical mediator of the metabolic responses to 
fasting. 
 
 
 
 
 
Figure 42: p21 is necessary for the efficient adaptation to fasting.  
p21 is highly upregulated upon fasting in a p53-independent process that is partly mediated by FOXO1 and CREB. In 
turn, p21 acts as a positive regulator of PPAR!, which promotes fatty acid #-oxidation and, thereby, metabolic 
efficiency and adaptation to fasting. 
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2.4 Fasting-induced senescence 
Senescence is a compensatory tumour-suppressive response, characterized by a persistent 
growth arrest (Hayflick and Moorhead, 1961) that is induced in response to several stimuli such 
as telomere shortening (Harley et al., 1990), oxidative stress (Lee et al., 1999; Parrinello et al., 
2003), active chromatin (euchromatin) inducers (Ogryzko et al., 1996), oncogenic activation 
(Serrano et al., 1997), and tumour suppressor loss (Alimonti et al., 2010). These stimuli are 
signalled through various pathways, many of which activate p53, and converge in the activation 
of the cyclin-dependent kinase inhibitors p16, p15, p21 and p27, as well as the tumour 
suppressor Rb. Furthermore, senescent cells present derepression of the CDKN2A locus, which 
encodes p16 and ARF, and elicit a complex pro-inflammatory response known as senescence-
associated secretory phenotype (SASP) that is principally mediated by NF-$B and 
CEBP# (Campisi and d’Adda di Fagagna, 2007; Collado et al., 2007; Muñoz-Espín and Serrano, 
2014).  
 Importantly, oncogene-induced senescence has been shown to diminish cancer 
development in vivo by inducing a stable growth arrest (Collado et al., 2005; Michaloglou et al., 
2005). This response was initially thought to depend on a high oncogenic stress. However, 
combination of a mild oncogenic stress together with the deletion of CDK2 (Campaner et al., 
2010) or CDK4 (Puyol et al., 2010) was shown to promote a full senescence response in mice 
thereby lowering the threshold that allows cells to senesce. Taking into account that fasting 
highly induces p21 expression in multiple tissues and that, in turn, p21 is a strong CDK 
inhibitor (principally of CDK2), we hypothesised that a low oncogenic stress combined with 
fasting may promote senescence, as well. One of the best-studied oncogenes is Myc, a 
transcription factor whose overexpression directly contributes to malignant transformation and 
is frequently present in human cancers (Kress et al., 2015). In fact, Eµ-Myc transgenic mice, 
carrying a c-Myc oncogene driven by the immunoglobulin µ or $ enhancer, are widely used as 
spontaneous high-incidence lymphoma and early B cells leukemia models (Adams et al., 1985). 
To ensure moderate oncogenic c-Myc stress, 10 weeks old male Eµ-Myc mice in pre-tumoural 
stage (free of lymphoma or other associated malignancies) were selected. Interestingly, 48 hours 
fasting induced a senescent response only in the pre-tumoural spleen of Eµ-Myc mice, as 
measured by staining with the senescence associated-# galactosidase (SA-# gal) marker and the 
increased expression of the senescence markers p16, p19 and p21. In contrast, standard fed Eµ-
Myc or WT littermate controls (fed or fasted) did barely show SA-# gal positive staining or 
altered p16, p19 and p21 expression in the spleen. Of note, fasted Eµ-Myc spleens presented 
highly variable senescence degrees, ranging from highly senescent to medium or low senescent. 
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In fact, elevated SA-# gal staining positively correlated with a higher p16, p19 and p21 
expression in pre-tumoural spleens of fasted Eµ-Myc mice.  
Senescence is a tumour-suppressive response that, among others, avoids proliferation of 
cancerous cells by inducing a stable cell cycle arrest (Campisi and d’Adda di Fagagna, 2007; 
Collado et al., 2007; Muñoz-Espín and Serrano, 2014). Given that 48 hours of fasting induces a 
senescent response in the pre-tumoural spleen of Eµ-Myc mice, and this presumably limits the 
proliferative capacity of tumour cells, we were next wondering whether this would be translated 
into an extended tumour-free survival of mice. Unfortunately, neither overall mice survival nor 
maximal survival was significantly extended in Eµ-Myc mice that had been subjected to a 
single event of 48 hours of fasting at 10 weeks of age. One possible reason for this lack of effect 
could be that a single fasting event may not be strong enough to halt proliferation in the spleen 
in the long-term. Therefore, we propose that the effects of alternative fasting periods on tumour-
free survival should further be assessed.  
Altogether, our data indicate that fasting can lower the threshold that allows a senescent 
response in the cells as a low oncogenic stress induces senescence in the pre-tumoural spleen of 
Eµ-Myc mice (Figure 43).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. Fasting lowers the senescence threshold.  
Oncogenic Eµ-Myc stress or fasting alone are not able to promote a full senescence response in cells, because they 
partially induce cell cycle inhibitors and retain moderate CDK activity. However, the combination of both conditions 
highly induces cell cycle inhibitors and inhibits CDKs, thereby stimulating senescence.  
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1. The pharmacological inhibition of PI3K is an efficient and safe anti-obesity treatment 
in obese mice.  
1.3 CNIO-PI3Ki treatment produces a progressive weight loss in obese mice until reaching 
a new balance that is 20% below the original weight. This body weight reduction is 
selectively restricted to the loss of adiposity and is caused by an increase in energy 
expenditure.  
1.4 CNIO-PI3Ki treatment reduces glycemia, hepatic steatosis and inflammation, thereby 
improving some of the pathologies associated to the metabolic syndrome.  
1.5 CNIO-PI3Ki treatment is reversible, does not lead to resistance and does not cause 
secondary toxic side effects in obese mice. Moreover, CNIO-PI3Ki only manifests its 
anti-obesity activity under conditions of nutritional overload.  
1.6 Selective inhibition of PI3K isoforms, both in vitro and in vivo, indicates that inhibition 
of PI3K-p110! is critical for the beneficial effects on obesity and metabolic syndrome. 
1.7 CNIO-PI3Ki treatment reduces adiposity and improves glycemia in obese rhesus 
monkeys in the absence of detectable toxic effects.  
 
2. The tumour suppressor gene p21 is an important mediator of the fasting response. 
2.3 p21, but not other tumour suppressors, is highly induced in numerous tissues upon 
fasting and in a p53-independent manner.  
2.4 p21-deficient mice cannot efficiently adapt to long-term, 48-hours fasting periods and 
show signs of premature energy exhaustion as well as accelerated physiological 
adaptations.  
2.5 p21-null mice show impaired PPAR! signalling activation in the liver upon fasting.  
2.6 p21-deficient hepatocytes cannot survive prolonged nutrient starvation periods and 
present reduced PPAR! activity after both, nutrient starvation and PPAR! agonist WY-
14,643 treatment. 
2.7 Fasting can induce senescence in oncogenically-stressed cells in vivo, as shown in the 
case of the pre-tumoural spleen of Eµ-Myc mice. 
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1. La inhibición farmacológica de PI3K es un método eficiente y seguro para tratar la 
obesidad en ratones obesos.  
1.1 El tratamiento con CNIO-PI3Ki produce una pérdida progresiva de peso en ratones 
obesos hasta alcanzar un nuevo equilibrio, un 20% por debajo del peso original. Esta 
pérdida de peso se debe a una reducción de la adiposidad, exclusivamente, y tiene como 
causa el aumento del gasto energético.   
1.2 El tratamiento con CNIO-PI3Ki reduce los niveles de glucosa, la esteatosis hepática y la 
inflamación, mejorando así algunas de las patologías asociadas al síndrome metabólico.  
1.3 El tratamiento con CNIO-PI3Ki es reversible, no causa resistencia y no presenta efectos 
secundarios tóxicos en ratones obesos. Además, sólo exhibe actividad anti-obesidad en 
un contexto de exceso nutricional 
1.4 La inhibición selectiva de las isoformas de PI3K, tanto in vitro como in vivo, indica que 
la inhibición de PI3K-p110! es clave para los efectos beneficiosos sobre la obesidad y 
el síndrome metabólico. 
1.5 El tratamiento con CNIO-PI3Ki reduce la adiposidad y mejora la glicemia, en ausencia 
de toxicidad, de macacos obesos.  
 
2. El gen supresor de tumores p21 es un importante mediador en la respuesta a ayuno.  
2.1 La expresión de p21, pero no de otros supresores de tumores, se induce tras un periodo 
de ayuno en numerosos tejidos y de manera independiente de p53.  
2.2 Ratones deficientes en p21 no pueden adaptarse eficientemente a periodos prolongados 
de ayuno (48 horas), ya que muestran una pérdida prematura de energía y adaptaciones 
fisiológicas prematuras. 
2.3 Tras un periodo de ayuno, los ratones deficientes en p21 presentan una menor 
activación de la señalización de PPAR! en el hígado. 
2.4 Hepatocitos deficientes en p21 no pueden sobrevivir en medio sin nutrientes y muestran 
una activación reducida de PPAR! tras su cultivo en medio de ayuno o tras su 
estimulación con el agonista de PPAR! WY-14,643. 
2.5 El ayuno es capaz de inducir una respuesta senescente en células bajo estrés oncogénico 
in vivo, tal y como sucede en el caso del bazo pretumoral de ratones Eµ-Myc. 
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Supplementary Table S1  
!
Differentially expressed genes in p21KO livers versus WT liver controls 
DEG: q < 0.05 
 
UPREGULATED GENES IN p21KO !
UP in p21KO ad libitum 
VS WT ad libitum 
UP in p21KO VS WT  
both conditions 
UP in p21KO fasting 
VS WT fasting 
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Glo1 
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 Mup17 
 
Igfbp2 
 
Pdk4 
 Zbtb16 
 
Rgs16 
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Pla2g12a 
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 Efna1 
 
Agxt2l1 
 
Hamp2 
 Dynlt1b 
 
Cobll1 
 
Adcy1 
 Junb 
 
Wnk4 
 
Ppp1r3g 
 Dynlt1a 
   
Cyp17a1 
 Spry4 
   
St5 
 Nr0b2 
   
Hamp 
 Eno1,Gm5506 
   
Hspb1 
 Bcl6 
   
Mt1 
 Pim1 
   
Mt2 
 Syvn1 
   
       3930402G23Rik 
Hsd17b6 
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 Il6ra 
   
Ddit4 
 Nfxl1 
   
Rab44 
 Mup5 
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 Rnft2 
   
Txnip 
 Il1r1 
   
Arl4a 
 Rnf39 
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 Dnajb9 
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Fgf21 
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Sfpq 
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Arhgef26 
   
        E030018B13Rik 
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Hilpda 
 G0s2 
   
Dusp8 
 Xlr3a 
   
Ppargc1a 
 Fam193b 
   
Nrg4 
 Arhgap32 
   
Map3k6 
 Mup9 
   
Parp16 
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 Lifr 
   
Rabggtb 
 Herpud1 
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 Trib3 
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Arhgef40 
 Cdk13 
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 Ces2c 
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BC057022 
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Slc25a33 
 
    
Acacb 
 
    
Lepre1 
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Pde4c 
 
    
Peg3as 
 
    
Creld2 
 
    
Atoh8 
 
    
Zfhx2 
 
    
Tnfrsf12a 
 
    
Rps4y2 
 
    
Chpf 
 
    
Paip1 
 
    
Il3ra 
 
    
Tnk2 
 
    
Pogk 
 
    
Vopp1 
 
    
Atf3 
 
    
Kctd15 
 
    
Ccnf 
 
    
Gadd45b 
 
    
Eppk1 
 
    
Elmod3 
 
    
       2010003K11Rik 
    
Nr4a1 
 
    
P4ha2 
  
 
 
 
           DOWNREGULATED GENES IN p21KO 
 
DOWN in p21KO ad libitum  
VS WT ad libitum 
DOWN in p21KO VS WT 
(both conditions) 
DOWN in p21KO fasting 
VS WT fasting 
Fgl1 
 
Apcs 
 
Irf7 
Gadd45g 
 
Lcn2 
 
Socs2 
Mfsd2a 
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Mt1 
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Stat1 
Mt2 
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Lrg1 
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H2-Eb1 
Fbf1 
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Fdps 
 
Tgtp1 
 
Lyz2 
Mid1ip1 
 
Tff3 
 
H2-Ab1 
Orm3 
 
Samd9l 
 
Col3a1 
            1810011O10Rik                      Cish 
 
                     Apol7a 
Slc3a1 
 
Ifi44 
 
Clec7a 
Cyp4a14 
 
Marco 
 
Chpt1 
Acacb 
 
Gbp6 
 
Cd5l 
Pmvk 
 
Tgtp2 
 
Tbc1d24 
Ppp1r3b 
 
Ifit1 
 
Ly6d 
Acsl3 
 
Ifi27l2b 
 
Slc44a3 
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Nedd9 
 
Gbp10 
 
Cd24a 
Apol9b 
 
Thrsp 
 
Arhgap19 
Gm5506 
 
Gm4070 
 
Rbfox2 
Serpina4-ps1 
 
Axl 
 
Emr1 
Usp18 
 
Cd36 
 
Abcd2 
Ucp2 
 
Mpeg1 
 
Cybb 
Prepl 
 
Pklr 
 
Lgals1 
Nnmt 
 
Rtn4 
 
Acly 
Prg4 
 
Tmem176a 
 
Cd97 
Tmem176b 
 
Prlr 
 
Arhgef9 
Chrna4 
 
Col15a1 
 
Iigp1 
Dnajb2 
 
Tifa 
 
Vcam1 
Tmem51 
 
Wdfy1 
 
Samhd1 
Pcsk9 
 
Zbp1 
 
Tlr12 
H2-T9 
 
Mmp19 
 
Paqr9 
Fads3 
 
Lrtm1 
 
Ces2c 
Hmgcs1 
 
Mmd2 
 
1110020G09Rik 
Steap4 
 
Ttc23 
 
Lyz1 
Orm1 
 
Psmb9 
 
Klhdc7a 
Tap1 
 
Gbp3 
 
Ubp1 
Hmgcr 
 
Erdr1 
 
Slc39a4 
Atp11a 
 
Wsb1 
 
Zfp207 
Hbb-b2 
 
Gm4841 
 
Arap1 
Aacs 
 
Aqp8 
 
Oxr1 
             2010003K11Rik                   Trim30a 
 
                     Osbpl3 
Extl1 
 
Psmb8 
 
Uap1l1 
Fam65b 
 
Ifi47 
 
Olfml1 
Smpd3 
 
Itgal 
 
Col1a1 
Gm8801 
 
Il18bp 
 
Siglec1 
Rgs3 
 
Gbp7 
 
Immt 
Shisa5 
 
Parp14 
 
Alas2 
Eif4e3 
 
Hacl1 
 
Slc41a2 
Oasl1 
 
Slc13a5 
 
Ptprc 
Sqle 
 
Slc13a3 
 
Lima1 
Tgm1 
 
Fam198a 
 
Lilrb4 
Gpr110 
 
Oas1a 
 
Gbp2 
Trafd1 
 
Gm12250 
 
Aoah 
Fgfr3 
 
Sirpa 
 
Flnb 
Pml 
 
Fam46a 
 
Keg1 
Lbp 
 
Gas6 
 
Cd52 
Gm14403 
 
Irgm2 
 
Cxcl12 
Lss 
 
Dmpk 
 
Nckap1l 
Sco2 
 
Trim12c 
 
Tmsb4x 
Cdhr5 
 
St6gal1 
 
Myof 
Cyp26a1 
 
C1qc 
 
Sdc3 
Tmie 
 
Gstt3 
 
Gigyf2 
Fdft1 
 
Pls1 
 
Ncald 
Unkl 
 
AW112010 
 
Ccl5 
Ifit3 
 
Csf1r 
 
Scd4 
Adar 
 
Ctss 
 
Cxcl13 
Acnat2 
 
C1qa 
 
Pik3r1 
Rasgef1b 
 
Irgm1 
 
Ubd 
Dhx58 
 
Tspan4 
 
Ptprg 
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Cd151 
 
Cxcl9 
 
Lrit1 
Srxn1 
 
Robo1 
 
Il2rg 
Tcirg1 
 
Pla2g7 
 
AF251705 
Jak3 
 
Rtp4 
 
Scd2 
Serpina7 
 
Gsdmd 
 
Ank3 
Ccrn4l 
 
A230050P20Rik                         Arhgap25 
S100a10 
 
Tnfrsf19 
 
Rbm3 
Gm7120 
 
Kifc3 
 
Ces1g 
Isg15 
 
Gm8979 
 
Scara3 
Trim34a 
 
Cd74 
 
Ghr 
Cebpe 
 
Wwtr1 
 
Vwa5a 
Fasn 
 
Fam84b 
 
Slc7a8 
Gstm4 
   
Cib3 
Hn1l 
   
Ces2d-ps 
Aldh1b1 
   
Cyp2a4 
Acss2 
   
Rps6ka1 
              1300015D01Rik 
  
                        Nat8 
Gm16551 
   
E330011O21Rik 
G6pc 
   
Rasa4 
Fam53b 
   
Klf13 
Mtmr11 
   
Lyn 
Slc16a5 
   
Ccr5 
Spsb3 
   
Scd3 
Hspb1 
   
Sorbs1 
Pnpla3 
   
Ugt1a9 
Ddc 
   
Clec4a3 
Rxrg 
   
Ociad2 
C1qtnf1 
   
Nr3c2 
Irf9 
   
Adcy7 
Pgd 
   
Irf8 
Bud13 
   
Erbb2ip 
Gck 
   
Rnf152 
Tagap1 
   
Clec12a 
Mlkl 
   
Aif1 
Tubb2a 
   
Tlr13 
Naip2 
   
Stk10 
Pltp 
   
Ces2e 
Serinc2 
   
Nnt 
Ildr2 
   
Lgals3 
Josd2 
   
Cyp3a25 
Tor1aip2 
   
C1qb 
Ddx60 
   
Rcbtb2 
Insc 
   
Zfp809 
Rap1gap 
   
Lpcat2 
Isyna1 
   
Cml5 
Hsp90aa1 
   
AI182371 
Slc37a1 
   
Gbp9 
Zc3hav1 
   
Myo1f 
Gtpbp2 
   
Abcg3 
Tceal8 
   
Nr1h4 
Sc4mol 
   
Pld4 
Tnfsf10 
   
Lphn2 
Tgfbr2 
   
Fyb 
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Clstn3 
   
Phldb2 
Csrp3 
   
Iqgap1 
Gm19619 
   
Fam55b 
Pvrl2 
   
B3galt1 
Dock9 
   
Tstd1 
Srp54b,Srp54c 
   
Csf1 
Bst2 
   
Cyp2c50 
Znrf1 
   
Dcun1d1 
Gm7694 
   
Cd68 
Mdp1 
   
Klra2 
Fam47e 
   
Ahnak 
Pdzk1ip1 
   
Gda 
Mcm6 
   
Gbp8 
Gnat1 
   
Lair1 
Gtf2ird1 
   
Hpgds 
St6galnac6 
   
Acbd5 
D14Ertd449e 
   
Fgd2 
Serpina11 
   
Cenpl 
Ctgf 
   
Arhgap30 
Nlrc5 
   
Acot4 
Sgsm1 
   
Rasal2 
Fam25c 
   
Lpl 
Ube2h 
   
Coro1a 
Herc6 
   
Gbp1 
Mvk 
   
Igfals 
Got1 
   
Pnldc1 
Fam129b 
   
Eif4g3 
Ifitm2 
   
Hck 
Zbtb4 
   
Gbp11 
Lgals3bp 
   
Blnk 
Nrp2 
   
Capg 
Aig1 
   
Cyp2a5 
Dhcr7 
   
Hk3 
I830012O16Rik 
  
                       Lgmn 
Steap2 
   
Taok3 
Cyp4a10 
   
Rdh9 
Sun1 
   
Cldn2 
St5 
   
Slc15a3 
Cpne8 
   
Tfrc 
Tmem98 
   
Ly86 
Zfp259 
   
Hnmt 
Trim21 
   
Gp49a 
Plac8 
   
Cxcl16 
Oasl2 
   
Tyrobp 
Grn 
   
BC013712 
Jub 
   
Fam129a 
Rras 
   
Laptm5 
Xaf1 
   
Anxa2 
Nsdhl 
   
Dut 
Slc25a25 
   
C730036E19Rik 
Trim12a 
   
Syk 
Cyb561 
   
Unc119 
             1700024P16Rik 
  
                      Adhfe1 
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Agpat9 
   
Cd48 
Filip1l 
   
Lilrb3 
Mtap7d1 
   
Slc2a9 
Sall2 
   
Cd180 
Cyp17a1 
   
Lsp1 
Oas1g 
   
Cbr1 
Sfxn5 
   
Rgn 
Arhgef19 
   
Itgb2 
Gm14431 
   
Adam33 
Ifitm3 
   
Phka2 
Mfge8 
   
Ptprd 
Tap2 
   
Timd4 
Ggt6 
   
Gstm3 
Elovl6 
   
Gm8989 
Gpc1 
   
Adra1b 
Cldn14 
   
Fabp5 
Golm1 
   
B430306N03Rik 
Htatip2 
   
Herc3 
Tm6sf2 
   
Efha1 
AB124611 
   
Pira2 
Ddhd1 
   
Gm4951 
Slc17a1 
   
Idi1 
Fam73b 
   
Parp12 
Hba-a1,Hba-a2 
   
S100a11 
Srp54a 
   
Magi1 
Cmpk2 
   
Mpp1 
Gm5480 
   
Trim24 
             D730039F16Rik 
  
                      Hmox1 
Alas1 
   
Mapkapk3 
Elovl5 
   
Lrrc25 
Abtb2 
   
Tmtc4 
Ppap2c 
   
Aifm3 
Ppl 
   
Gng2 
Ang 
   
Evi2b 
Litaf 
   
Mthfd1l 
    
Mmp15 
    
Clec4a1 
    
1600014C10Rik 
    
Clec4n 
    
Folr2 
    
Aatk 
    
Abr 
    
Marcks 
    
Gna14 
    
Hipk2 
    
Mta3 
    
Cxcl10 
    
Scd1 
    
Ctla2b 
    
Nfib 
    
Vsig4 
    
Cd276 
    
Cyp3a16 
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Supplementary Table S2  
 
Gene set enrichment analysis of p21KO livers versus WT liver controls 
GSEA: FDR < 0.25 
 
                  downregulated in                   
  
                    downregulated in 
 p21KO ad libitum VS WT ad libitum      m 
 
  
p21KO 24h fasting VS WT 24h fasting    gng 
 
 KEGG gene set  FDR  
 
KEGG gene set  FDR  
biosynthesis of steroids  0.001  
 
natural killer cell mediated cytotoxicity  0.002  
antigen processing and pesentation  0.010  
 
ECM-receptor interaction  0.009  
proteosome  0.032  
 
leucocyte transendothelial migration  0.009  
glycolysys/gluconeogenesis  0.062  
 
drug metabolism-other enzymes 0.009 
pentose phosphate pathway  0.106  
 
type II diabetes mellitus  0.012  
cell adhesion molecules   0.130  
 
B-cell receptor signaling pathway  0.012  
galactose metabolism  0.147  
 
toll-like receptor signaling pathway  0.012  
natural killer cell mediated cytotoxicity  0.203  
 
focal adhesion  0.017  
tyrosine metabolism  0.204  
 
cell adhesion molecules   0.022  
adipocytokine signaling pathway  0.214  
 
butanoate metabolism   0.028  
glycan structures-degradation 0.216 
 
T-cell receptor signaling pathway  0.039  
primary immunodeficiency   0.218  
 
fc epsilon ri signaling pathway 0.058 
DNA replication  0.231  
 
pentose and glucuronate interconversions  0.061  
autoimmune thyroid disease 0.234 
 
primary immunodeficiency   0.068  
   
androgen and estrogen metabolism  0.070  
   
apoptosis  0.088  
   
porphyrin and chlorophyll metabolism  0.089 
   
complement and coagulation cascades 0.090 
   
regulation of actin cytoskeleton  0.092  
   
biosynthesis of steroids  0.092  
   
hematopoietic cell lineage 0.093 
   
pancreatic cancer 0.093 
   
PPAR signaling pathway   0.094  
   
phosphatidylinositol signaling system  0.099  
   
adherens junction  0.101  
   
bile acid biosynthesis  0.104  
   
antigen processing and presentation 0.108 
   
colorectal cancer 0.114 
   
small cell lung cancer 0.114 
   
gamma hexachlorocyclohexane degradation 0.117 
   
dentatorubropallidoluysian atrophy 0.119 
   
mismatch repair 0.120 
   
drug metabolism-cytochrome P450  0.121  
   
drug metabolism-cytochrome P450 0.121 
   
DNA replication  0.123  
   
cytokine-cytokine receptor interaction 0.148 
   
biosynthesis of unsaturated fatty acids  0.161  
   
non-small cell lung cancer 0.171 
   
graft-versus-host disease 0.176 
   
glycosphingolipid biosynthesis  0.179  
   
ABC transporters 0.180 
   
metabolism of xenobiotics by cytochr. P450 0.189 
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